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Our laboratory has recently demonstrated that Bordetella pertussis, the 
etiological agent of whooping cough, produces a surface polysaccharide 
microcapsule. Pertussis vaccination initiative over the past 60 years has led to 
significant reduction of incidence rate among young children. However, emergence of 
adult pertussis cases in recent years suggests that current vaccination fails to provide 
long-term protection and underscores the need to further study this disease and revisit 
the pertussis vaccination strategies. Polysaccharide capsules represent an important 
vaccine and antimicrobial target for many pathogens. The role of the polysaccharide 
capsule during B. pertussis infection has not been investigated. In this work, we have 
explored the role of the capsule genetic locus in pertussis pathogenesis. 
 
We first constructed B. pertussis mutants containing unmarked in-frame 
deletion in different ORFs within the capsule operon. None of these mutants produced 
the microcapsule at their surface, similar to KOcaps mutant deleted for the entire 
capsule operon. Deletion of the second ORF in the capsule operon, namely kpsT, 
predicted to encode the polysialic acid transport ATP binding protein, led to 
significant attenuation in colonization of the mouse lungs compared to the parental 
strain, which recapitulated the virulence defect observed with the KOcaps mutant. In 
contrast, mutants deleted for kspE, the putative capsule exporter gene and vipC, the 
putative capsule biosynthesis gene displayed modest and no virulence defects 
respectively. These findings suggested that the polysaccharide capsule exposed at the 
surface of B. pertussis bacteria does not play a role in pertussis pathogenesis. 
Consistently, the attenuated phenotype observed in kpsT-deleted mutant correlated 
!! xi!
with the global down-regulation of a variety genes that are either related to bacteria 
virulence or that encode putative proteins in B. pertussis. Key virulence factors FHA, 
BrkA and PT were slightly down-modulated at both transcriptional and protein levels 
compared to the parental strain. Since the great majority of the virulence factors in B. 
pertussis is under the control of the two component system BvgA/S, we focused on 
studying the effect of kpsT deletion on the BvgS-mediated signal transduction. 
Interestingly, we demonstrated that the virulence defect observed with the kpsT-
deleted mutant was not observed in a B. pertussis mutant strain with constitutive 
activation of its BvgS sensor. This observation thus led us to propose that kpsT 
deletion impaired the function and activity of BvgS sensor. A BvgS pull down 
approach then revealed that BvgS sensor oligomerizes in parental B. pertussis strain, 
but not in the mutants deleted either for kpsT or for the entire capsule operon. This 
finding demonstrated that KpsT is involved in BvgS oligomerization, presumably 
BvgS dimerization, which is necessary for the sensor’s activity and regulation of bvg-
regulated genes. Sensitivity tests to antibiotic and chemical treatments supported that 
membrane associated KpsT protein participate to the plasma membrane integrity and 
permeability, which is crucial for the conformational integrity and optimal 
functionality of membrane proteins such as BvgS sensor. Collectively, our data 
demonstrate an alternative biological function of the capsular transporter KpsT in the 
central functioning of BvgS-mediated signal transduction in B. pertussis.  
 
In addition, we characterized the transcriptional regulation of the capsule locus 
in different B. pertussis strains. Both clinical and laboratory-adapted (BPSM) strains 
demonstrated increased expression of the capsule locus when the BvgA/S regulatory 
system is inactive (Bvg- phase) and vice versa (Bvg+ phase), supporting that the 
!! xii!
capsule locus belong to the class of vrgs. We hypothesized that RisA may regulate the 
transcription of the capsule locus in both BPSM phases; however, over-expression of 
RisA approaches failed to lend support to this hypothesis. In parallel, risA gene 
deletion could only be obtained in the presence of a wild-type copy of risA on a 
plasmid, thus demonstrating the essentiality of this gene in BPSM. The expression 
pattern of the capsule locus was also analyzed during ex vivo infection (epithelial cells 
and macrophages) and in the mouse model of pertussis infection. We observed that 
the capsule locus is highly expressed and dynamically modulated during cellular 
invasion as well as during the course of in vivo infection, reflecting the response of 
the bacteria to the host microenvironments during infection. These findings prompted 




























LIST OF TABLES !
Table 1.1: Classification of E. coli capsules..............................................................17 
Table 2.1: E. coli strain and plasmid .........................................................................61 
Table 2.2: Primers used for E. coli work...................................................................63!
Table 2.3: B. pertussis strains....................................................................................69!
Table 2.4: Primers used for B. pertussis PCR screening work and Southern blot ....72!
Table 2.5: Reaction components for RT-PCR amplification per sample tube for 
RNA input less than 1µg. The reaction was scaled up to a final volume 
of 40 µl when using more than 1 µg of RNA. ........................................80 
Table 2.6: Reaction components for Real-time PCR amplification per sample tube.
................................................................................................................81!
Table 2.7: List of primers used for Real-time PCR...................................................82!
Table 2.8: Antibodies used in Western blot. .............................................................91!


















LIST OF FIGURES !
Figure 1.1: Morphology of (A) extracellular polysaccharide capsules in Klebsiella 
pneumoniae serotype K20 and (B) polysaccharide capsules in E. coli 
serotype K30...........................................................................................13!
Figure 1.2: Mechanism of polysaccharide biosynthesis and secretion by the 
Wzy/Wzx, ABC-transporter and synthase dependent pathway..............15!
Figure 1.3: Model of Rcs signaling cascade in E. coli K12. .....................................25!
Figure 1.4: Regulatory network of Vi polysaccharide expression by Rcs and 
Enz/OmpR signaling system. .................................................................28!
Figure 1.5: The B. pertussis capsule operon..............................................................33!
Figure 1.6: A model of biosynthesis and assembly of group II capsules in E. coli. .33!
Figure 1.7: Visualization of the B. pertussis polysaccharide capsule by transmission 
electron microscopy................................................................................39!
Figure 1.8: Model of an "unorthodox" BvgA/S two-component system in B. 
pertussis. .................................................................................................45!
Figure 1.9: Signal transduction through BvgA/S two-component system and 
regulation of vags and vrgs.....................................................................51!
Figure 2.1: Semi-dry transfer of nucleic acids onto nitrocellulose membrane..........77!
Figure 2.2: Western blot setup for semi-dry transfer. ...............................................92!
Figure 2.3: Western blot setup for wet transfer. ........................................................92!
Figure 3.1: Schematic organization of the ORFs for B. pertussis capsule operon. .101!
Figure 3.2: Southern blot analysis of ΔkpsT, ΔkpsE and ΔvipC chromosomal DNA.
..............................................................................................................103!
Figure 3.3: Reverse transcription-PCR on downstream gene. ................................106!
Figure 3.4: Growth kinetics for BPSM, ΔkpsT, ΔkpsE and ΔvipC mutant. ............108!
!! xv!
Figure 3.5: Detection of the polysaccharide capsule at the surface of B. pertussis 
strains....................................................................................................111!
Figure 3.6: Lung colonization profile by B. pertussis BPSM, ΔkpsT, ΔkpsE and 
ΔvipC strains.........................................................................................114!
Figure 3.7: Production of bvg-regulated virulence proteins in capsule-deficient 
mutants..................................................................................................118!
Figure 3.8: Coomassie blue-stained 12% SDS-PAGE of whole cell lysates. .........119!
Figure 3.9: Relative transcriptional activity of vags in BPSM, ΔkpsT and ΔkpsTcom 
in virulent phase....................................................................................122!
Figure 3.10: Microarray analysis of relative expression levels of selected genes that 
was down-modulated in ΔkpsT mutant.................................................125!
Figure 3.11: Relative transcriptional activity of BP3818 and BP3838 ORFs in 
BPSM, ΔkpsT and ΔkpsTcom in virulent phase. ..................................126!
Figure 3.12: Lung colonization profile by B. pertussis BPSM, KOcaps, 
KOcaps:kpsT and KOcaps:kpsMT strains. ...........................................130!
Figure 3.13: Southern blot analysis of BvgS-VFT2-ΔkpsT chromosomal DNA. ...133!
Figure 3.14: Production and expression of virulence factors in BvgS-VFT2-ΔkpsT 
mutant. ..................................................................................................135!
Figure 3.15: Lung colonization profile by B. pertussis BvgS-VFT2, ΔkpsT and 
BvgS-VFT2-ΔkpsT strains....................................................................138!
Figure 3.16: Schematic diagram of His-BvgS chimera...........................................140!
Figure 3.17: Relative transcriptional activity of vags and kpsT in BPSM and BPSH 
in virulent phase....................................................................................142!
Figure 3.18: Western blot analysis for the detection of His-tagged BvgS. .............145!
Figure 3.19: Expression and purification of His-BvgS by Ni-NTA chromatography.
..............................................................................................................148!
Figure 3.20: Detection of purified BvgS by Western blotting and SDS-PAGE. ....152!
!! xvi!
Figure 3.21: Southern blot analysis of BPSH-KOcaps and BPSH-ΔkpsT 
chromosomal DNA...............................................................................156!
Figure 3.22: Detection of BvgS associated oligomers and BvgS monomer. ..........158!
Figure 3.23: Growth kinetics of BPSM, ΔkpsT and ΔkpsTcom in the presence of 
erythromycin.........................................................................................162!
Figure 3.24: Effect of SDS and EDTA on BPSM, ΔkpsT and ΔkpsTcom strain. ...163!
Figure 4.1: Relative transcriptional activity of risA, vrg6, bvgR and the capsule locus 
in BPSM, Tohama I and 18323 strain in virulent and avirulent phase.182!
Figure 4.2: Relative transcriptional activity of risA, bvgR, vrg6 and the capsule locus 
in BPSM and ΔbvgAS strain in virulent and avirulent phase. ..............185!
Figure 4.3: Construction of ris-deleted mutants in BPSM background strain. .......188!
Figure 4.4: Relative transcriptional activity of risA, vrg6, bvgR and the capsule locus 
in BPSM and BPSM-Pfha-risA strain in virulent phase.......................191!
Figure 4.5: Relative transcriptional activity of risA, vrg6, bvgR and the capsule locus 
in BPSM, ΔbvgAS, ΔbvgAS-PrecA-risA and ΔbvgAS-pbbr1mcs empty 
vector control strain in virulent and avirulent phase. ...........................192!
Figure 4.6: Relative transcriptional activity of kpsT and bvgA in BPSM recovered 
from A549 versus in vitro BPSM grown in virulent phase. .................195!
Figure 4.7: Relative transcriptional activity of kpsT and bvgA in BPSM recovered 
from J774.A1 macrophages versus in vitro BPSM grown in virulent 
phase. ....................................................................................................197!
Figure 4.8: Relative transcriptional activity of vrgs and vags in BPSM recovered 





LIST OF ABBREVIATIONS 
 
ABC ATP-binding cassette 
AC Adenylate cyclase  
ADP Adenosine diphosphate  
Amp Ampicillin 
AP Alkaline phosphatase 
ATP Adenosine triphosphate 
B. bronchiseptica Bordetella bronchiseptica 
B. holmesii B. holmesii 
B. parapertussis Bordetella parapertussis 
B. pertussis Bordetella pertussis 
BCIP 5-bromo-4-chloro-3'-indolyphosphate p-toluidine 
BG Bordet-Gengou 
bp Base pair 
BrkA Bordetella serum resistance to killing protein A 
BSA Bovine serum albumin 
bvg Bordetella virulence gene 
c-di-GMP Cyclic di-guanine monosphosphate 
CaCl2 Calcium chloride 
cDNA Complementary DNA 
cm Centimeter 
Cm Chloramphenicol 
CRD Carbohydrate recognition domain 
Ct Threshold cycle 
!! xviii!
dCTP Deoxycytidine triphosphate 
DEPC Diethylpyrocarbonate 
DIG Digoxigenin 
DNA Deoxyribonucleic acid 
DNT Dermonecrotic toxin 
dNTP Deoxyribonucleotide triphosphates 
E. coli Escherichia coli 
EAL Glu-Ala-Leu 
EDTA Ethylenedinitrilo tetraacetic acid 
EGTA Ethylene glycol tetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum 
FHA Filamentous hemagglutinin 
FITC Fluorescein isothiocyanate  
GDP Guanosine diphosphate 
Gm Gentamicin 
GTP Guanosine triphosphate 
h Hour 
H. influenzae Haemophilus influenzae 
HCl Hydrochloric acid 
hib Haemophilus influenzae type b 
His Histidine 
His-tag Histidine tag 
HK Histidine kinase 
!! xix!
Hpt Histidine-containing phosphotransfer 
HRP Horseradish peroxidase 
IPTG Isopropyl β-D-1-thiogalactopyranoside 











N. meningitides Neisseria meningitides 
N. meningitidis Neiserria meningitides 
NaCl Sodium chloride 
NaH2PO4 Sodium dihydrogen phosphate 
NaOH Sodium hydroxide 
NBT Nitro-blue tetrazolium chloride 
Ni-NTA Nickel-Nitrilotriacetic acid 
nm Nanometer 
OD Optical density 
ORF Open reading frame 
P-BvgA Phosphorylated BvgA 
!! xx!
P. aeruginosa Pseudomonas aeruginosa 
p.i. Post-infection 
PAGE Polyacrylamide gel electrophoresis 
PAS Per-Arnt-Sim 
PCR Polymerase chain reaction 
PT Pertussis toxin 
PVDF Polyvinylidene difluoride 
RE Restriction enzyme 
RNA Ribonucleic acid 
rpm Revolutions per minute 
RT-PCR Reverse-transcriptase PCR 
s Second 
S. aureus Staphylococcus aureus 
S. pneumoniae Streptococcus pneumoniae 
S. typhi Salmonella typhi 
SD Standard deviation  
SDS Sodium dodecyl sulphate 




SSC Saline-sodium citrate 
Ta Annealing temperature 
TAE Tris-acetate-EDTA 
TBS Tris-buffered saline 
!! xxi!
TCT Tracheal cytotoxin 
TE Tris-EDTA 
Tris-HCl Tris-hydrochloride 
UDP Uridine diphosphate 
UV Ultra violet 
V Volt 
vags bvg-activated genes 
VFT Venus Fly Trap  
















Chapter 1: Introduction 
! 1!
CHAPTER 1 INTRODUCTION !
1.1 PATHOGENESIS OF BORDETELLA PERTUSSIS !
1.1.1 B. pertussis Infection and Whooping Cough  
 
Bordetella pertussis is a Gram-negative, obligate aerobe and fastidious 
coccobacilli that can only be cultivated in an enriched media supplemented 
with blood. B. pertussis is a strict human pathogen and the sole etiological 
agent for pertussis disease, or commonly known as whooping cough; a 
respiratory disease that was highly prevalent amongst infants prior to the 
development of pertussis vaccine in the 1940s. First isolated in 1906 by 
French microbiologist Bordet and Gengou, B. pertussis has since then been 
widely studied and characterized on its pathogenic and virulence capabilities.  
 
The Bordetella genus comprises nine species, with four of them being 
phylogenetically closely related and all of them being respiratory pathogens of 
mammalian hosts (Diavatopoulos et al., 2005; Mooi, 2010). The four includes 
B. bronchiseptica, B. parapertussis, B. pertussis and B. holmessii. B. 
bronchispetica causes infectious bronchitis in a variety of mammals and 
although rarely, can be isolated from humans. The human-associated B. 
parapertussis and B. pertussis, which evolve from the former, causes pertussis 
in humans, while another sub-species of B. parapertussis has been reported to 
cause zoonotic respiratory tract infection in sheep (Diavatopoulos et al., 2005; 
Mooi, 2010).  
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B. pertussis is highly contagious with an attack rate of 80% among 
non-immunized population as it spreads easily via aerosolized droplets when 
coughed up by an infected host. The infected mammalian host, especially 
unvaccinated infants will ultimately develop chronic pertussis infection 
whereas adults will typically display an asymptomatic disease. During the 
course of infection, B. pertussis manifests its pathogenicity through multiple 
biological activities. The bacteria first establish infection by adhering to the 
ciliated epithelium linings at the upper respiratory tract by producing a group 
of virulence factors known as adhesins. Production and secretion of 
biologically active toxins from B. pertussis usually takes place at a later stage 
of infection, resulting in a more symptomatic and severe illness due to the 
destruction of mucosal epithelial lining by the toxins (Finger and von Koenig, 
1996). Severe, spasmodic coughs with continuous whooping sound and 
lymphocytosis are hallmarks of pertussis infection in infants (Finger and von 
Koenig, 1996; Mattoo and Cherry, 2005). Serious complications including 
bronchopneumonia, seizure and respiratory arrest frequently result in death 
among infants (Finger and von Koenig, 1996; Mattoo and Cherry, 2005). In 
addition, following the colonization of the respiratory tract, B. pertussis not 
only adheres to epithelial cells and multiplies extracellularly, it can also persist 
within epithelial cells and survive within macrophages (Bassinet et al., 2000; 
Lamberti et al., 2010; Masure, 1992). Such phenomenon indicates that both 
cellular and humoral mediated immunity are triggered in response to B. 
pertussis infection and elimination (Lamberti et al., 2010). 
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1.1.2 B. pertussis Treatment and Vaccine 
 
Pertussis disease and infectivity can be controlled and treated with 
common antibiotics including ampicillin, chloramphenicol, azithromycin and 
erythromycin (Bass et al., 1969; Lambert, 1979). Nevertheless, the 
development and widespread use of pertussis vaccine has been a primary 
focus to combat pertussis and has greatly reduced the disease burden among 
infants. Prior to the widespread use of pertussis vaccine in 1940s, pertussis 
was one of the most common causes of childhood morbidity and mortality 
with more than 200,000 cases reported annually in the United States alone 
according to the World Health Organization. Isolation and characterization of 
several virulence factors in B. pertussis has led to a better understanding of the 
pathogenesis of pertussis and immunity against the disease, which contributed 
to the development of acellular pertussis vaccines made of purified B. 
pertussis proteins. 
 
Development of the conventional, inactivated whole-cell pertussis 
vaccine used in combination with diphtheria and tetanus toxoid has 
dramatically reduced childhood mortality cases associated with pertussis for 
the past 60 years (Mattoo and Cherry, 2005). Despite the efficacy of the whole 
cell vaccine and its routine immunization since the early 1950s to early 1990s, 
it is no longer as widely used due to the presence of endotoxin component 
harbored by the bacteria resulting in adverse side effects in children (Cherry, 
1996; Cody et al., 1981). The acellular pertussis vaccine was refined in 1990s 
primarily as a booster for the whole cell vaccine and was subsequently 
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approved as primary pertussis vaccine due to its effectiveness and significant 
reduction in reactogenicity as compared to whole cell vaccine (Gustafsson et 
al., 1996; Olin et al., 1997; Zhang et al., 2011). The current five-component 
acellular pertussis consists of virulence factors filamentous hemagglutinin 
(FHA), inactivated pertussis toxin (PT), pertactin, fimbriae 2 and 3 subunits, 
all of which are major virulence factors that are either cell surface-associated 
or secreted (Gustafsson et al., 1996). The protective immunity of pertussis 
vaccine is highly dependent on cell-mediated and humoral immunity, with 
reports that acellular vaccine specifically drives the Th2 cell-mediated 
immunity (Mills et al., 1998; Watanabe et al., 2002). Recently, a live-
attenuated B. pertussis vaccine candidate known as BPZE1 has been 
developed through targeted genetic manipulation and has reached phase-I 
human clinical trial (ClinicalTrials.gov NCT01188512)(Skerry et al., 2009). A 
single nasal administration of live BPZE1 bacteria was shown to confer a 
long-lasting immunity and strong protection against virulent B. pertussis in a 
murine model of infection, thus promoting a viable and attractive alternative 
to the current acellular pertussis vaccine (Skerry and Mahon, 2011).  
 
1.1.3 Pertussis Epidemiology: A problem of re-emergence  !
Despite the widespread use and protective efficacy of acellular 
pertussis vaccines, pertussis is not completely eradicated unlike many other 
vaccine-eradicated infectious diseases such as smallpox, polio and rubella. As 
of 2011, the World Health Organization estimated about 140,000 reported 
cases of pertussis globally and the estimated number of deaths in 1998 was 
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close to 200,000. Interestingly, an epidemiological shift of pertussis infection 
towards adolescents and adults has been increasingly reported in developed 
countries with high acellular pertussis vaccine coverage (Berbers et al., 2009b; 
Cherry, 2005; Gilberg et al., 2002; He and Mertsola, 2008; Lin et al., 2007; 
Mattoo and Cherry, 2005; Pebody et al., 2005). This group of pertussis 
susceptible hosts, which are often asymptomatic increases the risk of 
transmission of pertussis to unvaccinated newborn infants, to whom the 
disease may be life-threatening (Cherry, 2005; Crowcroft and Britto, 2002; He 
and Mertsola, 2008).  
 
Several hypotheses have been made with regards to factors 
contributing to the resurgence of pertussis in adolescence and adults. These 
include waning vaccine-induced immunity for both whole cell and acellular 
vaccine 10 years after the primary immunization, typically without booster 
against pertussis over time (Berbers et al., 2009b; Cherry, 2005). Thus, regular 
immunization booster schedule for pertussis vaccine has been reinforced 
among the adults and adolescents in developing countries (Berbers et al., 
2009b). In contrary to the whole cell pertussis vaccine, the major component 
of acellular pertussis vaccines was limited to five B. pertussis virulence 
factors; FHA, PT, pertactin, fimbriae 2 and 3 subunit, hence resulting in a 
narrow, and specific immune response against the bacteria (He and Mertsola, 
2008). The relatively specific immune response against the five major 
virulence factors may drive the emergence of antigenic variants among the 
circulating B. pertussis strains, indicating the adaptative capability of B. 
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pertussis isolates to overcome the current vaccination niche (Berbers et al., 
2009b; He and Mertsola, 2008; Mooi et al., 2001).  
 
Antigenic divergence between B. pertussis vaccine strains and the 
circulating B. pertussis clinical isolates has been reported in vaccinated 
populations, with evidences pointing at genetic polymorphisms and allelic 
variation in the components of current accellular vaccines, mainly the genetic 
elements encoding PT and pertactin (Berbers et al., 2009a; Cassiday et al., 
2000; Gzyl et al., 2001; King et al., 2001; Mooi et al., 1998; Mosiej et al., 
2011). In particular, the immunological memory derived from the vaccine 
strain may not protect against the circulating B. pertussis strains that has 
undergone changes in their genetic elements (Gzyl et al., 2001; King et al., 
2001). The resurgence of pertussis in adults has also been attributed to 
improved disease surveillance and diagnosis methods; from culture to ELISA 
serology and the widespread use of PCR testing, which resulted in increased 
detection sensitivity and hence the number of cases being reported (Crowcroft 
and Pebody, 2006; Wendelboe and Van Rie, 2006). Factors that affect the 
epidemiological shift of pertussis remain a subject of debate and the current 
long-term goal focuses on developing a pertussis vaccine that is safe and 
confers lifelong immunity in children and adults.   
 
1.1.4 Virulence Determinants of B. pertussis  
 
The expression of the known virulence factors in B. pertussis is 
essentially governed by the BvgA/S two-component signaling system, which 
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consists of a sensor protein, BvgS and a cognate response regulator BvgA 
(Section 1.3). Based on our current understanding, B. pertussis BvgA/S 
regulated virulence determinants can be broadly classified into three groups; 
namely the toxins, autotransporters and adhesins In this section, we will 
discuss one major virulence determinant for each class, namely pertussis toxin 
(PT), the BrkA autotransporter and the filamentous hemagglutinin (FHA). .  
 
Production of toxins by B. pertussis typically results in respiratory 
disease manifestation in infected host through irritation of ciliated epithelial 
cells and the impairment of ciliary function in the respiratory tract. The 
surface of B. pertussis bacteria is coated with the heat stable 
lipopolysaccharide endotoxin. In addition, B. pertussis secretes several 
exotoxins, which have been shown to cause a variety of toxic effects. These 
include PT, an ADP-ribosyl-transferase that interferes with G-protein 
signaling (Finger and von Koenig, 1996; Katada et al., 1983), the adenylate 
cyclase (AC) toxin, which increases cAMP levels thereby inhibiting immune 
effector cell functions (Hanski, 1989), the tracheal cytotoxin (TCT), which 
causes local damage and extrusion of ciliated epithelia (Wilson et al., 1991) 
and the dermonecrotic toxin (DNT), which results in modification of GTPases 
and consequently tissue destruction (Fukui and Horiguchi, 2004). One of the 
main secreted exotoxins, PT comprises of five different subunits, namely the 
S2, S3, S4 and S5 subunits each with carbohydrate recognition domains that 
are capable of binding onto host cell surface receptors (van't Wout et al., 1992; 
Witvliet et al., 1989). The enzymatically active S1 subunit interferes with 
cellular GTP and G-protein signaling events (Carbonetti, 2010; Finger and von 
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Koenig, 1996). PT is transported across the bacterial outer membrane via type 
IV secretion system encoded by the ptl operon, which is located downstream 
the ptx genes (Weiss et al., 1993).  The ability for B. pertussis to adhere onto 
host surface is dependent on the production of PT, primarily the S2 and S3 
subunits (Tuomanen et al., 1985; van't Wout et al., 1992). 
 
The filamentous hemagglutinin (FHA) is a highly immunogenic, 220 
kDa protein, which serves as the dominant adhesin essential for the initial 
establishment of infection in Bordetella sp. Although it is not the sole adhesin 
in B. pertussis, deletion of FHA alone results in dramatic impairment of 
bacterial colonization in a mouse model of pertussis infection, implying the 
importance of FHA in colonization. Specifically the carbohydrate recognition 
domain (CRD) is crucial for the attachment of B. pertussis onto the respiratory 
tract of its infected host (Kimura et al., 1990; Relman et al., 1989). FHA also 
carries the glycosaminoglycan-binding site, which allows it to bind to 
sulphated glycolipids and heparin commonly found on the surfaces of various 
eukaryotic cells (Hannah et al., 1994; Menozzi et al., 1991b). In addition, the 
Arg-Gly-Asp (RGD) motif promotes bacterial adherence to macrophages and 
monocytes and possible other leukocytes via the leukocyte integrins (Ishibashi 
et al., 1994; Saukkonen et al., 1991). Initially, FHA is synthesized as a large 
360-kDa FhaB precursor in the cytoplasm and transported into the periplasmic 
space via the Sec secretion pathway (Chevalier et al., 2004). At the outer 
membrane, the large FhaB is proteolytically cleaved by SphB protease at the 
C-terminus end and processed to form the mature 220 kDA FHA adhesin 
protein (Coutte et al., 2001). Mature FHA is then secreted into the 
Chapter 1: Introduction 
! 9!
extracellular milieu or remains associated to the surface of B. pertussis 
through a specialized translocation system at the outer membrane known as 
FhaC (Guedin et al., 2000; Jacob-Dubuisson et al., 2013; Jacob-Dubuisson et 
al., 2001). 
 
Proteins that belong to the autotransporter family typically mediate 
their own export across bacterial cell envelope. As a large protein superfamily, 
autotransporters comprise of an N-terminal passenger domain and a conserved 
C-terminal domain, which folds into a beta-barrel channel resulting in the 
formation of a secretion pore at the outer membrane (Shannon and Fernandez, 
1999). Most autotransporters are proteolytically cleaved, resulting in a 
processed alpha domain that is either secreted into the extracellular milieu via 
the beta-barrel channel or remain non-covalently associated to bacterial cell 
surface (Dautin and Bernstein, 2007; Fink et al., 2001; Girard and Mourez, 
2006; Oliver et al., 2003; Suhr et al., 1996). BrkA autotransporter, involved in 
serum resistance, for example, is expressed as a 103 kDa precursor in B. 
pertussis, which is processed to yield a 73 kDa passenger domain and a 30 
kDa beta-barrel channel (Dautin and Bernstein, 2007; Shannon and Fernandez, 
1999). While BrkA has been implicated in adherence to and invasion of host 
cells in vitro, it also inhibits the classical complement pathway and 
accumulation of complement C4 proteins, which ultimately protects the 
bacteria against complement-mediated killing (Barnes and Weiss, 2001). 
 
1.2 BACTERIAL POLYSACCHARIDE CAPSULES !
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1.2.1 Properties, Structure and Classification  
 
Polysaccharide capsules form a discrete, mesh-liked or slimy layer 
surrounding the outermost structure of some bacteria species, thereby 
mediating the initial direct contact between the bacteria and the extracellular 
environment. First discovered and visualized under the microscope in the early 
1900s through various conventional positive and negative staining methods 
(Gerstley and Morton, 1954; Moller, 1951; Novelli, 1953), the polysaccharide 
capsule has been described as “a gelatinous ground substance between the 
micrococci which agglomerates” as illustrated from one of the earliest 
observations on Streptococcus pneumoniae (Austrian, 2011). Increasing 
evidence of the presence of a gelatinous structure surrounding a 
microorganism has led to the isolation of the polysaccharide capsules and 
detailed study of its role in pathogenesis.  
 
Bacterial capsules consist of long polysaccharide chains made of 
smaller repeating units, whose composition varies largely among bacterial 
species and among serotypes within the same species. For instance, almost 80 
different polysaccharide capsules, also known as K antigens, have been 
reported and described for Escherichia coli, but not all capsulated serotypes 
lead to the same pathological consequences (Orskov and Orskov, 1992; 
Roberts, 1996; Whitfield, 2006). The diversity of bacterial polysaccharide 
macromolecules conveys a diverse virulent potential and is distinguished by 
the individual polysaccharide chains or monosaccharide units, which are made 
up either from carbohydrate or non-carbohydrate moieties (Greenfield et al., 
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2012; Roberts, 1996; Vann et al., 1981; Whitfield, 1995). In general, 
polysaccharide capsule polymers are made up of repeating monosaccharide 
units linked together by glycosidic bond forming either hetero-polymers or 
homo-polymer as exemplified by the α-(28)`-linked sialic acid capsule of E. 
coli K1 strain (Vann et al., 1997). The Vi antigen of Salmonella typhi is 
organized in a linear homo-polymer of α-(14)-linked N-acetyl 
galactosaminuronic acid with a variable O-acetylation at the carbon 3 position 
(Martin et al., 1967; Yang et al., 2011).  
 
Among different bacterial species, polysaccharide capsules are 
distinguished by the nature of their branching pattern, chemical linkages and 
chemical modifications (Bentley et al., 2006; Shu et al., 2009). Although the 
overall biological and chemical structure of a polysaccharide capsule 
determines the antibody-mediated immune responses against the bacteria, 
antigenically similar capsules do not necessarily generate the same response. 
Chemically identical polysaccharide capsules expressed in different bacteria 
species such as S. typhi Vi antigen and E. coli K1 antigen were able to elicit 
cross-reactive antibody responses (Szewczyk and Taylor, 1983), whereas the 
structurally identical polysaccharide capsules in S. pneumoniae and Group B 
Streptococcus generated distinct anti-polysaccharide capsule response 
(Arjunaraja et al., 2012), suggesting the unlimited functional diversity of the 
polysaccharide capsules in the bacteria kingdom.  
 
The polysaccharide capsules polymer chains are firmly associated onto 
the bacteria cell surface, whereas those that are loosely connected on the 
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surface and often secreted into the extracellular milieu are known as 
exopolysaccharide or extracellular polysaccharide capsules (Figure 1.1) 
(Cuthbertson et al., 2009). For example, S. typhi forms shapeless slimy 
extracellular layer and releases its polysaccharide content into the extracellular 
milieu with limited association onto its cell surface (Daniels et al., 1989). In 
contrast, the E. coli surface polysaccharide capsule polymers are packed in 
matrices and establish into a discrete capsular structure, enveloping the entire 
outermost surface of the bacteria (Cuthbertson et al., 2009). Surface anchored 
polysaccharide capsules can also associate or interact with bacterial surface 
macromolecules or lipids such as phospholipids and lipid-A molecules to form 
a complex structure known as glycoproteins and glycolipids respectively 
(Whitfield and Valvano, 1993). In addition, for some Gram-positive bacteria, 
polysaccharide capsules also form an integral part of the bacterial cell surface 
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Figure 1.1: Morphology of (A) extracellular polysaccharide capsules in 
Klebsiella pneumoniae serotype K20 and (B) polysaccharide capsules in E. 
coli serotype K30.  
The surface capsules for both bacteria are labeled with cationized ferritin. 
Although both bacteria have identical repeat-unit polysaccharide structures, 
the capsules of E. coli retains most of the polymer in a well-defined structure 
but the capsules of K. pneumoniae has limited association on the bacteria 
surface as substantial amounts of polymer was dispersed at the extracellular 
meliue as evident by the black arrows in the above micrographs. Adapted with 
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1.2.2 Biosynthesis and Assembly  
 
Genetic and biochemical evidences have ascertained that the 
biosynthesis and transport machinery of polysaccharide capsules are broadly 
similar across different bacteria species. Essentially, three types of 
polysaccharide biosynthesis and assembly apparatus have been described 
widely in the literature for both Gram-positive and Gram-negative bacteria; 
namely the Wzy-dependent system, ATP-binding cassette (ABC) transporter 
dependent system and the synthase dependent system (Figure 1.2) (Whitfield, 
2006; Whitney and Howell, 2013; Yother, 2011). The Wzy and synthase 
dependent systems are widely characterized in both Gram-positive and Gram 
negative bacteria, whereas the ABC-transporter dependent system is mainly 
associated with the transport of capsules in Gram-negative bacteria (Whitfield, 
2006; Yother, 2011). In the Wzy-dependent system, the repeating 
carbohydrates moieties are linked and assembled into polymers at the 
cytoplasmic face of the inner membrane (Figure 1.2). In contrast, the ABC-
dependent pathway is characterized by the ATP-binding cassette transporter 
system that directs the elongated carbohydrate moieties that were synthesized 
and assembled independently in the cytoplasm (Figure 1.2). 
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Figure 1.2: Mechanism of polysaccharide biosynthesis and secretion by 
the Wzy/Wzx, ABC-transporter and synthase dependent pathway. 
Abbreviations: OPX, outer membrane polysaccharide export; PCP, 
polysaccharide copolymerase; TPR, tetratricopeptide repeat proteins; IM, 
inner membrane; PG, peptidoglycan sacculus; OM, outer membrane; c-di-
GMP, bis-(3′-5′)-cyclic dimeric guanosine monophosphate; ABC transporter, 
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The prototypical biosynthesis and assembly of polysaccharide capsules 
in Gram-negative bacteria are mainly based from the biosynthesis and 
assembly model of group or type 1, 2, 3, and 4 capsules in E. coli (Table 1.1) 
(Whitfield, 2006; Whitfield and Roberts, 1999). More than 80 different 
serotypes of E. coli capsules or K antigens were grouped and classified based 
on their biochemical composition, structural properties, regulation of 
expression (as described in Table 1.1) and as well as the sequences of the 
capsule gene clusters (Whitfield, 2006; Whitfield and Roberts, 1999). In 
general, the mechanisms of polysaccharide capsule biosynthesis and chain 
translocation requires multi-protein complexes for co-expression with O-
antigen and other carbohydrate moieties (Table 1.1). Biosynthesis usually 
takes place at the cytoplasm or at the cytoplasmic inner membrane face of the 
bacteria. Prior to polymer chain elongation, the pool of activated 
monophospho and/or diphospho-sugar precursors in the cytoplasm first 
assemble into a nascent polysaccharide at the cytoplasmic inter-face of the 
inner membrane by biosynthesis enzymes (Whitfield, 2006). Depending on the 
transporter system (Figure 1.2), the nascent polysaccharide chain grows 
successively with aid of enzymes for the addition of carbohydrate units or 
chemical groups at the reducing or non-reducing end of the polymers (Vimr 
and Steenbergen, 2009). Concurrently, a translocation protein complex 
spanning the entire cell wall will translocate the elongating mature polymer 
through the perisplasm and across the outer membrane to the bacterial cell 
surface, a process typically coupled with ATP hydrolysis for the ABC-
transporter system (Figure 1.2) (Whitfield, 2006). 
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Table 1.1: Classification of E. coli capsules 
E. coli capsules were classified into type 1, 2, 3 and 4 based on their 
biochemical properties, polymerization and transport-export system. Table 
adapted and modified with permission (Whitfield and Roberts, 1999). (?) 
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1.2.3 Bacteria Polysaccharide Capsules As Virulence Determinants  
 
Historically, the surface polysaccharide capsule was perceived as a 
hydrated shield that envelops the bacteria and protects it against external 
environmental threats, including the harsh effect of desiccation and drastic 
osmolarity changes (Gibson et al., 2006; Ophir and Gutnick, 1994). Protection 
against drastic external changes in their natural growth environment is 
particularly relevant for the survival of pathogens and transmission from one 
host to another. For many bacteria species, surface polysaccharide capsules 
also play a significant part in defense against classical host-mediated 
immunity and promote bacterial adherence onto biotic (host surfaces) and 
abiotic surfaces, which is often associated with biofilm development (Beloin 
et al., 2008; Costerton et al., 1981; Reisner et al., 2006).  
 
The later developmental stages of complex biofilm structures from a 
community of bacteria typically display enhanced resistance to antimicrobial 
agents and antibiotics treatment (Otto, 2006). Interspecies polysaccharide 
capsule-associated biofilm matrices reinforce the survival, colonization and 
invasion of pathogenic bacteria at the site of infection. The variability in 
carbohydrate and chain modifications are some of the biochemical aspects that 
drive the functional diversity of the polysaccharide capsules. Whilst certain 
capsules are associated with adherence as exemplified in K. pnenumoniae and 
S. pneumoniae on human respiratory epithelial cells (Favre-Bonte et al., 1999; 
Hammerschmidt et al., 2005), the surface capsules are also capable of masking 
surface adhesins, such as fimbriae, crucial for the attachment of the bacteria to 
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host cells (Favre-Bonte et al., 1999; Schembri et al., 2004). The K1 capsule of 
the uropathogenic E. coli promotes formation of intracellular bacterial 
communities consisting of polysaccharide-associated biofilm-like matrices 
within the cytosol of the bladder epithelium (Anderson et al., 2010), resulting 
in the development of severe and invasive urinary tract infection (Dautin and 
Bernstein, 2007). The E. coli intracellular bacterial communities in turn 
enhance bacteria proliferation at a distant site of infection, therefore resulting 
in the recurrence of UTI infection within the gut (Anderson et al., 2010; Goller 
and Seed, 2010).  
 
The polysaccharide capsules are also capable of subverting host 
immune recognition, thereby pertinently allowing bacteria to inhibit and evade 
the host immune defense mechanisms. For instance, the surface capsule of 
Neisseria meningitides protects the bacteria against phagocytosis by inhibiting 
adherence and uptake into human dendritic cells (Unkmeir et al., 2002). Such 
anti-phagocytic strategies favor the capsulated bacteria to survive, persist and 
disseminate within their infected host. This probably explains why capsulated 
bacteria such as K. pneumoniae and Group A Streptococcus, N. meningitides 
and Staphylococcus aureus are able to circumvent host defenses and are able 
to invade host tissues and bloodstream (Barroso et al., 2013; Schrager et al., 
1996).  
 
The Vi polysaccharide of Salmonella enterica serotype Typhi or 
commonly known as Salmonella typhi is one of the major virulence 
determinants responsible for typhoid fever. The Vi polysaccharide or Vi 
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antigen is a linear homopolymer of α-1,4-linked N-acetylgalactosaminuronate 
(GalNAcA) with variable O-acetylation at the carbon 3 position; a chemical 
modification that is targeted by majority of the anti-Vi antibody response 
(Robbins and Robbins, 1984). The surface Vi antigen is one of the major 
virulent factors for S. typhi, which mediates enhanced resistance to innate 
immune response including phagocytosis and host complement-mediated 
killing (Robbins and Robbins, 1984; Wilson et al., 2011). It has also been 
proposed that the capsular Vi antigen prevents host-pathogen recognition 
event by concealing bacterial LPS recognition by the host pattern recognition 
receptors (Wilson et al., 2008).  
 
1.2.4 Bacteria Polysaccharide Capsules As Subunit Vaccines  
 
 Advances in the knowledge of polysaccharide capsules structure, 
biochemical properties and host-mediated immune responses ensued the 
development of vaccines targeting the polysaccharide capsules of pathogenic 
bacteria. Various polysaccharide capsule-based vaccines have been developed 
to protect against deadly bacterial diseases including those caused by 
pneumococci (S. pneumoniae), menigococci (N. menigitidis), Haemophilus 
influenzae serogroup b (Hib), group B streptococci (Streptococcus agalactiae) 
and S. typhi. Immune response, specifically the activation of B-lymphocytes 
against the large polymeric polysaccharide capsules is largely limited to T-
lymphocyte independent mechanisms (Kelly et al., 2004; Weintraub, 2003). 
The lack of T-lymphocyte memory against capsules is associated with poor 
immunogenicity, especially in infants and adolescents due to under-developed 
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B-lymphocytes subpopulation and T-regulatory cells (Weintraub, 2003). To 
circumvent such immune limitation in children, polysaccharide capsules based 
vaccines are generally conjugated with protein carriers to enhance 
immunogenicity and confer stronger protection against encapsulated pathogen.  
 
Whilst the type B polysaccharide capsules of Hib are poorly 
immunogenic, covalent conjugation with a protein carrier such as diphtheria 
and tetanus toxoid successfully boosted T-cell immunity and strong antibody 
responses against Hib polysaccharide capsules (Anderson, 1983; Schneerson 
et al., 1980). The strong efficacy of Hib polysaccharide capsule-protein 
conjugated vaccine successfully reduced Hib infection among adolescents for 
the past 20 years. Similar success was also achieved with the diphtheria 
toxoid-conjugated meningococcal polysaccharide capsule vaccine used for the 
prevention of N. menigitidis infection among adolescents (Anderson et al., 
1994). The currently available diphtheria toxoid-conjugated tetravalent 
polysaccharide vaccine protects against four different serotypes of N. 
menigitidis (Campbell et al., 2002; Kimmel, 2008). Like many other T-
lymphocyte independent polysaccharide capsule based vaccine, the purified S. 
typhi Vi capsular polysaccharide (TYPHIM ViTM) is only limited for active 
immunization against typhoid fever in children more than two years of age 
(Pulickal and Pollard, 2007). To protect children below two years of age, the 
principle of chemical conjugation between a carrier protein and the capsule Vi 
antigen was recently developed and subjected to clinical trials. This includes 
Vi-conjugates with the recombinant, inactivated exoprotein A of 
Pseudomonas aeruginosa, which confers good protection against typhoid 
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fever in adolescents (Lin et al., 2001; Thiem et al., 2011) and as well Vi-
conjugates with diphtheria toxoid (Cui et al., 2010; Rondini et al., 2011). 
 
1.2.5 Genetic Regulation of Bacterial Capsule Expression !
The regulatory system that directs the expression of polysaccharide 
capsule in pathogenic bacteria has been characterized in E. coli and S. typhi, as 
they are both regulated by the same Rcs two-component regulatory system. 
Detailed analysis of effectors and regulators involved in the control of 
transcriptional activity of the capsule locus and its implication in virulence has 
been extensively reported for both bacteria. 
 
1.2.5.1 Genetic regulation of extracellular polysaccharide capsule 
synthesis in Escherichia coli  
 
Over 80 chemically distinct capsular polysaccharides or K antigens 
were reported and characterized in E. coli alone, and they are collectively 
grouped in four different categories. As described in section 1.1.2, the process 
of biosynthesis, elongation and translocation at the bacterial surface of group 2 
and 3 capsules typically requires expenditure of energy. Therefore, production 
of polysaccharide capsule at the protein and transcriptional levels are tightly 
regulated and modulated depending on the environmental conditions 
encountered by the bacteria.  
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Expression of E. coli group 2 capsules is essentially thermo-regulated, 
with up-regulation of region 1 and 3 at normal physiological temperature of 
37°C, but not at temperature below 18°C (Cieslewicz and Vimr, 1996; 
Whitfield, 2006). Region 1 and 3 denote the conserved group 2 gene clusters 
involved in the transport and modification of repeating units of the 
polysaccharide polymers (Roberts, 1996; Whitfield, 2006). Several 
overlapping regulatory circuits have been shown to mediate the regulation of 
temperature sensitive capsule promoter in E. coli. The transcriptional activator 
RfaH is necessary for E. coli capsule expression at 37°C (Stevens et al., 1994), 
whereas the H-NS and BipA regulatory proteins play a dual role; both are 
necessary for activation of the capsule expression at 37°C and repression at 
18°C (Rowe et al., 2000). Another transcriptional regulator known as SlyA 
interacts with H-NS regulator to promote transcription of E. coli K5 capsule 
gene cluster at 37°C.  
 
Different serotypes of encapsulated E. coli regulate their capsule 
differently and involve different molecular events and different regulators. 
The major exopolysaccharide capsule, also known as colanic acid in E. coli 
K12, is essentially regulated by the Rcs two-component regulatory system. 
Members of the Rcs signaling pathway consist of RcsC, a trans-membrane 
sensor kinase, and RcsB, the cystoplasmic response regulator (Figure 1.3) 
(Gottesman and Stout, 1991; Majdalani et al., 2005). The signal output of 
RcsS requires RcsD, a phospho-transfer protein formerly known as YojN, to 
activate the response regulator RcsB via a phospho-transfer reaction (Figure 
1.3) (Takeda et al., 2001). Transcriptional regulation of the cps gene cluster in 
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E. coli K12 strain depends on an additional cytoplasmic regulator known as 
RcsA, which interacts with the response regulator RcsB to activate 
transcription of cps operon (Figure 1.3) (Majdalani et al., 2005). 
Phosphorylated RcsB either homodimerizes to activate a certain group of 
genes or heterodimerizes with the accumulating pool of RcsA to activate the 
capsule cps operon (Figure 1.3), resulting in over-expression of colanic acid 
and mucoid phenotype (Gottesman and Stout, 1991; Majdalani and 
Gottesman, 2005). RcsF, an alternative sensor kinase for RcsB located at the 
outer membrane transduces extracellular signals to RcsC in an unknown 
mechanism (Figure 1.3) (Majdalani et al., 2005). At temperature below 20°C 
and in the presence of divalent cations, the Rcs signaling system is activated 
and hence resulting in increased capsule expression (Hagiwara et al., 2003). 
Intriguingly, a regulatory cross-talk between the Rcs system and PhoP/Q 
signaling systems has been described for the regulation of extracellular 
polysaccharide capsule expression in E. coli in response to the in vitro 
presence of divalent cations (Hagiwara et al., 2003). The model of Rcs 
signaling system in regulating the capsule expression illustrates the 
complexity of signal transduction mechanisms that are responsible for the 
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Figure 1.3: Model of Rcs signaling cascade in E. coli K12. 
The RcsB/C two-component system, including the RcsD phosphotransfer 
protein, RcsF sensor at the outer membrane and RcsA response regulator 
encompassed the complexity of the Rcs signaling mechanism in E. coli. 
Transcriptional regulation of the capsule cps gene cluster encoding the colanic 
acid polysaccharide capsule is essentially modulated by the Rcs signaling 
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1.2.5.2 Genetic regulation of capsule synthesis in Salmonella typhi  
 
S. typhi, the agent of typhoid fever, expresses the Vi polysaccharide 
capsule antigen or Vi antigen at its surface, which is an important virulent 
determinant for the bacteria during infection. Sequencing of the S. typhi 
genome revealed a large 134 kb pathogenicity island implicated in virulence, 
which inlcudes the locus required for biosynthesis and export of Vi antigen 
(Hashimoto et al., 1993; Seth-Smith, 2008). Expression of Vi antigen in S. 
typhi involves two genetic loci termed as viaA and viaB. The viaA locus, 
which encodes the TviA protein regulatory protein, is found in many other 
Salmonella serotypes, including in the Vi-negative strains and in other bacteria 
such as E. coli. The viaB operon, present only in the Vi-expressing strains, 
contains ten ORFs necessary for biosynthesis and export of Vi antigen to the 
cell surface (tviB to vexE) (Figure 1.4) (Hashimoto et al., 1991; Hashimoto et 
al., 1993; Kolyva et al., 1992).  
 
Interestingly, it has been shown that a similar RcsB/C regulatory 
system involved in colanic acid synthesis in E. coli (section 1.1.5.1) plays a 
role in activating the viaA locus in S. typhi under low osmolarity condition 
(Figure 1.4) (Houng et al., 1992; Virlogeux et al., 1996). The product of viaA 
locus, TviA positively regulates its own expression and acts as an auxiliary 
protein by interacting with RcsB, the response regulator of RcsB/C system in 
S. typhi, where both protein cooperatively modulate the expression of Vi 
antigen at the viaB operon, flagella and invasion proteins (Figure 1.4) (Arricau 
et al., 1998; Houng et al., 1992; Majdalani et al., 2005; Virlogeux et al., 1996). 
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 Interestingly, the osmo- sensitive OmpR/EnvZ two-component system 
in S. typhi has been shown to modulate Vi antigen expression TviA (Figure 
1.4) (Pickard et al., 1994). In addition, the alternative sigma factor RpoS, a 
stress response master regulator required for S. typhi survival under 
unfavorable conditions, has also been described as a repressor for Vi-antigen 
biosynthesis through the RcsB/C pathway (Figure 1.4) (Santander et al., 2008; 
Santander et al., 2007). Given the invasive properties of S. typhi, it is not 
surprising that this bacteria encounters a great diversity of microenvironments 
within the host and that various regulatory systems are involved in the 
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Figure 1.4: Regulatory network of Vi polysaccharide expression by Rcs 
and Enz/OmpR signaling system. 
The Rcs and OmpR/EnvZ two-component regulatory system are involved in 
the regulation of Vi antigen expression in S. typhi. Low osmolarity leads to an 
increased level of Vi antigen expression via TviA activation, whereas high 
osmolarity results in a negative regulation of Vi antigen expression via 
inhibition of rcsC expression. OM: Outer membrane; P: Periplasm; IM: Inner 
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Precise and temporal regulation of the capsule expression during the 
course of infection is crucial for bacterial adaptive response within the host 
environment. Regulation of polysaccharide capsule expression in vivo has 
been a topic of interest as it suggests the flexibility of bacterial regulons in 
responding to host factors, which in turn promotes bacterial survival and 
persistence. For instance, expression of S. typhi Vi-antigen biosynthesis gene, 
tviB was significantly up-regulated during invasion of intestinal epithelial cells 
in vitro (Tran et al., 2010). Moreover, in an in vivo bovine model of S. typhi 
infection, expression of Vi capsular antigen was shown to be induced upon 
invasion at the ileal mucosa (Tran et al., 2010). Over-expression of Vi antigen 
renders S. typhi less adherent and enhances phagocytic killing whereas, an 
optimal expression of Vi antigen is necessary for evasion of the host immune 
response, suggesting that a tightly controlled regulation of Vi antigen 
expression at different sites and times during infection is crucial for S. typhi 
pathogenesis (Janis et al., 2011; Robbins and Robbins, 1984; Waxin et al., 
1993).  
 
For group A Streptococcus, the expression of polysaccharide capsule 
was found immediately up-regulated at early stage of mucosal colonization in 
mice, which correlates with the bacterial enhanced resistance to opsonization 
and phagocytic killing by the host immune cells (Dale et al., 1996; Gryllos et 
al., 2001). In other pathogenic bacteria such as N. meningitides, expression of 
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the polysaccharide capsule was observed to be down-regulated at early stage 
of infection, upon interaction with epithelial cells to facilitate adherence and 
invasion of the bacteria (Deghmane et al., 2002; Grifantini et al., 2002). The 
remarkable flexibility of pathogenic bacteria to dynamically modulate its 
polysaccharide capsule expression highlights the basis of bacterial adaptability 
within its infected host environment and the important role played by the 
polysaccharide capsules for optimal infection. 
 
1.3 POLYSACCHARIDE CAPSULE OF BORDETELLA PERTUSSIS !
1.3.1 Sequencing and Characterization of The Capsule Operon  
 
Like many other encapsulated bacteria, the capsule locus of B. 
pertussis is organized in a single operon, which comprises of three genetic 
regions with ten open reading frames (ORF) involved in polysialic acid 
transport (black arrows), phospholipid modification/export (hashed arrows) 
and biosynthesis (open arrows) that encode a putative type II polysaccharide 
capsule (Figure 1.5) (Hot et al., 2003; Parkhill et al., 2003).  
 
The first and second genes of the B. pertussis capsule operon, kpsM 
and kpsT encode the putative polysialic acid transport and polysialic acid 
transport ATP-binding proteins respectively (Parkhill et al., 2003). The kpsM 
and kpsT genes are organized as a single transcriptional unit with an 
overlapping kpsM stop codon and kpsT start codon, implying that the two gene 
products are likely to be expressed in equal amounts. The polysialic acid 
Chapter 1: Introduction 
! 31!
capsules are a subclass of surface capsules that are well characterized for their 
role in pathogenesis especially in E. coli K1 strain (Bliss and Silver, 1996). In 
E. coli K1, the polysialic acid chain translocation across the inner membrane 
is facilitated by the KpsMT transporter complex at the inner membrane. The 
KpsMT complex is only functional upon interaction of KpsT with KpsM 
coupled with the binding of ATP to KpsT (Figure 1.6) (Bliss et al., 1996; 
Nsahlai and Silver, 2003; Pavelka et al., 1994; Pavelka et al., 1991). Binding 
of ATP to KpsT leads to a conformational change such that the polysialic acid 
associated domain on KpsT can be inserted into the KpsM transporter (Bliss 
and Silver, 1996; Nsahlai and Silver, 2003). This compelling evidence 
suggests that KpsM/KpsT transporters play a central role to the functioning of 
the entire polysaccharide capsule biosynthetic, transport and export machinery 
in E. coli (Bliss and Silver, 1996). The presence of motifs conserved in 
KpsM/T from B. pertussis, E. coli and H. influenzae suggests that KpsM and 
KpsT produced in B. pertussis are likely to form KpsM/T complexes involved 
in ATP-dependent active transport of a polymers.  
 
Predictive sequence analysis of the third ORF in the capsule operon, 
kpsE reveals a putative polysaccharide capsule export inner membrane protein 
that resembles the polysaccharide capsule export KpsE protein of E. coli, the 
CtrB protein of N. meningitides and BexC of H. influenzea. KpsE is located at 
the inner membrane of E. coli, has significant exposure at the periplasmic face 
and directs the export of polysaccharide capsule across the bacterial inner 
membrane (Figure 1.6) (Bronner et al., 1993a; Rosenow et al., 1995). 
Moreover, it has been proposed that KpsE functions in concert with the 
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specialized ABC transporters KpsM and KpsT for a proper translocation of 
polymers across the inner membrane to the periplasmic face (Figure 1.6) 
(Higgins et al., 1990; Rosenow et al., 1995). 
 
The predicted products encoded by the capsular biosynthesis genes 
(Figure 1.5) are homologous to the S. typhi Vi capsular antigen biosynthesis 
enzymes, in particular WbpT and VipC display 33.15% and 23%  homology 
to S. typhi Vi polysaccharide biosynthesis protein TviE and TviD respectively. 
This implies that the products of the capsule locus may be antigenically 
similar to the N-acetyl galactosaminuronic acid Vi antigen polymer. Similar to 
S. typi TviE, WbpT harbors a conserved glycosyltransferease domain, which 
catalyzes the transfer of sugar moieties from activated donor to a specific 
acceptor ranging from lipid, protein or another carbohydrate compound via 
glcosidic bonds (Zhang et al., 2006). These proteins usually transfer UDP, 
ADP, or GDP linked sugars to a variety of substrates and are widely involved 
in the biosynthesis of polysaccharides (Zhang et al., 2006). Little is known 
about the role and function of TviD protein except that a functional TviD is 
required for Vi antigen synthesis in S. typhi (Virlogeux et al., 1995).  
 
In B. pertussis, the central part of the locus (BP1624-BP1631) is intact, 
but the 3' region underwent an inversion event and an insertional sequence 
element-mediated rearrangement, which consists of genes involved in 
export/modification. Therefore, it has been speculated that the capsule genetic 
locus is non-functional in B. pertussis Tahoma I strain due the 
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abovementioned mutations end of the locus (black cross) (Figure 1.5) (Parkhill 
et al., 2003). 
 
!
Figure 1.5: The B. pertussis capsule operon. 
The capsule operon of B. pertussis regulated under the capsule promoter is as 
shown. Black cross represents mutational insertion found at the 3’ end of the 
opeon. Black, hashed and white arrows represent genes involved in 
polysaccharide capsule transport, polysaccharide modification/translocation 




                       !
Figure 1.6: A model of biosynthesis and assembly of group II capsules in 
E. coli. 
In this model, KpsT associate with polysialic acid polymers and translocate it 
via the ABC transporter complex; KpsM and KpsT at the inner membrane. 
The transport requires ATP expenditure. Translocation across the periplasm 
requires KpsE, possibly function as an adaptor protein. Figure adapted with 
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1.3.2 B. pertussis Capsule Controversy 
 
Earlier literature has reported that B. pertussis is capsulated by direct 
visualization using modified Wright’s staining on virulent and avirulent strains 
(Lawson, 1939; Ungar et al., 1954). Nevertheless, the authors also noted that 
the capsular structure observed could not be distinguished from extracellular 
slime layer, thus raising doubts on the significance of this structure in B. 
pertussis (Ungar et al., 1954). Later on, staining with calcofluor exo-
polysaccharide dye revealed that virulent B. pertussis may produce a surface 
capsule that is polysaccharide in nature (Weiss et al., 1989). However, 
calcofluor stains for all types of polysaccharides and cellulose, and thus they 
are considered non-specific dyes in detecting capsular polysaccharides. 
Moreover, conventional capsule stain India ink was unable to conclusively 
reveal the presence of a capsule in B. pertussis. Due to the lack of a capsule-
deficient B. pertussis mutant in all the staining approaches above mentioned it 
is not possible to conclusively demonstrate the presence of a polysaccharide 
capsule produced at the surface of B. pertussis bacteria. Since then, no further 
studies have been reported on the characterization and isolation of the B. 
pertussis polysaccharide capsule.  
 
Transcriptional fusion studies indicated that the B. pertussis capsule 
locus belongs to a new class of vrgs (Antoine et al., 2000), with similar 
modulating profile compared to the group of classical bvg-repressed genes 
vrg6, vrg18, vrg24, vrg53 (Chapter 1.4.1.3) (Beattie et al., 1990; Beattie et al., 
1993). Transcription of the capsule locus was being repressed in the Bvg+ 
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phase but elevated in the presence of MgSO4 in Bvg- phase (Chapter 1.4.1.4) 
(Antoine et al., 2000). Whereas the capsule operon is intact in B. 
bronchiseptica, the genes at the 3’ end of the capsule operon that are involved 
in export/modification of the polysaccharide capsule across the cell wall are 
interrupted in B. pertussis (Parkhill et al., 2003). This observation has led to 
the assumption that B. pertussis is unable to produce an intact polysaccharide 
capsule which thus appeared to be dispensable for pathogenesis in mammalian 
hosts. Furthermore, the reduced expression of this locus in Bvg+ phase virulent 
B. pertussis also supports that the capsule may not be necessary for bacterial 
virulence in Bvg+ phase (Antoine et al., 2000). The controversy regarding the 
presence and functional properties of a polysaccharide capsule in B. pertussis 
has thus remains, which prompted us to undertake a comprehensive study that 
addressed the production and the role of the polysaccharide capsule in 
pertussis pathogenesis.  
 
1.3.3 Biofilm Structures on Bordetella !
The phenomenon of biofilm formation in Bordetella genus has been 
recently reported. Several groups have presented a phenotypic view of the 
formation of biofilm structures in vitro, primarily in the broad host range 
pathogen, B. bronchipseptica and the human pathogen, B. pertussis (Irie et al., 
2004; Mishra et al., 2005; Serra et al., 2007). These studies indicated that 
biofilm formation is dominant in Bvg+ and Bvgi phase, but not in Bvg- phase 
bacteria (Irie et al., 2004; Mishra et al., 2005). Irie and colleagues also 
suggested that co-existing adhesins FHA and fimbriae are necessary for 
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maximum biofilm formation in B. bronchiseptica and that formation of 
biofilm is growth phase-dependent, and particularly increased when bacteria 
reach the stationary phase (Irie et al., 2004; Irie et al., 2006). Although the 
expression of the biofilm-associated carbohydrate components is Bvg-
independent, it appears that the BvgA/S two-component contributes to biofilm 
formation via its regulation of FHA and fimbriae expression (Irie et al., 2006), 
suggesting that a network of one or more macromolecules are involved in the 
formation of Bordetella biofilms.  
 
The genetic element responsible for the biofilm formation was first 
reported in B. bronchispetica and it is known as the Bordetella polysaccharide 
locus or bpsABCD locus, which displays significant sequence similarities with 
the pgaABCD locus in E. coli responsible for the synthesis of poly!β!
1,6!N!acetyl!D-glucosamine (Parise et al., 2007). The nature of B. 
bronchiseptica biofilm is antigenically similar to the extracellular poly!β!
1,6!N!acetyl!D-glucosamine-like material structure which function as surface 
polysaccharide adhesin in E. coli (Parise et al., 2007). Impairment in biofilm 
production in both B. bronchiseptica and B. pertussis due to mutational 
deletion within the bps locus resulted in a reduced bacterial adherence to 
murine nasal cavity and trachea whereas the colonization of murine lungs was 
not affected (Conover et al., 2010; Sloan et al., 2007). The B. bronchiseptica 
bps locus was annotated as BB1769 (bpsA), BB1768 (bpsB) and BB1767 
(bpsC), which is located way upstream of its putative polysaccharide capsule 
locus (BB2918-BB2934). Similarly, the B. pertussis bps locus (BP1942-
BP1944) is physically distinct from the polysaccharide capsule locus (section 
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1.4.1). It was also reported that expression of the bps locus is not under the 
regulation of the BvgA/S two-component system (Conover et al., 2012; Parise 
et al., 2007; Parkhill et al., 2003). Therefore, the biofilm structures observed in 
B. bronchisptica and B. pertussis are independent from the products of the 
capsule locus.  
 
1.3.4 Evidence For An Intact Pertussis Capsule  
 
By constructing a B. pertussis Tohama I derivative mutant deleted for 
the entire 10 kb capsule operon (Parkhill et al., 2003), our laboratory has 
recently demonstrated that B. pertussis BPSM strain produces an intact 
polysaccharide capsule at its bacterial surface using Alcian blue staining 
visualized by transmission electron microscopy (Figure 1.7) and immuno-
detection methods (Neo et al., 2010). The fact that a greater signal was 
obtained when B. pertussis bacteria were grown in Bvg- phase further supports 
that the capsule locus belongs to the family of vrgs (Neo et al., 2010). We 
termed the polysaccharide capsule of B. pertussis as “microcapsule” as it can 
only be visualized by TEM upon Acian blue staining, but not by conventional 
staining and/or light microscopy. Our findings supported earlier studies 
reporting B. pertussis as a capsulated microorganism (Lawson, 1940; Neo et 
al., 2010; Weiss et al., 1989).  
 
We also demonstrated that the B. pertussis capsular polysaccharide is 
not involved in classical capsule-mediated defense mechanisms, including 
adherence to mammalian host cell, complement-mediated killing and 
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antimicrobial attack (Neo et al., 2010). The B. pertussis capsule operon 
belongs to the vrg family with maximal expression in Bvg- phase (Antoine et 
al., 2000; Hot et al., 2003). Despite being categorized as a vrg family member, 
we and others have observed that the capsule operon of B. pertussis was 
transcriptionally active with basal expression detected in Bvg+ phase bacteria 
(Nakamura et al., 2006; Neo et al., 2010). The fact that the capsule locus is 
expressed in virulent Bvg+ phase suggests that this locus may play a role in 













Chapter 1: Introduction 
! 39!
!
Figure 1.7: Visualization of the B. pertussis polysaccharide capsule by 
transmission electron microscopy.  
 
Wild-type B. pertussis BPSM and KOcaps bacteria grown in Bvg- phase 
conditions were fixed, stained with alcian blue, and processed for analysis by 
transmission electron microscopy. Black scale bar on the bottom right of each 
figures represent 100 nm. The images were captured at x120,000 
magnification and x100,000 (for KOcaps on the lower right panel). White 
arrowhead shows the surface microcapsule. Figure adapted with permission 
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1.4 TWO-COMPONENT REGULATORY SYSTEM !
1.4.1 The bvg Regulon in B. pertussis !
1.4.1.1 Structure and function of BvgS !
BvgS is the 136 kDa virulence sensor protein and a member of the 
BvgA/S two-component system signaling in B. pertussis. The bvg locus was 
first identified as a virulence or vir locus crucial for maintaining B. pertussis 
virulent phenotype in vitro (Weiss and Falkow, 1984). It was later described in 
the late 1980s as the single genetic locus responsible for the regulation of the 
expression of major virulence factors in Bordetella sp. such as FHA, PT, AC 
toxin and DNT (Arico et al., 1989; Stibitz et al., 1989; Stibitz et al., 1988; 
Stibitz and Yang, 1991). The bvg locus encodes the BvgA/S two-component 
system, which comprises of BvgA protein, a DNA-binding transcriptional 
regulator and BvgS, the virulence sensor protein (Arico et al., 1989). 
Predictive sequence analysis suggests that bvg locus belongs to the family of 
environmentally sensitive bacterial regulatory systems involved in signal 
transduction in response to environmental stimuli (Ronson et al., 1987). 
Earlier findings have suggested that the BvgA/S system is sensitive to certain 
in vitro stimuli, such as changes in temperature and the presence of salts, for 
instance MgSO4 and nicotinic acid (Melton and Weiss, 1989; Miller et al., 
1989; Stibitz et al., 1988; Weiss and Falkow, 1984). Genetic inactivation on 
the bvgS locus demonstrated that a functional BvgS sensor is absolutely 
necessary for a full transcriptional expression of virulence factors in B. 
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pertussis thus conferring a virulent phenotype (Arico et al., 1989; Miller et al., 
1989; Weiss and Falkow, 1984). 
 
The structural features of BvgS protein comprise of unique multi 
domains segments corresponding to a histidine kinase sensor (Arico et al., 
1989). The BvgS sensor is considered an “unorthodox” histidine sensor 
kinase, as it has a four-step His-Asp-His-Asp phosphorelay transfer as 
opposed to a conventional histidine kinase sensor ubiquitously found in many 
Gram-negative bacteria comprising of two or three-step phosphorelay transfer 
mechanisms (Figure 1.8) (Arico et al., 1989; Stibitz and Yang, 1991; Stock et 
al., 2000). The amino acid sequence at the N-terminal end of BvgS contains 
consensus signal peptide, which harbors the Ala-Gln-Ala signal peptidase 
cleavage site (Ji et al., 1994; Stibitz and Yang, 1991). Adjacent to the signal 
peptide is the first trans-membrane domain of BvgS, transversing the inner 
membrane of B. pertussis in a helical manner, thus supporting the sub-cellular 
localization of BvgS at the inner membrane of the bacteria (Stibitz and Yang, 
1991). This is immediately followed by a large periplasmic domain folding 
into two tandem solute-binding cavities or grooves, presently known as the 
Venus Fly Trap 1 and 2 (VFT1 and VFT2) domains (Figure 1.8) (Herrou et 
al., 2009).  
 
The two VFT domains of BvgS have recently been characterized; they 
share sequence homology with bacterial solute-binding proteins and the 
periplasmic domain is apparently sensitive to BvgS modulators in vitro 
(Herrou et al., 2010; Martinez de Tejada et al., 1996). The ligand-binding 
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cavity within the VFT domains confer a hinge-bending motion; whereby it can 
either adopt an “open” or “close” ligand-binding pocket or cavity 
conformation, thus restricting the binding of specific solute(s) within the 
cavity (Herrou et al., 2010; Herrou et al., 2009; Quiocho and Ledvina, 1996). 
While VFT1 domain is insensitive to BvgS modulators, the VFT2 domain has 
been shown to display a high binding affinity towards a range of BvgS 
modulators, including nicotinic acid (Herrou et al., 2010). The flexibility of 
VFT ligand-binding cavity, and hence as the name “Flytrap” suggests, allows 
for a rapid response to environmental ligands. Unlike common solute-binding 
proteins for which binding of extracellular ligands or agonists at the 
periplasmic receptor results in a close conformational structure (Quiocho and 
Ledvina, 1996), BvgS VFT2 is by default active and adopts a close 
conformation even in the absence of ligands or signals (Herrou et al., 2010). It 
has been proposed that binding of negative signal ligands or antagonists from 
the milieu into VFT2 clef destabilizes and modifies the entire conformation of 
BvgS, resulting in an inactive sensor (Herrou et al., 2010). The unusually 
strong positive electrostatic potential within VFT2 cavity possibly explains for 
the paradoxical nature of this domain in attracting opposite, negatively 
charged organic carboxylates or inorganic ions (Herrou et al., 2010).  
 
Mutations within the PAS domain, or formerly known as the linker 
region located immediately after the second trans-membrane domain (Figure 
1.8), renders BvgS insensitive to environmental modulators, leading to the 
isolation of Bvg-constitutive mutants (Goyard et al., 1994; Manetti et al., 
1994; Miller et al., 1992). Although the exact function of PAS domain in B. 
Chapter 1: Introduction 
! 43!
pertussis is relatively uncharacterized, however by homology, PAS domain in 
most Gram-negative bacteria responds to oxygen concentrations, redox 
potential, light and small ligands (Taylor and Zhulin, 1999). Mutations at the 
BvgS PAS domain (linker region) are dominant over specific mutations at the 
BvgS periplasmic domain (Goyard et al., 1994; Manetti et al., 1994; Miller et 
al., 1992), but this does not exclude the importance of the periplasmic domain, 
including the tandem VFTs domains in stimulus perception. It has been 
recently shown that the integrity of PAS domain of B. pertussis is required for 
communication of signals from the periplasmic to the downstream kinase 
domain of BvgS (Dupre et al., 2013).  
 
A signal integration model has been suggested for B. pertussis by 
which the periplasmic VFT domain initially perceive extracellular signals, 
while the PAS domain transduces the signal recognition events or information 
to the cytoplasmic histidine-kinase (HK) domain, also known as transmitter 
domain, thus initiating the autophosphorylation activity at the His residue on 
the HK domain (Herrou et al., 2010; Herrou et al., 2009; Martinez de Tejada 
et al., 1996). Moreover, biochemical and structural study in E. coli expression 
system reported that dimerization of BvgS takes place at the HK domain, 
which is a common dimerization interface domain for a classical two-
component system and at the receiver-output domain (Figure 1.8) (Beier et al., 
1995). Reconstitution of active phosphotransfer reaction in trans between 
BvgS domains further supports the dimerization capacity of BvgS in vivo 
(Beier et al., 1995; Perraud et al., 2000). Dimerization and higher order 
oligomerization of signaling complexes in general is important for intrinsic 
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phospho-transfer activity and activation of downstream regulator proteins 
(Maeda et al., 2006; Scheu et al., 2010).    
 
The phosphorylation event is successfully transferred downstream 
towards the C-terminal end of BvgS; from histidine-kinase domain to the Asp 
residue on the receiver domain, and next to the His residue on the histidine 
phosphotransfer (Hpt) domain and finally to the Asp residue on the receiver 
domain of BvgA response regulator (Figure 1.8) (Uhl and Miller, 1994). The 
primary output of such phosphorelay mechanism ultimately determines the B. 
pertussis virulence genes expression profile and consequently the virulent 
phenotype of the bacteria.   
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Figure 1.8: Model of an "unorthodox" BvgA/S two-component system in 
B. pertussis. 
The BvgA/S two-component system of B. pertussis, when in an active form, 
participates in a four-step phosphorelay event on B. pertussis BvgS sensor. 
The putative signal perception domain comprised of the periplasmic Venus 
flytrap domains, namely VFT1 and VFT2 domain and the cytoplasmic PAS 
domain. His-Kin denotes the cytoplasmic histidine-kinase and dimerization 
domain where autophosphoylation occurs, similar to a classical two-
component system. Following the autophosphorylation event at the His 
residue on His-Kin domain, the phosphate group is transferred to Asp residue 
on downstream receiver domain and then to the His residue on Hpt domain. 
Finally the phosphate group is transferred to Asp residue on the receiver 
domain of BvgA response regulator.  
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1.4.1.2 Structure and function of BvgA !
As the response regulator or the final phosphate receiver for the 
BvgA/S two-component system, phosphorylation of BvgA would ultimately 
activate its function thus influencing the overall transcription of a group of 
genes known as bvg-regulated genes in B. pertussis (Roy and Falkow, 1991; 
Uhl and Miller, 1994). Phosphorylated BvgA (P-BvgA) auto-regulates its own 
transcription at the bvg promoter, implying a positive regulatory feedback on 
the bvgAS operon. Analysis of the BvgA amino acid sequence predicts a 23-
kDa cytoplasmic protein with an N-terminal phosphate receiver domain and a 
helical C-terminal DNA-binding domain homologous to bacterial DNA-
binding regulatory proteins such as FixJ and UhpA (Arico et al., 1989; 
Boucher et al., 1994; Stibitz and Yang, 1991).  
 
The presence of negative modulators in the extracellular milieu 
represses BvgS sensor activation, thus inhibiting the overall phosphorylation 
of BvgA. P-BvgA protein function as a dimer to activate transcription of bvg-
regulated genes (Scarlato et al., 1990) and the dimerization capacity of P-
BvgA was further supported by several experimental approaches by other 
groups (Beier et al., 1995; Boucher et al., 1994). The mechanism by which P-
BvgA differentially activates the transcription of bvg-regulated genes was 
deciphered from detailed analysis of a few bvg-regulated promoters in B. 
pertussis. DNase foot-printing assay on ptx and fhaB promoters showed 
variable length of protection, implying that each promoter carries multiple P-
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BvgA binding sites, which is consistent with the oligomerization of multiple 
P-BvgA dimers including the RNA polymerase enzyme at the promoter region 
to promote mRNA elongation (Boucher et al., 1997; Boucher and Stibitz, 
1995). The stability of P-BvgA and RNA polymerase complex interaction is 
dependent on the promoter architecture. Studies on fha promoter revealed that 
P-BvgA dimer initially binds to high affinity binding site located far upstream 
of the transcription start site followed by cooperative binding of another set of 
P-BvgA dimers and RNA polymerase to the next, downstream primary and 
secondary binding sites (Boucher et al., 2001a; Boucher et al., 2001b; Steffen 
et al., 1996). The unusually lengthy secondary binding site of ptx promoter 
requires even far more P-BvgA dimers to cooperatively sit on the promoter 
site as compared to fha promoter. Since occupancy of P-BvgA and RNA 
polymerase at the secondary promoter region is necessary to activate gene 
transcription, the ptx promoter is one of the earliest promoters to have its 
activity negatively affected when the levels of P-BvgA decreases (Zu et al., 
1996).  
 
1.4.1.3 Signal-transduction through BvgA/S two-component system: 
Regulation of bvg-activated and bvg-repressed gene 
 
Production and modulation of the great majority of virulence factors in 
B. pertusssis are coordinately regulated by the BvgA/S two-component 
system. It is essential for B. pertussis to rapidly program its cellular responses 
by modifying its genes expression to adapt to environmental changes (Melton 
and Weiss, 1989). As described in the above section, BvgA/S activation is 
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characterized by a sophisticated His-Asp-His-Asp phosphorelay transfer 
mechanism from the trans-inner membrane sensor; BvgS to the cytoplasmic 
transcriptional activator; BvgA (Cotter and Jones, 2003; Uhl and Miller, 
1994). In vitro, BvgA/S system is active when bacteria are grown at 37°C, 
corresponding to the normal human body temperature, and in the absence of 
known negative modulators such as MgSO4 or nicotinic acid. Under these 
conditions, also known as virulent Bvg+ phase, high intracellular 
concentrations of P-BvgA are reached thereby allowing the activation of bvg-
activated promoters, and leading to the up-regulation of a subset of genes 
important for virulence, referred to as bvg-activated genes (vag) (Figure 1.9A). 
The Bvg+ phase plays a central role in B. pertussis pathogenesis (Cotter and 
Jones, 2003; Cotter and Miller, 1994). In addition, transcription of another set 
of genes known as bvg-repressed genes (vrg) is repressed in Bvg+ phase by the 
vag-encoded transcriptional repressor protein, BvgR (See section 1.4.1.5) 
(Merkel et al., 2003). In contrast, the BvgA/S system is inactive when bacteria 
are grown at temperature lower than 26°C or in the presence of milimolar 
concentrations of MgSO4 or nicotinic acid in the culture media (Figure 1.9A) 
(Melton and Weiss, 1993). Under these culture conditions, B. pertussis 
bacteria are in avirulent Bvg- phase, which is characterized by minimal 
expression of vags and maximal expression of vrgs as well as outer membrane 
proteins of unknown function (Vra proteins) (Stenson and Peppler, 1995). 
However, gene products that are negatively regulated by the BvgA/S two-
component in B. pertussis such as Vrg6 and Vra proteins and in B. 
bronchiseptica such as flagella, sidephore alcaligin, urease do not appear to be 
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involved in pertussis pathogenesis (Akerley et al., 1992; Giardina et al., 1995; 
Knapp and Mekalanos, 1988; McMillan et al., 1996).   
 
Although the activity of BvgA/S two-component system can be easily 
tweaked under laboratory conditions, the true signals perceived by the BvgS 
sensor during host infection have yet to be defined. Current understanding of 
the BvgA/S-signaling pathway suggests that in vitro B. pertussis cultures do 
not require any positive signals to activate the BvgA/S two-component 
system, active by default. However, recent studies interestingly provided some 
evidence that BvgS is able to perceive a positive stimulus in the environment. 
Experiments by Hester and colleagues recently showed that Bordetella sp. 
bacteria are able to modulate the expression of virulence genes in response to 
experimental in vivo levels of carbon dioxide (Hester et al., 2012). By 
exposing B. pertussis and B. parapertussis to 5% carbon dioxide, an increase 
in the expression of virulence gene transcripts encoding FHA, AC toxin, 
fimbriae, pertactin and type III secretion system was observed (Hester et al., 
2012). In another study, BvgS response to potential in vivo stimulus, likely via 
the PAS domain has been directed to redox signals; for instance the kinase 
activity was abolished when purified truncated form of BvgS is exposed to 
oxidized ubiquinone (Bock and Gross, 2002). 
 
1.4.1.4 Phenotypic modulation 
 
Rather than an on/off switch, the phenotypic transition between Bvg+ 
and Bvg- phase functions like a rheostat and an intermediate phase, namely 
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Bvgi has more recently been described (Figure 1.9) (Cotter and Miller, 1997; 
Jones et al., 2005; Scarlato et al., 1991; Williams and Cotter, 2007). This 
distinct intermediate Bvgi phase between the Bvg+ and Bvg- phases can be 
observed experimentally when B. pertussis bacteria are grown in vitro at 
concentration of nicotinic acid and MgSO4 below those that induce the Bvg- 
phase (Cotter and Miller, 1997). This Bvgi phase is characterized by maximal 
expression of adhesins, surface localized factor, BipA as well as repression of 
toxins expression (Deora et al., 2001; Stockbauer et al., 2001). Interestingly, 
the Bvgi phase-locked mutant of B. pertussis was able to persist only at the 
upper murine respiratory tract, leading to the postulation that Bvgi phase is 
probably necessary for the transmission of B. pertussis from one host to 
another (Vergara-Irigaray et al., 2005). The role of the vrg-encoded products 
family in B. pertussis virulence has not been clearly established; a Bvg+ phase-
locked B. pertussis mutant has been described to colonize and establish 
infection in mice as efficiently as the wild-type strain, suggesting that the 
virulent Bvg+ phase is necessary and sufficient for respiratory infection 
(Martinez de Tejada et al., 1998). The bvg-mediated changes on the 
transcriptional profile in response to environmental signals are also referred to 














Figure 1.9: Signal transduction through BvgA/S two-component system 
and regulation of vags and vrgs. 
(A) The BvgA/S two-component signalling event.! Left panel: BvgA/S 
system is inactive under modulating conditions in the presence of MgSO4, 
nicotinic acid and environmental temperature at 25°C, which is referred to as 
Bvg- phase. Right panel: BvgA/S system is active standard growth 
temperature, which ultimately leads to the transfer of phosphate group to the 
response regulator BvgA. Phosphorylated BvgA then binds to the promoter 
region of vags and activates its transcription, which is referred Bvg+ phase. 
Intermediate phase, referred to Bvgi phase where concentration of nicotinic 
acid and MgSO4 is below the concentration used to induced the Bvg- phase. 
(B) Phenotypic transition from Bvg- to Bvgi to Bvg+ phase. Each of the 
phases corresponds to differential expression level of various virulence genes.  
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1.4.1.5 BvgR: A repressor for bvg-repressed genes 
 
The fact that the group of vrgs are repressed in Bvg+ phase under 
37°C, but elevated at a Bvg- phase temperature below 25°C (presumably the 
temperature outside of the infected host), suggests that vrgs may be necessary 
for transmission of aerosolized bacteria into the outside environment from one 
host to another. The bvgR locus, located immediately downstream the bvgAS 
locus is directly and positively regulated by the BvgA/S two-component 
system in Bvg+ phase (Merkel et al., 1998). The bvgR locus encodes the BvgR 
repressor protein, which in turn mediates the transcriptional repression on vrgs 
promoter (Merkel et al., 1998; Merkel and Stibitz, 1995).  
 
In the presence of negative modulators Bvg- phase, BvgA/S system is 
inactive with low intracellular levels of P-BvgA thus resulting in low 
expression of the BvgR repressor. Repression on vrgs promoters is thus 
relieved; therefore allowing effective transcription of vrgs in Bvg- phase. In 
addition, a BvgA/S-independent transcriptional factor, RisA was found to 
promote the transcription of some vrgs in Bvg- phase (Section 1.4.2) (Croinin 
et al., 2005). However, there has been to date no direct experimental evidence 
demonstrating how BvgR mediates the repression of vrgs in B. pertussis. A 
direct DNA binding of BvgR onto the vrgs promoter region was postulated 
based on sequence homology with a putative transcriptional regulator (Beattie 
et al., 1993; Galperin et al., 2001). Alternatively BvgR might exert its 
repressive effect on vrgs expression indirectly through the modulation of the 
transcriptional regulator of vrgs, RisA. The protein sequence of BvgR 
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revealed a unique and conserved EAL domain (Merkel et al., 1998), which can 
be found in a variety of signaling proteins involved in controlling the levels of 
bacterial second messenger, c-di-GMP (D'Argenio and Miller, 2004; Galperin 
et al., 2001). By modulating the intracellular levels of c-di-GMP, the EAL 
domain has been implicated in regulating a diversity of bacterial phenotypes, 
including biofilm formation (Cotter and Stibitz, 2007). In B. pertussis, it is 
hypothesized that BvgR acts as a putative c-di-GMP phosphodiesterase, which 
modulates the activity of RisA through control of the intracellular levels of c-
di-GMP (Stibitz, 2001). Further experimental evidence is warranted to 
elucidate the crosstalk between c-di-GMP signaling with BvgR and RisA in B. 
pertussis.  
 
1.4.2 The ris Regulon in B. pertussis !
1.4.2.1 Discovery of RisA/S two-component system  
 
In addition to the BvgA/S regulatory system, a second two-component 
regulatory system known as the RisA/S system was identified in all Bordetella 
sp. (Jungnitz et al., 1998). The risA-risS locus shares a high degree of 
homology with the ompR-envZ locus in E. coli, which is involved in the 
regulation of genes in response to osmolarity, and to the S. typhi phoP-phoQ 
locus, which is required for bacterial survival within macrophages (Jungnitz et 
al., 1998; Zimna et al., 2001). A functional RisA/S system is required for B. 
bronchiseptica to resist against oxidative stress and regulating the production 
of acid phosphatase necessary for intracellular survival (Jungnitz et al., 1998; 
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Zimna et al., 2001). However, the RisA/S system of B. bronchiseptica is 
considered as an ortholog to E. coli OmpR-EnvZ system, as the RisA/S 
system does not respond to extracellular osmolarity signals (Stenson et al., 
2005). A risAS-deleted B. bronchispetica mutant strain displayed significant 
attenuation of its ability to colonize the mouse respiratory tract and reduced 
intracellular survival in macrophages, suggesting that the ris locus, 
presumably via the ris-regulated products are necessary for bacterial virulence 
(Jungnitz et al., 1998; Zimna et al., 2001).  
!
Sequence analysis of the risAS locus in B. pertussis Tohama I strain 
revealed a frameshift mutation within the risS locus with a pre-mature stop 
codon, suggesting that RisS in B. pertussis lacks the Enz-like transmitter and 
autophosphorylation domain (Stenson et al., 2005). However, the risS 
frameshift mutation is absent in B. bronschisptica strains. Located 
immediately downstream the risS locus is the risA locus, whose amino acid 
sequences share almost 65% identity with E. coli OmpR protein (Stenson et 
al., 2005), the risA locus is co-transcribed with the risS locus as a single 
operon. The risAS operon in B. pertussis BP536 strain was identified to 
govern and activate the full expression of bvg-repressed surface products 
VraA and VraB, under modulating conditions, but it does not regulate the 
expression of vags. Furthermore, the risA and risS locus expression is 
independent of BvgA/S regulation (Stenson and Peppler, 1995). 
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1.4.2.2 Regulation of vrgs by transcriptional factor RisA and repressor 
BvgR  
 
Purified transcriptional RisA was found to be able to bind onto the 
promoter of the bvg-repressed genes vrg6 and vrg18 in B. pertussis BP536 
strain (Croinin et al., 2005), suggesting that vrg6 is directly regulated by RisA. 
Due to the insolubility of BvgR protein, similar approach was not successful 
in an attempt to study the promoter binding capacity of the repressor protein 
(Croinin et al., 2005). However, results obtained with a bvgR-deleted mutant 
implied that BvgR is required for the repression of vrgs under Bvg+ phase, but 
does not regulate the expression of RisA (Croinin et al., 2005). It was 
speculated that repressor BvgR acts either by binding to the vrg6 promoter 
thus competing with the binding of RisA, or by affecting the function or 
activity of RisA protein via c-di-GMP signaling (section 1.3.1.5) (Croinin et 
al., 2005). However, the authors failed to fully demonstrate the conclusive 
relationship between BvgR and RisA on the regulation of bvg-repressed genes. 
As all B. pertussis strains display a frameshift mutation within the risS locus, 
risA activation is believed to be independent of RisS. Phospho-activation of 
OmpR in an envZ-deleted E. coli mutant suggests that OmpR can be 
phosphorylated by another regulatory system besides the EnvZ sensor kinase 
(Forst et al., 1990). It is unclear how RisA is activated and possible 
speculation includes activation through another sensor kinase via a molecular 
crosstalk either with the BvgA/S sytem or with another two-component 
system in B. pertussis. At this stage, it is unclear whether RisA and BvgR 
regulate the capsule locus expression in B. pertussis.  
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1.5 RATIONALE AND OBJECTIVES 
 
The first and major aim of this thesis is to address the role of the 
capsule locus in pertussis pathogenesis and characterize the mechanisms 
involved (Chapter 3). To do so, mutants deleted for ORF involved in the 
transport, export and biosynthesis of the capsular polysaccharide have been 
generated and their in vivo and in vitro phenotypes have been studied. A 
combination of molecular biology and biochemistry approaches has allowed 
us to demonstrate a novel and unique mechanism by which the capsule locus 
is involved in B. pertussis virulence.   
 
 In the second part of this thesis (Chapter 4), we aimed at characterizing 
the expression of the capsule locus in various environmental conditions that 
include in vitro, ex vivo (macrophage infection) and in vivo (mouse model of 
pertussis) conditions. Furthermore, there has been increasing evidence of some 
co-regulation between the BvgA/S (via BvgR) and RisA/S two-component 
systems to modulate the expression of vrgs in B. pertussis (see section 
1.3.2.2). However, the regulation of the capsule locus has not been 
investigated in details. We thus studied the regulation of the capsule locus 
expression by BvgR and RisA. 
 
 Re-emergence of pertussis cases in adult population has been 
increasingly reported, suggesting that current vaccination fail to provide long-
term protection against pertussis infection. Understanding how the capsule 
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locus in B. pertussis affects bacterial virulence opens up opportunities to 
exploit it, either by developing new vaccine, drug target or improving current 
vaccination strategies. Moreover, study on the regulation of a bvg-repressed 
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CHAPTER 2 MATERIALS AND METHODS !
(A) ESCHERICHIA COLI WORK !
2.1 BACTERIAL STRAINS, PLASMIDS AND GROWTH 
CONDITIONS  !
2.1.1 E. coli Strains and Plasmids !
 The E. coli strains and plasmids used or generated in this study are 








For general purpose cloning, blue/white 





Ampr, Kanr; high copy number TA 
cloning vector with single 3’thymidine 
overhangs and covalently-bound 
Topoisomerase I, LacZα gene for 
blue/white screening 
Invitrogen 
pBR322 Ampr, Tetr; medium to low copy number 
plasmid, used as an intermediate plasmid  




Gmr, Sms; low copy number suicide 




pBBR1MCS Cmr; broad-host-range cloning vector (Elzer et al., 
1995) 
pUC19 Ampr; High copy number cloning vector; 
LacZα gene for blue/white screening 
(Yanisch-Perron 
et al., 1985) 
pUC57 Ampr; high copy number E. coli cloning 
vector derived from pUC19 
Genescript 
Plasmids for ∆kpsT cloning 
TOPO-T1 Ampr, Kanr; TOPO® derivative 
containing the PCR1 (kpsM) insert 
This study 
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flanked by BamHI and NheI restriction 
sites  
TOPO-T2 Ampr, Kanr; TOPO® derivative 
containing the PCR2 (kpsE) insert 
flanked by NheI and HindIII restriction 
sites  
This study 
pBR-T1 Ampr, Tetr; pBR322 derivative 
containing the PCR1 insert flanked by 
BamHI and NheI restriction sites  
This study 
pBRT1-2 Ampr, Tetr; pBR322 derivative 
containing the PCR1 + PCR2 fragment 





Gmr, Sms; pJQ200mp18-rpsl derivative 
containing the PCR1 + PCR2 flanked by 
BamHI and HindIII restriction sites, used 
for the construction of ΔkpsT 
This study 
Plasmids for ∆kpsE cloning 
TOPO-E1 Ampr, Kanr; TOPO® derivative 
containing the PCR1 (kpsT) insert 
flanked by EcoRI and HindIII restriction 
sites  
This study 
TOPO-E2 Ampr, Kanr; TOPO® derivative 
containing the PCR2 (wbpT) insert 
flanked by HindIII and BamHI restriction 
sites  
This study 
pBR-E1 Ampr, Tetr; pBR322 derivative 
containing the PCR1 insert flanked by 
EcoRI and HindIII restriction sites  
This study 
pBRE1-2 Ampr, Tetr; pBR322 derivative 
containing the PCR1 + PCR2 fragment 





Gmr, Sms; pJQ200mp18-rpsl derivative 
containing the PCR1 + PCR2 flanked by 
EcoRI and BamHI restriction sites, used 
for the construction of ΔkpsE 
This study 
Plasmids for ∆vipC cloning 
pJQV1-2 Gmr, Sms; pJQ200mp18-rpsl derivative 
containing the PCR1 + PCR2 flanked by 
EcoRI and BamHI restriction sites, used 
for the construction of ΔvipC 
This lab (Neo 
Y.L) 
Plasmids for complementation of ∆kpsT mutant  
pUC57-Pcaps Ampr; pUC57 derivative containing 866 
bp of native B. pertussis capsule 





Cmr; pBBR1MCS derivative containing 
B. pertussis kpsT ORF flanked by BamHI 
This study 
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and HindIII restriction sites 
pBBR::Pcapsk
psT 
Cmr; pBBR1MCS derivative containing 
native B. pertussis capsule promoter and 
kspT ORF flanked by XbaI and HindIII 
restriction sites 
This study 
Plasmids for KOcaps mutant expressing the kpsT and kpsMT ORFs 
TOPO-Pcaps2 Ampr, Kanr; TOPO® derivative 
containing 858 bp of native B. pertussis 
capsule promoter flanked by XbaI and 
BamHI restriction sites (using pUC57-




Cmr; pBBR1MCS derivative containing 
native B. pertussis capsule promoter and 
kspT ORF flanked by XbaI and HindIII 
restriction sites 
This study 
pUC57-kpsMT Ampr; pUC57 derivative containing 1529 
bp B. pertussis kpsM and kpsT ORFs 
flanked by BamHI and HindIII restriction 
sites 
This study 
pBBR-kpsMT Cmr; pBBR1MCS derivative containing 
1529 bp B. pertussis kpsM and kpsT 





Cmr; pBBR1MCS derivative containing 
native B. pertussis capsule promoter and 
kspM + kpsT ORFs flanked by XbaI and 
HindIII restriction sites 
This study 
Plasmids for His6-BvgS cloning 
TOPO-
BvgAS-PCR1 
Ampr, Kanr; TOPO® derivative 
containing the PCR1 (bvgA and bvgS) 
insert flanked by BamHI and XbaI 





Ampr, Kanr; TOPO® derivative 
containing the PCR2 insert flanked by 





Gmr, Sms; pJQ200mp18-rpsl derivative 
containing the PCR1 + PCR2 flanked by 
BamHI and HindI restriction sites  
This study 
pJQSY4 Gmr, Sms; pJQ200mp18-rpsl derivative 
containing the PCR1 + PCR2 flanked by 
SalI and EcoRI restriction sites, used for 
the construction of KOcaps mutant 
(Neo et al., 
2010) 
Plasmid for over-expression of risA 
TOPO-Pfha Ampr, Kanr; TOPO® derivative 
containing fha promoter insert flanked by 
KpnI and BamHI restriction sites  
This study 
TOPO-PrecA Ampr, Kanr; TOPO® derivative 
containing recA promoter insert flanked 
by HindIII and BamHI restriction sites  
This study 
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TOPO-risA Ampr, Kanr; TOPO® derivative 
containing risA insert flanked by BamHI 




Cmr; pBBR1MCS derivative containing 
native fha promoter insert and risA ORF 




Cmr; pBBR1MCS derivative containing 
native recA promoter insert and risA ORF 
flanked by HindIII and XbaI restriction 
sites  
This study 
Plasmid for cloning of ΔrisAS 
TOPO-RisAS-
PCR1 
Ampr, Kanr; TOPO® derivative 
containing the PCR1 (risA) insert flanked 




Ampr, Kanr; TOPO® derivative 
containing the PCR2 (ahpC) insert 
flanked by NheI and HindIII restriction 
sites  
This study 
pJQrisAS1+2 Gmr, Sms; pJQ200mp18-rpsl derivative 
containing the PCR1 + PCR2 flanked by 
BamHI and HindIII restriction sites, used 
for the construction of ΔrisAS mutant 
This study 
 
Table 2.1: E. coli strain and plasmid 
!
2.1.2 Growth Conditions  
 
 All E. coli strains were grown at 37°C overnight in 3 ml of fresh Luria-
Bertani broth (Difco, Detroit, Mich.) with shaking at 220 rpm or on LB agar 
(Difco) plates. When appropriate, 100 µg/ml ampicillin, 50 µg/ml kanamycin, 
10 µg/ml gentamicin and 30 µg/ml chloramphenicol were added to select for 
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2.2 MOLECULAR BIOLOGY !
2.2.1 List of Primers  
 
 The list of primers that were used for cloning, screening and/ or 
sequencing in E. coli is as shown in Table 2.2. When necessary, primers used 
to amplify inserts had appropriate restriction sites added at their 5’ ends 
(shown in bold and underlined) to facilitate subsequent cloning work. 
Annealing temperature (Ta) was calculated according to the following 
equation:  [(4 x NG/C) + (2 x NA/T)]– 5, where NG/C is the number of G and C 
bases and NA/T is the number of A and T bases.  
Oligo 
name 
Sequence (5’ to 3’)  Description 
Primers for ∆kpsT cloning 
kpsM1F ttggatcctgtccaccaccatctacgtggtgt 
kpsM2R ttgctagccagctccatgccgcagatca 
Forward and reverse 
primers to amplify 
PCR1 (kpsM) fragment  
kpsE1F ttgctagccttggacgaaaccatcgcgc 
kpsE2R ttaagcttgccagctgcagattggcctc 
Forward and reverse 
primers to amplify 
PCR2 (kpsE) fragment !
Primers for ∆kpsE cloning 
kpsT1F ttgaattccgcatgatctgcggcatcga 
kpsT2R ttaagcttgacatactggtcggacgcaat 
Forward and reverse 
primers to amplify 
PCR1 (kpsT) fragment  
wbpT7F ttaagcttgaggccaatctgcagctggc 
wbpT6R ttggatcctatgcccgcggcgcggctt 
Forward and reverse 
primers to amplify 
PCR2 (wbpT) fragment  
Primers for ∆kpsT mutant complementation cloning/screening 
kpsTcomF ttggatcccgttgatggagacggccatg 
kpsTcomR ttaagctttcaggattgctcagcgtcgac 
Forward and reverse 
primers to amplify B. 
pertussis kpsT ORF 







Forward and reverse 
primers to amplify B. 
pertussis capsule 
promoter (Pcaps2) 
using pUC57-Pcaps as 
template 
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Forward and reverse 
primers to amplify 
PCR1 from 3’ end of 
bvgA ORF to 5’ end of 











Forward and reverse 
primers to amplify 
PCR2 downstream of 




for six histidines 
Primers for risA over-expression 
Pfha-F ttggtacctttgagtttcgtggcgag 
Pfha-R ttggatcccatattccgaccagcgaagtgaag 
Forward and reverse 




Forward and reverse 
primers to amplify B. 







Forward and reverse 
primers to amplify B. 
pertussis risA ORF 







Forward and reverse 
primers to amplify 







Forward and reverse 
primers to amplify 
PCR2 (ahpC) fragment 
Prmers for sequencing 
M13-F gtaaaacgacggccag 
M13-R caggaaacagctatgac 
Forward and reverse 




Table 2.2: Primers used for E. coli work !!!
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2.2.2 Polymerase Chain Reaction  !
2.2.2.1 Polymerase Chain Reaction  
 
All PCR reactions were carried out using HotStarTaq® PCR kit 
(Qiagen, Hilden, Germany) or GoTaq® DNA polymerase (Promega, MA, 
Wisconsin) with suitable primer pairs (Table 2.2). A 50 µl reaction mix was 
set up for each of the PCR amplification according to the manufacturer’s 
instruction. Amplification was conducted in the GeneAmp® PCR system 2400 
thermal cycler (PE Applied Biosystem, CA, USA) with initial denaturation 
step of 95°C for 15 min or 2 min, followed by 25-35 cycles of DNA 
denaturation at 95°C for 45 s, primer annealing at suitable Ta for 50 sec -1 
min, and DNA elongation at 72°C for 1 min-2 min depending on the size of 
the product to be amplified (approx. 1 min / kb of DNA template). A final 
extension step of 5-10 min at 72°C was also included, after which the reaction 
was maintained at 4°C in the machine. !
 
2.2.2.2 Colony PCR screening  !
A loopful of bacteria was dissolved in 30 µl of ultrapure water, heated 
at 95°C for 10 min and centrifuged at 13,000 rpm for 5 min. PCR was 
performed as described in Section 2.2.2.1 for 35 cycles, using 2 µl of the 
supernatant as template.  
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2.2.3 Restriction Enzyme Digestion  !
DNA digestion was performed with appropriate restriction enzymes 
(RE) with their corresponding buffers (New England Biolabs, Ipswich, MA) 
following the manufacturer’s protocol. A one-step digestion of 1-2 h at 37°C 
was performed in case of single RE or when two REs share the same buffer. 
Sequential digestion was carried out when two or more REs have incompatible 
buffers. In this scenario, the first RE was heat-inactivated according to 
manufacturer’s instructions, followed by membrane dialysis (Millipore, 
Billerica, MA) against deionized water for 10 min prior to setting the digestion 
reaction with the second RE. The restriction profile was analyzed by DNA gel 
electrophoresis (Section 2.2.4). 
 
2.2.4 Agarose Gel Electrophoresis !
2.2.4.1 Gel migration 
 
DNA/RNA electrophoresis was performed using 0.8% to 1.5% agarose 
in 1x Tris-Acetate (TAE) running buffer (0.04 M Tris-Acetate and 0.0001 M 
ethylenedinitrilo tetraacetic acid (EDTA), pH 7.8). Each DNA/RNA sample to 
be analyzed was mixed with 1/5 volume of blue/orange 6x loading dye 
(Promega) containing 0.4% orange G, 0.03% bromophenol blue, 0.03% 
xylene cyanol FF, 15% Ficoll® 400, 10 mM Tris-HCl (pH 7.5) and 50 mM 
EDTA (pH 8.0) prior to loading into gel wells. 6 µl of 1 kb or 100 bp DNA 
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ladder (Promega) were used as markers to estimate bad sizes. Electrophoresis 
was carried out at 100 V for 45 min, after which the gel was stained in 0.5 
µg/ml of ethidium bromide (Invitrogen, Carlsbald, CA) for 15 min before 
visualization under a ultra-violet (UV) transilluminator (ChemiGenius, 
Syngene, UK). 
 
2.2.4.2 Gel extraction 
 
After agarose DNA electrophoresis, DNA fragments of interest were 
excised from agarose gel under low UV light (366 nm) to prevent DNA 
damage. The DNA fragments were purified directly using the QIAquick Gel 
Extraction and PCR Purification Kit (Qiagen) as described in the 
manufacturer’s protocol. 
 
2.2.5 Plasmid Extraction 
 
Plasmid DNA was isolated and purified using the QIAprep Spin 
Miniprep Kit (Qiagen) or GeneJET Plasmid Miniprep Kit (Thermo, Waltham, 
MA) according to the manufacturer’s instructions. High and low copy 
plasmids were eluted in 50 and 20 µl of elution buffer respectively. 
 
2.2.6 DNA Cloning 
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 Digestion with appropriate RE(s) was performed on plasmids to open 
up the cloning vectors and to generate DNA inserts. Both digested vectors and 
inserts were electrophoresed on agarose gel and the DNA bands of interest 
were excised and purified from the gel as described in Section 2.2.4.2. 
Cloning of inserts into the TOPO® vector was performed using the TOPO® TA 
Cloning Kit (Invitrogen), while DNA inserts were ligated into pBR322, 
pBBR1MCS and pJQ vectors using the Fast-Link DNA Ligation Kit 
(Epicentre Technologies, Madison, WI) or Takara DNA Ligation Kit (Otsu, 
Shiga, Japan) according to the manufacturer’s protocol. !
2.2.7 Transformation of Chemically Competent E. coli 
 
 Chemically competent One Shot® TOP10 E. coli (Invitrogen) were 
transformed with slight modifications from the manufacturer’s protocol. Half 
of the ligation mix (section 2.2.6) was added into one vial of TOP10 cells and 
mixed gently. The vial was incubated on ice for 30 min, followed by heat 
shock at 42ºC for 45 s. The tube was immediately transferred on ice and 500 
µl of LB medium without antibiotics was added to the mixture. After 
incubation at 37ºC for 1 h, 100 µl of the transformation mixture was plated on 
LB agar supplemented with appropriate antibiotics or on imMediaTM Amp 
Blue ready-mix agar (Invitrogen) for blue-white screening selection. The 
plates were incubated at 37ºC overnight.  !!!
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!
2.2.8 DNA sequencing 
 
 
Plasmids from the recombinant clones were sent for DNA sequencing 
(AIT Biotech) with suitable primers (Table 2.2). Alignment of the obtained 
sequences with the relevant nucleotide databases was performed using the 
NCBI BLAST programme (http://blast.ncbi.nlm.nih.gov/) and the sequence 
alignment programme ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/).  
 
(B) BORDETELLA PERTUSSIS WORK !
2.3 BACTERIAL STRAINS AND GROWTH CONDITIONS !
2.3.1 B. pertussis Strains !
The B. pertussis strains used in this study are listed in the table below.  
Strain Description Source/ 
Reference 
BPSM TohamaI derivative, mutant rpsL; 
Sm resistance  
Pasteur Institute 
of Lille 












KOcaps BPSM carrying an in-frame (Neo et al., 2010) 
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deletion from kpsM to wcbO 
ORFs 
ΔkpsT  BPSM carrying an in-frame 
deletion in kpsT ORF 
This study 
ΔkspE  BPSM carrying an in-frame 
deletion in kpsE ORF 
This study 
ΔvipC  BPSM carrying an in-frame 
deletion in vipC ORF 
This lab (Neo 
Y.L.) 
ΔkpsTcom BPSM carrying an in-frame 
deletion in kpsT ORF containing 
vector pBBR::Pcaps-kpsT 
This study 
BvgS-VFT2 BPSM carrying amino acid 
substitution at F375E and Q461E 
at the periplasmic VFT2 domain  




BvgS-VFT2 carrying an in-frame 
deletion in kpsT ORF 
This study 
KOcaps:kpsT KOcaps containing vector 
pBBR::Pcaps-kpsT 
This study 
KOcaps:kpsMT KOcaps containing vector 
pBBR::Pcaps-kpsMT 
This study 
BPSH BPSM derivative expressing his-
tagged BvgS at the N-terminal  
This study 
BPSH-KOcaps BPSH cotaining an in-frame 
deletion from kpsM to wcbO 
ORFs 
This study 
BPSH-ΔkpsT  BPSH carrying an in-frame 




BPSH carrying an in-frame 















BPSM containing vector 
pBBR1MCS 
This study 
ΔbvgAS BPSM carrying an in-frame 
deletion in bvgAS ORF 









ΔbvgAS containing vector 
pBBR::PrecA-risA 
This study 
ΔrisAS BPSM carrying an in-frame 
deletion in risAS ORF 
This study 
 
Table 2.3: B. pertussis strains 
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2.3.2 Growth Conditions  !
All B. pertussis strains were grown at 37ºC on pre-warmed sterile 
Bordet-Gengou (BG) agar (Difco) supplemented with 1% glycerol and 10% 
defibrinated sheep blood or in pre-warmed sterile modified Stainer-Scholte 
(SS) medium containing 1 g/L 2,6-O-dimethyl-ß-cyclodextrin (Sigma) as 
described previously (Menozzi et al., 1991a). When appropriate, 10 µg/ml 
gentamicin, 100 µg/ml streptomycin, 30 µg/ml chloramphenicol or 0.05 µg/ml 
of erythromycin (Sigma) were added to select for antibiotic-resistant strains. 
For EDTA treatment assay, B. pertussis strains grown on BG agar for 24 h 
were adjusted to initial OD600nm of 0.02. The bacterial suspension (50 µl) was 
incubated with 1 or 2 mg/ml of EDTA for 2  h at 37°C. Treated and untreated 
controls were serially diluted and plated onto BG agar. The number of CFU 
(colony forming units) was determined after 3-4 days incubation at 37°C.  
 
2.4 MOLECULAR BIOLOGY 
2.4.1 List of primers  !
The list of primers that were used for screening of B. pertussis strain 




Sequence (5’ to 3’)  Description 




Forward and reverse primers to 
amplify upstream of PCR1 
(kpsM) for screening 




Forward and reverse primers to 
amplify downstream of PCR2 
(kpsE) for screening 
kpsEKO1F attctcgatgacgtgtcgttcg 
kpsEKO1R atcaccgtgtacagcacctgg 
Forward and reverse primers to 
amplify upstream of PCR1 




Forward and reverse primers to 
amplify upstream of PCR2 




Forward and reverse primers to 




Forward and reverse primers to 
amplify upstream of 5’ kpsM 





Forward primer binds to the six 
histidine coding nucleotides 
and reverse primer bind 






Forward and reverse primers 
flanking the six histidine 
coding nucleotides used for 
sequencing  
Primers for PCR screening of B. pertussis strain over-expressing risA 
Pfha-F acttcacttcgctggtcggaa 
risA-R cgggttgaagggcttggaca 
Forward and reverse primers to 
screen for pBBR::Pfha-risA 
plasmid in BPSM  
precArisA-F ggatacgcatgcgtgcaacat 
precArisA-R cgggttgaagggcttggaca 
Forward and reverse primers to 
screen for pBBR::PrecA-risA 
plasmid in BPSM and ΔbvgAS 





Forward and reverse primers 
flanking to screen for 
pBBR::Pfha-risA plasmid   
AhpD-Fp acgtacggataccaggtgtt 
risA-Rp ctgctggttctcgacctgatg 
Forward and reverse primers 
flanking the risAS deleted 
region 
Primers for Southern blot probe synthesis 
kpsTKO1F atcgagccgatcctgcacgt 
kpsT3R cgaacgacagctcatcgagaat 
Forward and reverse primers to 
amplify probe for screening of 




Forward and reverse primers to 
amplify probe for screening of 
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Forward and reverse primers to 
amplify probe for screening of 
BPSH-KOcaps mutant 
 
Table 2.4: Primers used for B. pertussis PCR screening work and 
Southern blot !!
2.4.2 Transformation of B. pertussis !
2.4.2.1 Preparation of electrocompetent cells 
 
10 ml of bacteria exponentially grown up to OD600 3 to 4 in SS 
medium were centrifuged at 7,000 rpm for 10 min at room temperature. The 
bacteria pellet was washed 3 times with 10 ml of sterile 10% glycerol. After 
the final wash, the pellet was re-suspended in 1 ml of 10% glycerol and the 
cells were immediately used for electroporation.  
 
2.4.2.2 Electroporation of plasmid DNA into B. pertussis !!
About 1 µg of plasmid DNA was mixed with 200 µl of 
electrocompetent B. pertussis cells in an electroporation cuvette (0.2 cm) 
(Biorad) and incubated on ice for 5 min. An electrical pulse of 2.5 kV, 800 Ω 
resistance and 25 µF capacitance was administered. 1 ml of pre-warmed SS 
medium without antibiotics was added to recover the bacteria cells, which 
were then incubated for 5 h at 37°C with shaking. 200 µl of bacteria cells were 
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plated onto pre-warmed BG agar plates containing appropriate antibiotics and 
incubated for 5-7 days at 37°C. !!
2.4.3 Selection of Transformants !
Gentamicin-resistant (Gmr) colonies obtained upon electroporation 
were patched first onto streptomycin then on gentamicin plates. Streptomycin 
sensitive (Sms) and Gmr clones were observed within 24 h and were identified 
as transformants that have successfully undergone first event of 
recombination. These intermediate transformants were then streaked onto a 
Sm plate to select for the second event of recombination. After incubation 5-7 
days at 37°C, isolated Smr colonies were then patched first onto Gm then onto 
Sm plates. Smr and Gms clones were observed within 24 h and were identified 
as transformants with completed second event of recombination. 
 
2.4.4 Analysis of True Recombinants 
 
 Colony PCR screening was performed on Sms and Gmr intermediate 
clones and Smr and Gms clones to distinguish between true recombinants from 
revertants at the genomic level. DNA template was harvested as described in 
section 2.2.2.2 except that B. pertussis bacteria were heated for 30 min instead 
of 10 min. PCR was carried out as described in section 2.2.2.1 for 35 cycles 
using appropriate primers (Table 2.4) followed by agarose gel electrophoresis 
(Section 2.2.4.1).   !
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2.4.5 Chromosomal DNA Extraction !
10 ml of B. pertussis liquid culture grown in SS medium was 
centrifuged at 8,000 rpm for 10 min and DNA extraction was performed using 
Genomic-tip 100/G Anion-Exchange Resin and Genomic DNA Buffer Set 
(Qiagen) according to the manufacturer’s instructions. DNA was finally 
precipitated in 100% isopropanol and dissolved in 0.5-1 ml of ultrapure water 
at 4°C overnight. Alternatively, B. pertussis chromosomal DNA was harvested 
by phenol-chloroform extraction method.  2 ml of B. pertussis culture grown 
to mid-exponential phase in SS medium was centrifuged at 8,000 rpm for 10 
min, re-suspended in 600 µl of lysis buffer (3% SDS, 1 mM CaCl2, 10 mM 
Tris-HCl, 100 mM NaCl, pH 8.0) and heat-inactivated at 95°C for 30 min. 
Cell debris were pelleted by centrifugation at maximum speed for 10 min and 
the supernatant was mixed with EGTA to a final concentration of 2mM. The 
supernatant was transferred to a MaXtractTM High Density phase-locked 
Eppendorf tube (Qiagen). Equal volume of phenol/chloroform/isoamylalcohol 
(49:49:2, vol/vol/vol) (Invitrogen) was added to supernatant in the phased 
locked tube. The liquid mixture in the phase-locked tubes was mixed 
vigorously for 1 min to evenly mix the liquid phases. The phase-locked tubes 
were centrifuged at maximum speed for 5 min to separate the aqueous phase, 
inter phase containing MaXtractTM gel and the organic phase. The aqueous 
phase was transferred to a clean tube and 0.8 volume of 100% isopropanol and 
0.1 volume of 3 M sodium acetate were added for precipitation of 
chromosomal DNA. The mixture was centrifuged at maximum speed for 15 
min and the chromosomal DNA pellet was washed once with 70% ethanol, 
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air-dried at room temperature and dissolved in 1 ml TE buffer (10 mM Tris 
pH 8.0, 0.2 mM EDTA).  The extracted chromosomal DNA was quantified by 
NanoDropTM ND-1000 spectrophotometer (Thermo) and was visualized by 
DNA gel electrophoresis (Section 2.2.4.1).  
 
2.4.6 Southern Blot Analysis !
2.4.6.1 Synthesis of DIG-labeled probe  !
 Probes for Southern blot analysis were PCR synthesized and labeled 
with digoxigenin (DIG) using the PCR DIG Probe Synthesis Kit (Roche) 
according to the manufacturer’s instructions. To estimate probe-labeling 
efficiency, an unlabeled control reaction without DIG-labeled dNTPs was 
included. Amplification of DIG-labeled probe was conducted in GeneAmp® 
PCR system 2400 thermal cycler (Biorad) with initial denaturation at 95°C for 
2 min, followed by 35 cycles of DNA denaturation at 95°C for 30 s, primer 
annealing at appropriate annealing temperature for 40 s and DNA elongation 
at 72°C for 1 min. An additional 7 min of DNA extension at 72°C was 
included, after which the reaction was maintain at 4°C. The synthesized 
probes, both labeled and unlabeled, were analyzed and quantified by gel 
electrophoresis (Section 2.2.4.1). 
 
2.4.6.2 Southern blot 
 
Approximately 1 µg of B. pertussis chromosomal DNA was digested 
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for 4 h with appropriate RE(s) as described in Section 2.2.3 and the digested 
chromosomal DNA was subjected to 0.8% agarose gel electrophoresis. The 
agarose gel containing the digested DNA was treated twice in depurination 
solution (0.25 M HCl) for 10 min with gentle agitation, rinsed in deionised 
water, soaked twice in denaturation solution (5% of 10 N NaOH and 8.75 % 
NaCl) for 15 min and finally soaked twice in neutralization solution (7.7 % 
ammonium acetate, 0.2 % 10 N NaOH solution) for 30 min. The DNA 
fragments were transferred for 2-4 h onto a nitrocellulose membrane 
(Milipore). Before the assembly as illustrated in Figure 2.1, the nitrocellulose 
membrane was pre-wet in neutralization solution. After transfer, the 
membrane was UV-fixed for 1 min and equilibrated with 10 ml of pre-heated 
DIG Easy Hyb solution (Roche) at 65°C for 20 min, with gentle agitation. For 
hybridization, about 5-25 ng/ml of heat-denatured DIG-labeled DNA probe in 
DIG Easy Hyb solution was incubated with the membrane overnight at 65°C. 
After hybridization the membrane was washed twice in 2xSSC (0.15 M NaCl 
and 0.015 M sodium citrate) containing 0.1% SDS for 5 min at room 
temperature, followed by 2 wash steps in 0.1x SSC containing 0.1% SDS for 
15 min at 65°C. Blocking and washing were done using the DIG Wash and 
Block Buffer Set (Roche) according to the manufacturer’s instructions. 
Detection was performed by incubating the membrane with alkaline 
phosphatase (AP)-conjugated anti-DIG antibody (Roche) at a dilution of 
1:5,000 for 1 h at room temperature. The membrane was developed using 
NBT/BCIP AP substrate (Chemicon) and reaction was stopped by washing the 
developed membrane in deionised water. 
 





Figure 2.1: Semi-dry transfer of nucleic acids onto nitrocellulose 
membrane. !
2.4.7 RNA Extraction !
2.4.7.1 RNA extraction from in vitro B. pertussis culture !
500 µl of mid-exponential bacterial culture was harvested into 1 ml of 
RNAprotectTM Bacteria Reagent (Qiagen). The mixture was immediately 
vortexed and incubated at room temperature for 15 min. The bacterial cells 
were centrifuged for 10 min at 8,000 rpm, and the supernatant was discarded. 
The bacterial pellet was first re-suspended in 100 µl 1x TE buffer (Tris-EDTA 
at pH 8) containing 20 mg/ml of lysozyme (Sigma) and was incubated at room 
temperature for 10 min, vortexed for 10 s for every 2 min of incubation. RNA 
extraction was carried out using the RNeasy Mini Kit (Qiagen) according to 
the manufacture’s protocol. The RNeasy clean up with an on-column DNase 
treatment was employed using the DNase-I set (Qiagen) as recommended by 
the manufacturer’s protocol. Finally, total RNA was eluted using 30-50 µl of 
DEPC-RNase free water (Invitrogen).  
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2.4.7.2 RNA extraction from B. pertussis infected eukaryotic cells !
10 ml of RNAprotectTM Bacteria Reagent (Qiagen) were added into the 
tissue culture flasks of B. pertussis infected mammalian cells. The cell 
monolayers were then mechanically scraped, pooled and centrifuged at 
maximal speed. The cell pellet obtained was then re-suspended in 2 ml of 
DPEC water, vortexed vigorously and incubated at 37ºC for 20 min for lysis 
of mammalian cells. Free bacteria and cell debris were then pelleted at 10,000 
rpm for 10 min, followed by re-suspension of the pellet in 300 µl of of 1 x TE 
buffer containing 50 µl of 20 mg/ml lysozyme. The RNA extraction procedure 
was similar to that described in section 2.4.7.1 except that the amount of RLT 
buffer and ethanol used per collecting tube was scaled up to 700 µl and 500 µl 
respectively. In addition, in-solution DNA digestion with DNase-I was 
performed according to the manufacturer’s protocol to further eliminate 
genomic DNA contaminants. The essentially cleaned RNA was then eluted in 
20-30 µl of DPEC water. !!
2.4.7.3 RNA extraction from B. pertussis infected mice lungs !
B. pertussis-infected BALB/c mice (CARE) were  euthanized and their 
lungs were aseptically removed (as described in section 2.12) and immediately 
immersed in 3 ml of RNAprotectTM Bacteria Reagent (Qiagen) for 1 h in 4ºC. 
The stabilized lungs were homogenized using the High Shear homogenizer 
(Omni International, Reasearch Biolabs). The lung homogenates from 
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individual lungs were filtered through a cell strainer. The filtered suspension 
was centrifuged at 1,500 rpm for 7 min to pellet the remaining cell debris. The 
supernatant containing free bacteria was centrifuged at 10,000 rpm for 10 min. 
The bacterial pellet was again stabilized in 1 ml of RNAprotect Bacteria 
Reagent for 5 min at room temperature. Bacterial RNA was extracted using 
lysozyme and RNeasy Mini Kit buffer as described in section 2.4.7.1. In-
solution DNA digestion was performed with DNase-I, and finally total RNA 
was eluted in 20-30 µl of DPEC water. 
 
2.4.7.4 Quantification of total RNA !
The concentration of total RNA extracted was quantified by UV 
spectroscopy using the NanoDropTM Spectrophotmeter (Thermo). 
Quantification was done in an absorbance range from 220 nm to 750 nm. 2 µl 
of the total RNA extracted was placed onto the measurement pedestal to 
estimate its concentration in ng/µl and the ratio of absorbance measured at 260 
nm and 280 nm (A260/A280) was determined to assess RNA purity. RNA 
preparations with an absorbance ratio within the range of 1.8 to 2 are 
considered of satisfactory purity. The quality of the total RNA extracted was 
checked visually upon agarose gel electrophoresis as described in section 
2.2.4.1.   !
2.4.8 Reverse-transcription Polymerase Chain Reaction (RT-PCR) !
Chapter 2: Materials and Methods 
! 80!
Total bacterial RNA extracted from in vitro culture (10 ng) from the 
infected cell lines (1 µg) and from infected mice lungs (1 µg) was subjected to 
RT-PCR to synthesize complementary DNA (cDNA) strands using the 
iScriptTM cDNA synthesis kit (BioRad) (Table 2.5). For each RNA sample, a 
reaction with (+RT) or without (-RT) reverse transcriptase was set up. 
Amplification was conducted in the iCyclerTM Thermal Cycler system 
(BioRad) with a pre-incubation at 25ºC for 5 min and cDNA amplification at 
42ºC for 40 min. Finally, the RT was inactivated at 85ºC for 5 min and 
reaction was kept at 4ºC.  
 
Component Volume per reaction (µl) 
5x iScript reaction mix 4 
iScript reverse transcriptase 1 
Nuclease-free water 10 
RNA template (10 ng-1 µg) 10 
Total volume 20 
 
Table 2.5: Reaction components for RT-PCR amplification per sample 
tube for RNA input less than 1µg. The reaction was scaled up to a final 
volume of 40 µl when using more than 1 µg of RNA. !!
2.4.9 Real-Time Polymerase Chain Reaction !
2.4.9.1 Reaction setup 
 
iTaqTM SYBR Green Supermix with ROX cocktail (BioRad) was used 
in all real-time quantitative PCR (qPCR) reaction. A 50 µl singleplex PCR 
reaction mix was prepared according to the manufacturer’s instructions as 
shown in Table 2.6. 2-4 µl of cDNA template was added in triplicates into 
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each of the assigned wells in the MicroAmp® Optical 96-well Reaction Plate 
(Applied Biosystem). A master mix consisting of the iTaqTM cocktail, 
forward-reverse primers and DEPC water was initially prepared before adding 
48 µl of this master mix into each of the assigned optical wells containing 
either the cDNA sample, the no-template control as well as the –RT control. 
For no-template control, 2-4 µl of RNase-DNase free DEPC water was added 
into the optical well instead of the cDNA template, which is used to estimate 
the formation of primer-dimer and to ensure the PCR reaction proceeds in a 
contamination-free environment. The -RT control was used to estimates the 
amount of genomic DNA contamination present in the target samples. Passive 
reference ROX dye in the iTaqTM cocktail provides an internal fluorescence 
reference to which the reporter SYBR dye signal was normalized during data 
analysis. 
 




iTaqTM SYBR Green Supermix with ROX 25 1x 
Forward primer 0.5 500nM 
Reverse primer  0.5 500nM 
DEPC water 20-22  
cDNA template  2-4  
Total volume  50  
 
Table 2.6: Reaction components for Real-time PCR amplification per 
sample tube. !!
Both forward and reverse primers were designed with the Applied 
Biosystem Primer Express® and OligoTech software. The list of primers is as 
shown in Table 2.7. Annealing temperature (Ta) was calculated according to 
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the following equation: (4 x nG/C) + (2 x nA/T) – 5 where nG/C and nA/T represent 







































BP3818 CCATCGGGTTGCGCTACC AACAGATAGCCCGCGACCG 
 
Table 2.7: List of primers used for Real-time PCR. !!
Amplification and relative quantification for gene expression was 
conducted using the Applied Biosystem Standard 7500 sequence detector. 
Both forward and reverse primers for selected targets and endogenous control 
is as listed in Table 2.7. The amplification begins with an initial denaturation 
step at 95ºC for 3 min, followed by PCR cycling for 45 cycles consisting of 
DNA denaturation at 95ºC for 15 s and primer annealing and extension steps 
at suitable Ta of various primers for 45 s. A dissociation stage was added for 
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melting curve analysis at 95°C for 15 s, 60°C for 15 s, and a slow ramp to 
95°C for 15 s. 
 
2.4.9.2 Configuring data analysis setting in real-time PCR !
The real-time data on gene expression quantitation or RQ was 
automatically collected by the Applied Biosystem Standard 7500 system 
throughout the PCR cycling process. At the end of the run, data analysis was 
done either on a single plate document or multi-plates document. SYBR green 
fluorescence intensity was depicted by the amplification curve generated from 
the system. Baseline value was set at initial stage of cycling where minimal 
change in SYBR green fluorescent signal was detected. Significant 
amplification was characterized by the point in time during cycling when 
amplification of a target is first detected above the set threshold value, which 
was set above the baseline and within the exponential part of the amplification 
curve. The threshold cycle (Ct) value was determined at which the 
amplification curve intersects with the set threshold value. The determination 
of Ct values across the samples is essential for subsequent relative quantitation 
assay. To quantify the relative expression of each gene, the average Ct values 
calculated from the triplicate samples was normalized against the endogenous 
reference gene, recA (equation 1 and 2). Normalization step is necessary to 
correct for fluorescence fluctuations caused by variations in template 
concentration or in volume from one well to another. The selected endogenous 
control recA was expected to be constitutively expressed in all the 
experimental samples. The ΔCt value obtained was then compared with a 
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calibrator, using the ΔΔCt method (equation 3). From the ΔΔCt values, the 
relative gene expression of target sample was calculated (equation 4). 
 
(ΔCttarget = Cttarget – CtrecA) ------------(equation 1) 
(ΔCtcalibrator = Ctcalibrator – CtrecA)-------(equation 2) 
(ΔΔCt = ΔCttarget - ΔCtcalibrator)---------(equation 3) 
(RQ= 2-ΔΔCt)------------------------------(equation 4) !
The calibrator sample was used as the basis for comparative gene 
expression in which its RQ value was set as 1. Consequently, an increase in 
gene expression would have an RQ greater than 1 whereas a decrease in gene 
expression would be reflected by an RQ < 1. Relative fold change was then 
calculated from the RQ values obtained. !!
2.4.10 Microarray Analysis  
 
8 ml of mid-exponential bacterial culture was harvested at OD600nm 2 
and mixed with 2 ml of phenol-ethanol mixture containing 5% of UltraPure™ 
Buffer-Saturated Phenol (Invitrogen) and 95% Ethanol. The bacteria-phenol-
ethanol mixture was pelleted at 8,000 rpm for 10 min. The pellet was frozen 
and shipped to the Institute Pasteur Lille, France for whole genome 
transcriptomics analysis. In brief, long oligonucleotide probes were designed 
from the sequences of the 3554 open reading frames (all coding CDS except 
transposases of IS elements) of B. pertussis Tohama I genome using 
OligoArray v2.1 (Rouillard et al., 2003). Oligonucleotides were synthesized 
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by Sigma-Aldrich and spotted on Nexterion AL slides (Schott Nexterion) in 
1x SciSpot-AM buffer (Scienion) using a Q-Array II spotter (Genetix). For 
each sample, 15 µg of total RNA was reverse transcribed with 400 units of 
SuperScript III (Invitrogen) in presence of 100µM Cy3-dCTP or Cy5-dCTP 
(GE) and 300 mM of random hexanucleotide (Roche). The labelled cDNA 
was then NaOH treated to degrade RNA and purified on Qiaquick PCR 
purification kit (Qiagen). Hybridization was performed in 40% formamide, 5x 
Denhardt’s solution, 0.1% SDS, 1 mM sodium pyrophosphate and 5x SSC for 
14-16 h at 52°C under agitation. Slides were then washed sequentially in 2x 
SSC with 0.2% SDS for 5 min, 0.5x SSC for 10 min, 0.05x SSC for 5 min and 
0.01x SSC for 1 min before drying. Hybridized slides were scanned using an 
Innoscan 700 (Innopsys) microarray scanner and analyzed with Mapix v3.1 
(Innopsys). Normalisation and differential expression were carried out using 
the LIMMA package (Linear Models for Microarray Data) (Smyth et al., 
2003) running under the statistical language R v2.11.1. Identification of 
statistically significant regulation was performed using moderated t-statistic 
with empirical Bayes shrinkage of the standard errors (Lonnstedt and Speed, 
2002). Because of multiple testing, obtained P values were corrected using 
Benjamini & Hochberg method to controls the false discovery rate (Benjamini 
and Hochberg, 1995).!!
2.5 PROTEIN EXPRESSION STUDIES !
2.5.1 Preparation of B. pertussis Samples for Protein Expression Studies !




10 ml of B. pertussis culture grown in SS medium were harvested in 
mid-exponential phase at OD600nm and centrifuged at 8,000 rpm for 10 min at 
room temperature. The supernatant was collected and subjected to further 
spinning for 10 min at maximum speed to remove any remaining cell debris. 
Equal volume of commercial protein loading buffer; the Laemmli Blue sample 
buffer (Biorad) mixed with 5% β-mercaptoethanol (Sigma) was added to 500 
µl of the clarified supernatant and the mixture was heated at 95°C for 15 min. 
When necessary the supernatant was concentrated up to 10 times using Ultra-4 
Centrifugal Filter Device (Amicon) according to the manufacturer’s 
instructions prior to adding the Laemmli Blue sample buffer and 5% β-
mercaptoethanol.  
 
2.5.1.2 Whole cell extract 
 
1 ml of B. pertussis culture grown in SS medium was harvested in 
mid-exponential phase at OD600nm and centrifuged at 8,000 rpm for 10 min at 
room temperature.  The pellet was re-suspended in 500 µl of RNases-free 
water, and an equal volume of Laemmli Blue sample buffer and 5% β-
mercaptoethanol was added before heating the mixture at 95°C for 15 min. 
Chomosomal DNA was sheared by passing the suspension through a 27G 
needle followed by heating at 95°C for 15 min.  
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2.5.2 Preparation of B. pertussis Samples for Protein Purification 
Studies 
 
2.5.2.1 Growth of bacteria !
A 10 ml pre-culture of B. pertussis culture grown in SS medium was 
used to inoculate 50 ml of SS medium to an initial OD600nm of 0.1. The culture 
was incubated overnight until OD600nm 2-2.5 was reached.  !
2.5.2.2 Clarified whole cell extract 
 
50 ml of B. pertussis culture were centrifuged at 8,000 rpm for 10 min 
and washed twice with 25 ml of 1x PBS. The washed bacteria pellet was re-
suspended in 5 ml of lysis buffer A (containing 20 mM Tris-HCl pH7.9, 10 
mg/ml lysozyme, 50 µM KCL, 10% glycerol and 1xprotease inhibitor) and 
incubated at 37°C with rocking for 1 h. The bacterial cells were sonicated in a 
bioruptor closed system (Diagenode) for 15 min with 15 s ON/OFF interval. 
Cellular contents and debris were removed upon centrifugation at 8,000 rpm 
for 10 min. The bacteria pellet was re-suspended again in 5ml lysis buffer A, 
with an addition of 1% Triton-X-100. The bacterial cells were incubated at 
37°C with rocking for 1 h, prior to centrifugation at 10,000 rpm for 10 min. 
Finally, the supernatant was discarded and the bacteria pellet was solubilized 
in 5 ml of solubilization buffer (containing 20mM Tris-HCl, 50 µM KCL, 
10% glycerol and 6 M guanidine hydrochloride, pH 8) with rocking for 1 h at 
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4°C. The cellular lysate was clarified by centrifugation at maximum speed for 
15 min to pellet unsolubilized cells and debris. 
 
2.5.3 Protein Quantification Using Bicinchoninic Acid (BCA) Assay 
 
200 µl of BCA working reagent diluted 1:50 (Thermo) were added to 
10 µl of the sample cellular lysate and to a range of bovine serum albumin 
standards at 2 mg/ml, 1 mg/ml, 0.5mg/ml, 0.25 mg/ml and 0.125 mg/ml. The 
mixture was incubated at 37°C for 30 min and absorbance was measured at 
562 nm with Infinite200 Pro (Tecan, Switzerland) 96-well plate reader.  
 
2.5.4 Protein Purification Using Ni-NTA Column Chromatography 
 
400 µl of Ni-NTA slurry (Qiagen) were centrifuged at 5,000 rpm for 5 
min to remove slurry solution. The beads were pre-equilibrated with 400 µl of 
solubilization buffer containing 20 µM imidazole. Pre-equilibration of the Ni-
NTA beads was performed on a rocker for 10 min at room temperature. 
Approximately 5 mg of clarified lysate were mixed with imidazole to a final 
concentration of 20 µM. If obvious viscosity was observed, 20 units of 
TURBO DNase-I (Invitrogen) was added to the cell lysate. The cell lysate was 
then mixed with the pre-equilibrated Ni-NTA beads at 4°C overnight with 
rocking. The mixed lysate and Ni-NTA beads were loaded onto an empty 
Poly-PrepTM chromatography column (Biorad). The Ni-NTA beads were 
allowed to settle at the bottom of the tube before the bottom cap was opened 
for gravity flow purification. The Ni-NTA beads were washed with 5 column 
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volumes of wash buffer (containing 6 M urea, 100 mM NaH2PO4, 10mM Tris-
HCl and 20 µM of imidazole. pH6.3). Proteins bound to the Ni-NTA beads 
were batch eluted four times in elution buffer (containing 6 M urea, 100 mM 
NaH2PO4, 10mM Tris-HCl and 200 µM of imidazole. pH 4.5). Eluted proteins 
were aliquoted in batch and stored at -80°C. Prior to SDS-PAGE, defrost 
purified proteins were mixed with Laemmli Blue sample buffer alone and 
unheated or with β-mercaptoethanol and heated at 95°C for 15 min.  
 
2.5.5 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)  
 
Protein separation was conducted under denaturing conditions via 
SDS-PAGE using a vertical slab gel unit (Hoefer, USA) according to the 
manufacturer’s instructions. The slab gel consisted of a 5% polyacrylamide 
stacking gel and a 8%, 10% or 12% polyacrylamide resolving gel, both 
containing 10% SDS. Cell extract, supernatant samples or purified proteins 
were heated at 95ºC (or not for purified proteins) for 5-15 min immediately 
before loading onto the SDS-gels. 5 µl of BenchMarkTM Pre-Stained protein 
ladder (Invitrogen) or Spectra Multicolor Broad Range protein ladder 
(Thermo) were loaded as well as the molecular weight standard. 
Electrophoresis was conducted in 1xTris-Glycine SDS running buffer at 
constant 80 V for the first 20 min and increased to 100 V for protein 
separation in resolving gel for 2 h.  
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2.5.6 Coomassie Blue Staining 
 
To visualize the protein bands after electrophoresis, the PAGE gel was 
soaked in Coomassie Staining InstantBlueTM solution (Expedeon, Cambridge, 
UK) for 1-2 h with constant shaking until bands appeared. The PAGE gel was 
then destained in deionized water with constant shaking until the protein bands 
could be visualized as sharp blue bands against a clear background. The gel 
was placed on clear cellophane and scanned for record and analysis.  
 
2.5.7 Western Blot 
 
After SDS-PAGE, the separated proteins were electro-transferred to a 
methanol activated PVDF membrane (Bio-Rad) using either a semi-dry 
transfer system (Vann et al.) at 65 mA for 2-4 h or a wet transfer system 
(Biorad) at 30 V overnight. Prior to assembly for semi-dry transfer, the SDS-
PAGE gel, PVDF membrane and filter papers were soaked in transfer buffer 
containing 1xTowbin buffer made up of Tris-Glycine and methanol 
(containing 25 mM Tris, 192 mM glycine and 20% (v/v) methanol) for 15 
min. Similarly for wet transfer, the PVDF membrane and filter papers were 
soaked in 1xTowbin buffer containing 40% (v/v) methanol instead of 20% 
methanol. PVDF membranes from completed semi-dry or wet transfer were 
blocked in 5% skim milk (Bio-Rad) diluted in 1xTBS with 0.1% Tween20 at 
room temperature for 1 h. The membranes were then incubated with the 
appropriate primary antibody (Table 2.8) diluted in the same blocking buffer 
for 1 h at room temperature or at 4ºC overnight, followed by 3-5 washing 
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steps in an excess of washing buffer (containing 1xTBS, 0.1% Tween20) at 15 
min intervals. Thereafter, the membrane was incubated for 1 h with gentle 
shaking at room temperature, with the appropriate AP-conjugated or HRP-
conjugated secondary antibody (Table 2.8) diluted in blocking buffer, 
followed by washing as described above. Finally, the AP-conjugated antibody-
reactive bands were revealed by chromogenic detection upon addition of 
NBT/BCIP alkaline phosphatase substrate (Chemicon, Temecula, CA). For 
chemiluminescent detection, the membrane with HRP-conjugated secondary 
antibody was incubated with Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare, Waukesha, WI) and reactive bands were 
developed on CL-XPosure X-ray Film (Thermo). 
 
Primary antibody Dilution Secondary Antibody Dilution 
Rabbit anti-BrkA polyclonal 
antibody (New England 
Peptide, Gardner,MA) 
1:30,000 Goat anti-rabbit IgG 
AP conjugate (H+L) 
(Bio-rad) 
1:3000 
Mouse anti-FHA monoclonal 
antibody (National Institute 
for Biologica Standards and 
Control, UK) 
1:5000 
Mouse anti-PTX monoclonal 
antibody (National Institute 
for Biologica Standards and 
Control, UK) 
1:1500 
Goat anti-mouse IgG 
AP conjugate (H+L) 
(Bio-rad) 
1:3000 
Rat anti-BvgS polycolonal 
antibody (Kind gift from Dr. 
F. Jacob-Dubuisson, Institute 
Pastuer Lille)  






HRP conjugated monoclonal 
antibody (Qiagen) 
1:10,000 NA  
 
Table 2.8: Antibodies used in Western blot. !!!









Figure 2.3: Western blot setup for wet transfer. !!!!!!!
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2.6 FLUORESCENCE ACTIVATED CELL SORTING (FACS) !
2.6.1 Preparation of B. pertussis Samples for FACS !
To detect surface polysaccharide capsule, 5 ml of B. pertussis strains 
grown in SS medium containing 50 mM MgSO4 were harvested at mid-
exponential phase and centrifuged at 8,000 rpm for 10 min. The bacteria pellet 
was washed twice with 2 ml of sterile HEPESG buffer (1xHEPES, 5% 
glycerol; 0.05% Tween80). Bacteria concentration was adjusted to 108 
CFU/ml in 2 ml of HEPESG. 500 µl of the bacteria were incubated with 
mouse anti-Vi antiserum (see section 2.10) diluted 1:50 for 2 h at 4°C with 
constant agitation. The bacteria-antibody complexes were centrifuged at 8,000 
rpm for 10 min and gently washed twice with 2 ml of HEPEG. The bacteria-
anti-Vi antibody complexes were then gently re-suspended in 500 µl of 
HEPESG with 1:100 dilution of FITC-conjugated goat anti-mouse IgG 
(Chemicon) for 1 h at room temperature with constant agitation. The 
suspension was centrifuged at 8,000 rpm for 10 min, washed twice with 2 ml 
of HEPEG and finally re-suspended in 100 µl of 1xHEPES with 4% 
paraformaldehyde to fix the bacteria cells.  
 
To evaluate bacteria membrane integrity with propidium iodide (PI) 
staining assay, B. pertussis strains grown on BG agar for 24 h were washed 
once with PBS and adjusted to initial OD600nm of 0.7 with SS media. 500 µl of 
bacterial suspension was incubated with or without 0.02% SDS for 2 h at 
37°C. 50 ng of PI (BD Pharmigen) was then added to! the culture and 
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incubated for 15 min at room temperature. Bacteria cells were washed twice 
with 1xPBS prior to fixing with 4% paraformaldehyde for 30 min and 
analyzed with LSRFortessa cell analyzer (BD Pharmigen).!
 
2.6.2 FACS Analysis 
 
100 µl of each sample were diluted with 700 µl of BD FACSFlowTM 
sheath fluid (Becton-Dickinson, Heidelberg, Germany) prior to FACS 
profiling and acquisition. A Coulter Epics machine (Beckman Coulter, Palo 
Alto, CA) was used for the flow cytometric study. Samples were analyzed 
with laser excitation at 488 nm, and data acquisition was performed using 
EXPO Version 2.0 software (Applied Cytometry Systems, Sheffield, U.K.) 
and analyzed with WinMDI-2.8 software. 
 
2.7 CELL BIOLOGY !
2.7.1 Cell Line and Culture Conditions  !
J774.A1 murine macrophages (ATCC, TIB 67) were cultured at 37ºC 
and 5% CO2 atmosphere, and were maintained in Dulbecco’s modified 
essential medium (DMEM) medium supplemented with 10% heat-inactivated 
fetal calf serum (FCS) (Gibco, Invitrogen), 2% of 200 mM GlutaMAX-I 
(Gibco, Invitrogen) and 1% of 100mM sodium pyruvate (Gibco, Invitrogen). 
A549 human lung epithelial cells (ATCC, CCL-185) cells were cultivated in 
RPMI-1640 medium containing L-glutamine and 25 mM HEPES buffers 
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(Gibco, Invitrogen), supplemented with 10% heat-inactivated FCS (Gibco, 
Invitrogen), 2% of 200mM Glutamax-I (Gibco, Invitrogen) and 1x penicillin-
streptomycin (100U/ml of penicillin and 100 µg/ml of streptomycin) 
antibiotics (Gibco, Invitrogen). Both J774.A1 and A549 cells were cultivated 
in 25 cm2 and 75 cm2 tissue culture flasks. Upon 80% confluency, usually 
within 2-3 days, the spent medium was discarded and the cell monolayers 
were rinsed thrice with 10 ml sterile 1xPBS to remove dead cells. Cells were 
detached from the tissue culture flask surface by mechanical scraping. 
J774.A1and A549 cells were passage in a ratio of 1:3 in 75 cm2 tissue culture 
flasks.  
 
2.7.2 Trypan Blue Assay !
Single cell suspensions were mixed with equal volume Trypan blue 
dye (Sigma) and transferred to a cover slip chamber on a hemocytometer. 
Under the inverted light microscope, the viable and non-viable cells can be 
distinguished, whereby viable cells exclude the trypan blue dye whereas dead 
cells take up the blue dye. The number of viable (unstained) cells located in 
the 25 squares of the hemocytometer was counted and the cell concentration 
per ml was determined using the following calculation:  
   
 Cells per ml = the average count in 25 squares x dilution factor x 104 
 
2.7.3 Cell Culture Infection Assay 
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J774.A1 and A549 cells were grown as described in section 2.7.1. Two 
days before the infection assay, B. pertussis strains were plated on BG agar as 
mentioned in section 2.3.2. The bacterial lawns were harvested and washed 
once in 5 ml sterile 1x PBS, followed by centrifugation at 8,000 rpm for 10 
min at room temperature to remove traces of blood agar. Bacteria pellet was 
re-suspended in 1 ml of incomplete cell culture medium (without FCS) for OD 
measurement at 600 nm. The final bacterial concentration was adjusted with 
appropriate incomplete cell culture medium to allow a multiplicity of infection 
(M.O.I) of 100 for Real-time PCR analysis of bacterial gene transcripts 
(Section 2.4.9). In addition, 200 ul of the final bacterial suspension were 
serially diluted and plated on BG agar for quantification of the inoculums. 
 
Prior to infection assay, J774.A1 and A549 cell monolayers were 
washed with 10 ml of 1xPBS and 10 ml of bacterial suspension in incomplete 
medium were added into the 75 cm2 tissue culture flasks. Similarly, 10 ml of 
incomplete DMEM medium were added into the non-infected flask. The tissue 
culture flasks were incubated in 37ºC at 5 % CO2 atmosphere for 1.5 h. After 
1.5 h, bacterial suspension was removed from all flasks and the monolayers 
were rinsed thrice with 1xPBS. The monolayers were either lysed (time point 
1.5 h p.i.) or further incubated with medium containing 100 µg/ml of 
gentamicin for 2 h at 37ºC at 5 % CO2 atmosphere to kill extracellular 
bacteria. After 2 h, the flasks were washed thrice with sterile 1x PBS. Except 
for those cells, which are to be lysed immediately (time point 3.5 h p.i.), cell 
culture medium containing 20 µg/ml of gentamicin was added into the flasks. 
For each time point, prior to cell lysis, the flasks were washed thrice with 1x 
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PBS and the monolayers were immediately processed for bacterial RNA 
extraction as described in section 2.4.7.2. 
 
(C) ANIMAL WORK !
2.8 Ethics Statement 
 
All the animal experiments were approved by NUS IACUC under the 
protocol number 089/09. The animal experiments were carried out under the 
guidelines of the National Advisory Committee for Laboratory Animal 
Research (NACLAR) in the AAALAC-accredited NUS animal facilities. All 
efforts were done to minimize suffering of the animals and all non-terminal 
procedures were performed under anesthesia.  
 
2.9 Mouse Strain 
 
6-8 weeks-old pathogen-specific free (SPF) female BALB/c mice were 
purchased from Centre for Animal Resources (CARE), NUS Singapore. The 
mice were housed in individual ventilated cages (IVCs) in a ABSL2 facility. 
 
2.10 Generating Polyclonal Anti-Vi Antisera 
 
BALB/c mice were immunized intraperitoneally (ip.) with 5 µg (100 µl) 
of Typhoid Vi polysaccharide vaccine of S. typhi Ty2 strain (TYPHIM ViTM, 
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Aventis Pasteur SA, France) mixed with equal volume of incomplete Freund’s 
adjuvant (Calbiochem, San Diego, USA). Immunization was performed once 
and blood was collected from the sedated immunized mice by retro-orbital 
plexus puncture after 10 days and 17 days post-immunization. The blood was 
allowed to clot at 37°C for 30 min and 4°C for 1 h, followed by centrifugation 
at 3,500 rpm for 10 min at 4°C. The serum was collected and stored at -20°C 
until used. 

2.11 Intranasal Infection 
 
B. pertussis strains grown on BG agar at 37ºC for 3 days were re-
suspended in sterile PBST (containing 1x PBS, 0.05% Tween80) and adjusted 
to a final concentration of approximately 2.5x107 CFU/ml (for colonization 
assay) or 2.5x109 CFU/ml (for bacterial RNA extraction). Prior to infection, 
mice were sedated upon ip. administration of 150 µl per mouse of an 
anaesthetic cocktail (6% valium, 10% atropine, 20% ketamine, 64% 1x sterile 
PBS) . Infection was performed through the intranasal route with 20 µl of the 
bacterial suspension slowly deposited onto the nostrils of the animals. 
 
2.12 Murine Lung Colonization Study 
 
 Four mice per time point were sacrificed at the indicated time points 
after intranasal infection with various B. pertussis strains. The lungs from each 
individual mouse were aseptically removed and homogenized in 2 ml or 5 ml 
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sterile PBST using High Shear homogenizer (Omni International, Reaserch 
Biolabs). Serially diluted lung homegenates from individual mice were then 
plated onto BG agar supplemented with 100 µg/ml Sm and the total CFU per 
lung was counted after 4-5 days incubation at 37ºC.  
 
2.13 Statistical Analysis 
 
Statistical analysis of all results was performed using the unpaired 
Student t-test. Differences were considered significant at a P value of < 0.05. 
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CHAPTER 3 ROLE OF THE CAPSULE OPERON IN 
PERTUSSIS PATHOGENESIS !
(A) CHARATERIZATION OF B. PERTUSSIS MUTANTS CARRYING 
A SINGLE GENE DELETION WITHIN THE CAPSULE OPERON  !
3.1 RESULTS !
3.1.1 Construction of B. pertussis kpsT, kpsE and vipC-deleted Mutants 
 
A non-polar single gene deletion was constructed for kpsT, kpsE and 
vipC ORFs via double homologous recombination at the chromosomal locus 
of wild-type BPSM. Approximately, 600-800 bp of genes, termed as PCR1, 
flanking from the 5’ internal region and PCR2, flanking from the 3’ internal 
region of the respective ORFs to be deleted, were PCR amplified from BPSM 
chromosomal DNA using the primers listed in Table 2.2 (Figure 3.1). The 
PCR1 and PCR2 fragments were cloned into TOPO vector for sequencing and 
then into pBR322 intermediate vector. PCR1+2 were eventually cloned into 
the Bordetella suicide vector pJQ200mp18rpsL, yielding pJQT1-2, pJQE1-2 
and pJQV1-2 respectively. Electrocompetent B. pertussis BPSM strain was 
electroporated with pJQT1-2, pJQE1-2 and pJQV1-2 plasmids as described in 
section 2.4.2. B. pertussis clones deleted for kpsT, kpsE and vipC genes, 
respectively, were selected as described in section 2.4.3 and colony PCR 
screening was performed using primers as listed in Table 2.4.  






Figure 3.1: Schematic organization of the ORFs for B. pertussis capsule 
operon. !
The capsule operon of B. pertussis regulated under the capsule promoter is as 
shown. Black cross represents mutational insertion found in the locus. Black, 
hashed and white arrows represent genes involved in polysaccharide capsule 
transport, polysaccharide modification/translocation and polysaccharide 
biosynthesis respectively. The homologous PCR1 and PCR2 fragments 
indicated by the filled red and green arrowheads (ΔkpsT), dotted red and green 
arrowheads (ΔkpsE) and filled red and green rounded arrowheads (ΔvipC) 
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3.1.2 Obtaining The ΔkpsT, ΔkpsE and ΔvipC Mutants  !
3.1.2.1 Southern blot analysis !
The BPSM-derivative knockout (KO) mutant strains designated as 
ΔkpsT, ΔkpsE and ΔvipC were further analyzed by Southern blot analysis. 
Chromosomal DNA from wild-type BPSM, ΔkpsT, ΔkpsE and ΔvipC strain 
was extracted and restriction digested as described in section 2.4.5 and 2.2.3. 
Southern blot strategy for ΔkpsT, ΔkpsE and ΔvipC mutant and the 
hybridization of DIG-labeled probes are as shown in Figure 3.2 A. The band 
sizes obtained for ΔkpsT (~2.7 kb), ΔkpsE (~3.9 kb) and ΔvipC (~3.4 kb) 
versus the BPSM counterpart confirms that kpsT, kpsE and vipC is deleted at 














Figure 3.2: Southern blot analysis of ΔkpsT, ΔkpsE and ΔvipC 
chromosomal DNA. 
(A) Strategy for Southern blot analysis for ΔkpsT, ΔkpsE and ΔvipC 
mutant.  
Dotted triangle in panel indicate site of deletion that render each mutant non-
capsulated. The DIG-labeled probe binding region (black rounded arrow), 
restriction sites and size of restriction-digested chromosomal DNA for 
Southern blot analysis are as shown. 
(B) Southern blot analysis of B. pertussis chromosomal DNA.  
Chromosomal DNA of ΔkpsT was digested with EcoRI, whereas chromosomal 
DNA of ΔkpsE and ∆vipC was digested with HindIII and NcoI. Chromosomal 
DNA of BPSM was used as control and digested with the same RE used for 
each of the respective mutants. Restriction-digested chromosomal DNA from 
BPSM, ∆kpsT, ∆kpsE and ∆vipC were electrophoresed, transferred onto a 
nitrocellulose membrane and hybridized with the DIG-labeled probe (Figure 
3.2 A showed probe binding site). Panel a, EcoRI-restricted BPSM and ∆kpsT 
DNA yielded 2.7-kb and 3.2-kb respectively. Panel b, HindIII-NcoI restricted 
BPSM and ∆kpsE DNA yielded 4.8-kb and 3.9-kb respectively. Panel c, 
HindIII-NcoI restricted BPSM and ∆vipC DNA yielded 4.8-kb and 3.4-kb 
respectively. M, DIG-labeled DNA ladder.  
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3.1.3 Construction of B. pertussis ΔkpsT-Complement Strain !
An 866 bp DNA fragment corresponding to the native capsule 
promoter in BPSM was synthesized and cloned into XbaI and BamHI digested 
pUC57 plasmid (GenScript, Piscataway, NJ), yielding pUC57-Pcaps. A 764 
bp DNA fragment corresponding to the kpsT ORF was PCR amplified from 
purified BPSM chromosomal DNA using primers listed in Table 2.2. The kpsT 
ORF was cloned into pBBR1MCS to form pBBR-kpsT. The 866 bp capsule 
promoter fragment from pUC57-Pcaps was cloned upstream kpsT ORF in 
pBBR-kpsT, yielding pBBR::PcapskpsT.  
 
3.1.4 Obtaining the ΔkpsT-Complemented Strain 
 
 Electrocompetent B. pertussis ΔkpsT bacteria were electroporated with 
pBBR::PcapskpsT replicative plasmid. Complemented ΔkpsT clones were 
selected on Cm–containing BG plates. Using primers as listed in Table 2.4, B. 
pertussis ΔkpsTcom (complemented) strains were further confirmed by PCR 
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3.1.5 Transcriptional Analysis of Downstream Genes in ΔkpsT, ΔkpsE 
and ΔvipC Mutants 
 
To confirm that the in-frame deletion of these individual ORFs does 
not terminate the transcription efficacy of the downstream ORFs within the 
capsule operon, reverse transcription-PCR was performed on total RNA 
purified from ΔkpsT, ΔkpsE and ΔvipC strains grown in Bvg- phase using 
primers mapping in downstream ORFs of the respective deleted regions. The 
KOcaps mutant strain (Neo et al., 2010) for which the entire capsule operon 
has been deleted was used as negative control. Specific PCR products were 
obtained for both parental BPSM and ΔkpsT, ΔkpsE and ΔvipC strains (Figure 
3.3). Taking into account the variation in loading levels for risA in Figure 
3.3B and Figure 3.3C, these variations probably lead to the observed changes 
in the intensity level observed for the PCR products amplified from wbpT and 
wbpO region (Figure 3.3 B and C). This study suggests that deletion of the 
respective kpsT, kpsE and vipC ORF does not affect transcription efficacy of 












































Figure 3.3: Reverse transcription-PCR on downstream gene.  
Total RNA extracted from exponential SS liquid cultures of BPSM, KOcaps 
and (A) ΔkpsT, (B) ΔkpsE and (C) ΔvipC was reverse-transcribed followed by 
PCR amplification using primers specific to the endogenous control gene recA 
and primers mapping to the respective downstream region of the deleted 
ORFs. The KOcaps strain which was deleted for the entire capsule locus was 
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3.1.6 In vitro Fitness of ΔkpsT, ΔkpsE and ΔvipC Mutants !
3.1.6.1 Growth kinetics 
 
To determine the in vitro fitness of B. pertussis ΔkpsT, ΔkpsE and 
ΔvipC mutants, their growth kinetic was determined and compared to the 
wild-type BPSM in virulent (Bvg+) culture conditions. All the mutant strains 
displayed similar growth profiles to BPSM, except ΔvipC, which showed a 
delay in growth at the mid-logarithmic growth phase. Nevertheless, all of 
mutant strains were able to multiple up to a maximum OD600nm of more than 5 
at the late growth phase, indicating that the in-frame single gene deletion of 





















   !
Figure 3.4: Growth kinetics for BPSM, ΔkpsT, ΔkpsE and ΔvipC mutant. 
SS liquid medium was inoculated with BPSM (closed circles), ΔkpsT (open 
circles), ΔkpsE (closed triangles) and ΔvipC (open triangles) at initial OD600nm 
of 0.5 at time-point 0 h. OD600nm was monitored throughout 52 h of incubation 
at 37ºC. The growth kinetics assay was performed twice independently for 
each strain and each culture conditions. The data shown is a representative of 
two independent experiments. 
 !!!!!!!!!!!!!!
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3.1.7 Expression of Surface Polysaccharide Capsule !
3.1.7.1 FACS analysis 
 
Based on homology mapping, KpsT and KpsE are membrane proteins 
predicted to be involved in the transport-export of the polysaccharide capsule 
accross the bacterial cell wall, whereas VipC is cytoplasmic and involved in 
capsule biosynthesis. Therefore, the absence of KpsT, KpsE and VipC 
proteins in ΔkpsT, ΔkpsE and ΔvipC strains, respectively, is expected to result 
in the absence of the capsule at the bacterial surface, due to the lack of 
effective capsule polymer transport and biosynthesis, respectively (Pavelka et 
al., 1994). To confirm this hypothesis, FACS analysis was performed on non-
permeabilized bacterial cells using the cross-reactive anti-Vi antigen immune 
sera as previously described by our laboratory (Neo et al., 2010) and as 
described in Chapter 2.10. The parental BPSM and capsule-deleted mutant 
KOcaps strains were used as positive and negative controls, respectively 
(Figure 3.5 A and B). All the strains were grown in Bvg- phase culture 
conditions to allow optimal expression of the capsule operon, which is known 
as a vrg (Hot et al., 2003). Whereas approx. 20% of the parental BPSM cells 
exhibited a substantial shift in fluorescent signal compared to isotype control; 
KOcaps, ΔkpsT, ΔkpsE and ΔvipC cells displayed background levels of 
fluorescent shift, indicating the absence of polysaccharide capsule at the 
surface of these mutant bacteria (Figure 3.5 C, D and E). ΔkpsTcom displayed 
approx. 18% shift in the detection of surface capsule, similar to that of 
parental level (Figure 3.5 F).  
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Altogether, these results indicate that deletion of the single ORF kpsT, 
kpsE or vipC within the capsule locus is sufficient to prevent the production of 
the polysaccharide capsule at the bacterial surface.  !!!!! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!






Figure 3.5: Detection of the polysaccharide capsule at the surface of B. 
pertussis strains.  
Mouse polyclonal anti-Salmonella typhi Vi antigen immune serum was co-
incubated with non-permeabilized (A) BPSM, (B) KOcaps, (C) ΔkpsT, (D) 
ΔkpsE, (E) ΔvipC and (F) ΔkpsTcom bacteria strains grown in avirulent (Bvg-) 
phase, followed by anti-mouse FITC-conjugated secondary antibody. Isotype-
matched controls are incubated with an anti-mouse antibody as shown in 
black/grey. The fluorescent cells were detected by flow cytometry, with 
20,000 events counted for each sample. A representative experiment is shown, 
with percentage of fluorescent cells indicated in each panel.  
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3.1.8 Lung Colonization Profile of ΔkpsT, ΔkpsE and ΔvipC Mutants 
 
To investigate whether the B. pertussis polysaccharide capsule plays a 
role during infection, Balb/c mice were nasally infected with wild type BPSM, 
KOcaps, ΔkpsT, ΔkpsE and ΔvipC strains, and the bacterial loads in the lungs 
were monitored over time. The parental BPSM showed typical lung 
colonization profile with a multiplication peak at 7 days post-infection (p.i.) 
followed by a progressive reduction in bacterial load over the next 3 weeks p.i. 
(Figure 3.6 A). In contrast, mice infected with KOcaps bacteria displayed no 
peak of multiplication, and instead a rapid decrease in the bacterial load was 
observed as early as 3 days p.i. with complete clearance within 17 days 
(Figure 3.6 A), indicating that deletion of the 10-kb capsule operon in B. 
pertussis greatly impaired its colonization efficiency, thus supporting that the 
polysaccharide capsule plays a role during pertussis pathogenesis.  
 
Since the ΔkpsT, ΔkpsE and ΔvipC mutants do not produce any surface 
polysaccharide capsule; a similar attenuated phenotype was expected to be 
observed in the mouse model. Consistently, the ΔkpsT mutant displayed a 
colonization profile comparable to that observed with KOcaps (Figure 3.6 B). 
The complemented strain ΔkpsTcom displayed a colonization profile similar to 
that of BPSM (Figure 3.6 B), demonstrating that kpsT deletion is responsible 
for the attenuated phenotype observed with the ΔkpsT mutant. Interestingly, 
since kpsT complementation was achieved using the pBBR1MCS replicative 
plasmid (Elzer et al., 1995; Kovach et al., 1994), substantial loss of the 
plasmid occurred during in vivo bacterial replication as evidenced by the 
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increasingly reduced percentage of colonies recovered over time from the 
infected mouse lungs that have retained the plasmid construct (Appendix 2). 
Nevertheless parental colonization efficacy was observed with the ΔkpsTcom 
strain at all the time points analysed, suggesting a bystander or paracrine effect 
whereby bacteria that have retained the plasmid are able to support the 
colonization of those that have lost the plasmid, likely through the secretion of 
critical virulence factors such as PT and FHA as reported before (Alonso et 
al., 2001). The lung colonization profile observed in mice nasally infected 
with ΔkpsE bacteria was also significantly attenuated throughout the course of 
infection compared to the parental BPSM strain (Figure 3.6 C), albeit to a 
much lesser extent than the KOcaps and ΔkpsT strains. In contrast, the 
colonization efficiency of the ΔvipC mutant was comparable to the parental 
BPSM strain, with the exception of a lower bacterial load at day 17 p.i. 
(Figure 3.6 D).  
 
Taken together, it appears that although the capsule was absent from 
the cell surface of all the mutant strains, their colonization profile substantially 
differed ranging from drastic (KOcaps and ΔkpsT) to moderate (ΔkpsE) or no 
(ΔvipC) attenuation. This observation thus suggests that the presence of the 
polysaccharide capsule at the bacterial surface does not play a critical role in 
pertussis pathogenesis. Instead, we propose that the membrane-associated 
polysaccharide transport proteins KpsT and to a lesser extent KpsE, are 
specifically involved in B. pertussis ability to colonize the mouse respiratory 
tract.  
 







Figure 3.6: Lung colonization profile by B. pertussis BPSM, ΔkpsT, ΔkpsE 
and ΔvipC strains.  
 
Balb/C mice were infected intranasally with 5x105 CFU of B. pertussis BPSM 
(solid circles) and (A) KOcaps (open circles), (B) ΔkpsT (open circles) and 
ΔkpsTcom (open triangles), (C) ΔkpsE (open circles) and (D) ΔvipC (open 
circles). At the indicated time points, four infected mice per group were 
euthanized and their lungs were harvested, homogenized and plated on blood 
agar to determine the total number of CFU per lung. The results are expressed 
as the mean ± SEM of four mice per group. ** p value < 0.01 and * p value < 
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3.1.9 Expression of Virulence Factors in ΔkpsT, ΔkpsE and ΔvipC 
Mutants !
3.1.9.1 Western blot analysis 
 
To further investigate the mechanism(s) involved in the capsule-
mediated virulence in B. pertussis, we examined the production of several 
major virulence factors responsible for bacteria colonization including the 
adhesin filamentous hemagglutinin; FHA, the serum resistance protein; BrkA, 
and pertussis toxin; PT in ΔkpsT, ΔkpsE and ΔvipC mutants compared to wild 
type BPSM strain all grown in virulent (Bvg+) phase in order to mimic the 
growth conditions in vivo. All bacteria cultures were harvested at OD600nm 3. 
Compared to BPSM, production in the ΔkpsT mutant for FHA, BrkA and PT 
in the whole cell lysate or in the concentrated and non-concentrated culture 
supernatant were markedly reduced (Figure 3.7 I A, B and C). However, 
taking into account the slight variation in ΔkpsTcom whole cell lysate loading 
control analyzed by Coomassie-stained SDS-PAGE (Figure 3.8), 
production/secretion level of FHA, PT and BrkA was concluded to be partially 
restored to parental level in ΔkpsTcom strain (Figure 3.7 I A, B and C), 
implying that a negative feedback event occurs in the ΔkpsTcom. 
 
A 40% reduction in the production BrkA and secretion of PT in the 
ΔkpsE mutant (Figure 3.7 II B and C) was observed compare to wild type 
BPSM. ΔvipC mutant also displayed similar fold reduction in BrkA 
expression, while expression of FHA and PT remains comparable to wild type 
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BPSM (Figure 3.7 II B). From the protein expression analysis between the 
wild-type and capsule-deleted mutant strains, we propose that the absence of 
the membrane-associated KpsT protein and to a lesser extent KpsE, results in 
reduction of the production and/or secretion of key virulence factors in B. 
pertussis. Nevertheless, it is unlikely that such mild reduction observed in 
these three virulence factors in ΔkpsT and ΔkpsE could compromise the 





























Figure 3.7: Production of bvg-regulated virulence proteins in capsule-
deficient mutants.  
(I) BPSM, ΔkpsT and ΔkpsTcom strains and (II) BPSM, ΔkpsE and ΔvipC 
were exponentially grown in virulent (Bvg+) phase. Western blot analysis was 
performed on 10x concentrated or non-concentrated culture supernatants, and 
whole cell lysates using (A) anti-FHA, (B) anti-BrkA or (C) anti-PT primary 
antibodies. The results are representative of three independent experiments. 
Molecular weights are indicated on the right side. Densitometry plot 
corresponding to the each of the blots is plotted as percentage of fold change 
relative to wild type BPSM.   !!!!!!!!!!!!!!!!!!!!
 




Figure 3.8: Coomassie blue-stained 12% SDS-PAGE of whole cell lysates.  
 
(A) BPSM, ΔkpsT and ΔkpsTcom strains and (B) BPSM, ΔkpsE and ΔvipC 
strains were exponentially grown in virulent (Bvg+) phase. Equal amount of 
protein from whole cell lysate was loaded in each well. SDS-PAGE and 
Coomassie blue staining was performed to estimate equal loading of protein 
content, as indicated by the band intensity as shown by the black arrowhead. 
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3.1.10 Transcriptional Analysis of Virulence Genes Expression !
3.1.10.1 Real-time PCR analysis 
 
To gain further insights in the mechanisms responsible for the lower 
production and/or secretion of key virulence factors observed with the ΔkpsT 
mutant, the relative expression of the corresponding genes in ΔkpsT namely 
brkA, ptx, and fhaB was measured by real-time PCR. Relative quantification 
of these transcripts in ΔkpsT was compared to that obtained with wild type 
BPSM grown in virulent (Bvg+) phase at early logarithmic phase. Consistent 
with the Western blot analysis (Figure 3.7), the transcriptional activity of 
brkA, ptx and sphB1 was significantly down-regulated about 10-fold, 4-fold 
and 2.5-fold, respectively in ΔkpsT compared to BPSM (Figure 3.9). The clear 
transcriptional down-regulation of brkA and ptx does not seem to correlate 
with the modest down-modulation of the corresponding protein levels (Figure 
3.7 I), as the translation efficiency in ΔkpsT appears almost as efficient as in 
wild-type BPSM. However, it is to be noted that the sensitivity of the methods 
employed to monitor the transcriptional and translational activities 
respectively is significantly different. It is thus not surprising that a 2-3 fold 
difference observed by real-time PCR is not reflected by a 2-3 fold difference 
by Western blot analysis. The expression level of brkA, ptx and sphB1 genes 
in the complemented strain ΔkpsTcom was partially restored up 2-fold for 
brkA, 2-fold for ptx and 1.25-fold for sphB1 compared to BPSM (Figure 3.9). 
Consistently, the corresponding protein expression level observed in 
ΔkpsTcom was close to the parental level (Figure 3.7 I).  




Instead, expression of the fhaB gene in ΔkpsT was not significantly 
different from that measured in the parental BPSM and ΔkpsTcom strains, 
supporting the expression of FHA detected by Western blot analysis in the 
whole cell lysate of BPSM, ΔkpsT and ΔkpsTcom (Figure 3.7 I A). The lower 
levels of FHA detected by Western blot in the culture supernatant of ΔkpsT 
but not in the total cell lysate (Figure 3.7 I A) could imply that the secretion of 
FHA but not its production may be impaired in ΔkpsT. Alternatively, fhaB 
translational efficiency and/or post-translational modification aberration in 
ΔkpsT may also result in FHA degradation and secretion impairment. Since, 
the FHA, BrkA and PT encoding genes are regulated by the two-component 
system BvgA/S, we also investigated the transcriptional activity in the ΔkpsT 
mutant of the bvgAS locus (Antoine et al., 2000; Roy and Falkow, 1991) and 
bvgR (Merkel et al., 2003). Comparable transcriptional activities of bvgAS and 
bvgR were obtained in ΔkpsT, ΔkpsTcom and BPSM strains (Figure 3.9), 
suggesting that the lower expression of ptx and brkA in ΔkpsT is not directly 
correlated to a lower expression of the bvgAS locus.  
 
Together, these data indicate that deletion of the kpsT ORF in the 
capsule locus altered the expression of at least two key bvg-regulated genes 











      
Figure 3.9: Relative transcriptional activity of vags in BPSM, ΔkpsT and 
ΔkpsTcom in virulent phase.  
 
Total RNA was extracted from BPSM (solid bars), ΔkpsT (dotted bars) and 
ΔkpsTcom (stripped bars) strains grown in virulent Bvg+ phase. Real-time 
PCR analysis was performed using primers mapping in the brkA, ptx, fhaB, 
bvgA and bvgR genes. recA gene was used as the endogenous control. Results 
are expressed as average relative quantification (RQ) vs wild type BPSM 
(RQ=1). Results are expressed as the average relative quantification RQ ± SD 

















Chapter 3: Role of The Capsule Locus 
 
! 123!
3.1.10.2 Microarray analysis  
 
 
To further explore the effect of kpsT deletion on the expression of bvg-
regulated genes, the global transcriptional profile in the ΔkpsT mutant was 
determined and compared to its parental counterpart BPSM using DNA 
microarray technology which screens for a total of 3554 B. pertussis ORFs. 
Mid-exponential Bvg+ phase BPSM and ΔkpsT strains (OD600nm 2) were 
harvested and processed for RNA extraction and microarray hybridization as 
described in section 2.4.10.  
 
The global transcriptional profiling revealed a large number of genes 
that were significantly (adjusted P value < 0.01) down-regulated in the ΔkpsT 
mutant (Appendix 3). The down-regulated transcripts included genes coding 
for autotransporters (vag8, brkA), serine protease (sphB1), putative RNA 
polymerase sigma factor (brpL), components and effector of the type 3 
secretion system T3SS (bcrD, bscD, bopD, bopN, bsp22), pertussis toxin 
accessory genes (ptxABDE), tracheal colonization factor A (tcfA), outer 
membrane porin (ompQ) and components for iron acquisition (hemC, bfrD) 
(Figure 3.10). Furthermore, consistent with our Real-time PCR analysis, 
expression of the bvgAS locus and fhaB was not found to be down-regulated in 
the ΔkpsT mutant (Appendix 3). Notably, expression of the loci BP0454 and 
BP0455, which encode for the hypothetical tripartite ATP-independent 
periplasmic transporters (TRAP) was strongly down-modulated in ΔkpsT 
mutant (Appendix 3). The energy dependent TRAP is ubiquitous in gram-
negative bacteria and plays a crucial role in bacteria physiology and virulence 
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by driving carboxylate sugar and sialic acid uptake into bacteria cell across the 
inner membrane (Mulligan et al., 2011).  
 
The transcriptomic analysis also revealed a gene cluster (BP3812-
BP3838), which exhibited an increased amount of transcripts in a range from 
1.7 to 4 fold in ΔkpsT compared to parental BPSM (Appendix 3). A search 
from GeneDB database (Sanger Institute) revealed that this particular gene 
cluster is flanked by short insertional sequence element (ISE), also known as 
transposable element that encodes transposase. To address whether up-
regulation of this gene cluster is due to kpsT deletion, Real-time PCR analysis 
was performed on BPSM, ΔkpsT and ΔkpsTcom strains with two different sets 
of primers mapping within the BP3812-BP3838 cluster. Consistent with the 
microarray data, increased transcript levels compared to BPSM were observed 
for ΔkpsT (Figure 3.11). However, comparable expression levels were 
obtained for both ΔkpsT and ΔkpsTcom strains, thus indicating that the 
increased expression of the BP3812-BP3838 gene cluster in the ΔkpsT strain is 
independent of kpsT deletion (Figure 3.11). It is possible that this cluster has 
undergone some genetic rearrangement in the ΔkpsT mutant. 
 
In addition to support our Real-time PCR analysis, the microarray data 
revealed that the absence of KpsT affects negatively the expression of a large 
number of bvg-regulated genes. Such overall down-regulation is likely to be 
responsible for the attenuated phenotype observed with the ΔkpsT mutant in 
mice. These observations led us to draw the hypothesis that the BvgA/S-
mediated gene regulation is affected in the ΔkpsT mutant.  






Figure 3.10: Microarray analysis of relative expression levels of selected 
genes that was down-modulated in ΔkpsT mutant.  
 
Total RNA was extracted from BPSM and ΔkpsT strains grown in virulent 
Bvg+ phase. Microarray gene expression values were selected based on log2 
fold change < -0.8, with adjusted P value <0.01. Results are expressed as 
average fold change ΔkpsT compared to BPSM, negative value indicates gene 
repression. Solid bars represent fold change ± SD of 2 independent 
experiments.  
!!!!!!!!!!!!!!!






Figure 3.11: Relative transcriptional activity of BP3818 and BP3838 
ORFs in BPSM, ΔkpsT and ΔkpsTcom in virulent phase.  
 
Total RNA was extracted from BPSM, ΔkpsT (black bar) and ΔkpsTcom (grey 
bar) strains grown in virulent phase. Real-time PCR analysis was performed 
using primers mapping in the BP3818 ORF and BP3838 ORF. recA gene was 
used as the endogenous control. Results are expressed for each target gene as 
average fold change ± SD of triplicate Ct values obtained ΔkpsT and 
ΔkpsTcom versus the Ct value obtained with BPSM strain. The results are 
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 (B) ROLE OF KPST AND THE POLYSACCHARIDE CAPSULE 
TRANSPORT-EXPORT COMPLEX IN THE VIRULENCE OF B. 
PERTUSSIS !
3.2 RESULTS  !
3.2.1 Construction of The B. pertussis KOcaps Strains Expressing kpsT 
and kpsMT Under The Control of Native Capsule Promoter !!
Since deletion of the kpsT ORF did not affect the expression of the 
upstream and downstream ORFs in the capsule operon, it is expected that the 
corresponding proteins involved in polysaccharide capsule transport-export 
and biosynthesis are still being produced in the ΔkpsT mutant. We postulate 
that the role of KpsT on the modulation of bvg-regulated virulence factors 
may require the presence of some other capsule locus-encoded proteins, in 
particular those located in the bacterial envelope, thus susceptible to affect the 
function of BvgS sensor located within the inner membrane. To test this 
hypothesis, kpsT ORF was expressed in KOcaps mutant (deleted for the entire 
capsule operon) under the control of native capsule promoter. Plasmid 
pBBR::PcapskpsT  was electroporated into KOcaps strain and selected based 
on Cm resistance and PCR screening.  
 
In addition, in E. coli, KpsT is a peripheral inner membrane protein 
that binds ATP for active transport of capsule polymers from the cytoplasm to 
the periplasmic face through the integral inner membrane KpsM, forming the 
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KpsMT transporter (Bliss et al., 1996; Pigeon and Silver, 1994). Thus, we 
reasoned that similarly in B. pertussis, KpsM and KpsT may form the KpsMT 
transporter and instead of KpsT alone, KpsMT could interact with the BvgA/S 
signaling pathway. To address this possibility, kpsMT was expressed into the 
KOcaps mutant under the control of native capsule promoter. This strain was 
obtained upon electroporation of the KOcaps mutant with the 
pBBR::PcapskpsMT plasmid construct. 
 
3.2.2 Lung Colonization Profile 
 
To evaluate whether KpsT and/or KpsMT alone is sufficient to restore 
bacterial virulence when expressed in KOcaps, the lung colonization profile of 
KOcaps:kpsT and KOcaps:kpsMT strains was determined in mice and 
compared with wild type BPSM and KOcaps mutant. The KOcaps, 
KOcaps:kpsT and KOcaps:kpsMT strains displayed a significant reduction in 
CFU counts at 3 days and 7 days p.i. compared to BSPM (Figure 3.12). 
However, significantly higher CFU counts were obtained with KOcaps:kpsT 
and KOcaps:kpsMT at 3 days p.i. compared to KOcaps mutant but far lower 
than those observed with BPSM  (Figure 3.12). The results here support that 
neither KpsT alone nor the KpsMT complex is sufficient to restore a parental 
colonization efficacy of the KOcaps mutant, suggesting that the role of KpsT 
on the modulation of bvg-regulated factors and the overall virulence requires 
the entire polysaccharide capsule transport-export machinery. Moreover, it is 
plausible that absence of KpsT at the inner membrane may compromise 
structurally the overall capsule transport-export complex across the cell wall 
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and consequently affect the bvg-mediated virulence, as single gene deletion of 
kpsT leads to bacterial attenuation in vivo and decreased transcriptional 





























Figure 3.12: Lung colonization profile by B. pertussis BPSM, KOcaps, 
KOcaps:kpsT and KOcaps:kpsMT strains.  
 
Balb/C mice were infected intranasally with 5x105 CFU of B. pertussis BPSM 
(solid bars), KOcaps (striped bars), KOcaps:kpsT (dotted bars) and 
KOcaps:kpsMT (open bars). At the indicated time points, four infected mice 
per group were euthanized and their lungs were harvested, homogenized and 
plated on blood agar to determine the total number of CFU per lung. The 
results are expressed as the mean ± SEM of four mice per group. ** p value < 
0.01 relative to KOcaps. Results are representative of two independent 
experiments.  !!!!!!!!!!!!!!!!!
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(C) STUDY OF THE ROLE OF THE CAPSULE LOCUS IN BVG-
MEDIATED SIGNAL TRANSDUCTION !
3.3 RESULTS !
3.3.1 Effects of kpsT Deletion In a Bvg-Constitutive Background !
3.3.1.1 Construction of the B. pertussis kpsT-deleted mutant in a Bvg-
constitutive active strain, BvgS-VFT2 !
Our data so far demonstrate that bvg-regulated gene expression is 
altered in the absence of KpsT. Given the predicted localization of KpsT at the 
inner membrane, we hypothesized that KpsT may directly or indirectly exert 
its effect on the BvgS sensor, an integral plasma membrane protein, thus 
affecting the overall BvgS-mediated phosphorelay and signal transduction. To 
test this hypothesis, we introduced the kpsT deletion in a BPSM-derivative 
Bvg+ phase-locked mutant (Herrou et al., 2009). Such mutant, termed as 
BvgS-VFT2, contains amino acid substitutions at the periplasmic solute-
binding Venus Fly Trap 2 (VFT2) domain of the BvgS sensor, which becomes 
insensitive to environmental modulator MgSO4, thereby resulting in the 
constitutive expression of vags in both modulating and non-modulating 
conditions (Herrou et al., 2010; Herrou et al., 2009). The BPSM derivative 
BvgS-VFT2 strain was kindly provided by Dr. F. J. Dubuisson from Institute 
Pasteur Lille, France.  
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Electrocompetent B. pertussis BvgS-VFT2 strain was electroporated 
with pJQT1-2 plasmid used for the construction ΔkpsT as described in section 
3.1.1. The recombinant pJQT1-2 construct was integrated into BvgS-VFT2 
genome via double homologous recombination, leading to an in-frame 
deletion of the kpsT ORF. Using primers as listed in Table 2.4, BvgS-VFT2 
clones deleted for kpsT were selected by colony PCR screening based on the 
integration into the correct locus. Positive clones were propagated and 
subjected to Southern blot analysis using the same probing strategy as 
described in Figure 3.2 A for the construction of ΔkpsT strain. Southern blot 
reveals a larger fragment size for BvgS-VFT2 and a smaller fragment size for 
BvgS-VFT2-ΔkpsT mutant. The size obtained for BvgS-VFT2-ΔkpsT (~2.7 
kb) versus BvgS-VFT2 (~3.2 kb) counterpart confirms kpsT deletion in the 















Figure 3.13: Southern blot analysis of BvgS-VFT2-ΔkpsT chromosomal 
DNA.  
Restriction-digested chromosomal DNA from BvgS-VFT2 and BvgS-VFT2-
ΔkpsT were electrophoresed, transferred onto a nitrocellulose membrane and 
hybridized with the DIG-labeled probe (Refer to Figure 3.8 A showed probe 
binding site). EcoRI-restricted BvgS-VFT2 and BvgS-VFT2-ΔkpsT 
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3.3.1.2 Production and expression of virulence factors  
 
The production of the three major virulence factors FHA, BrkA and PT 
in BvgS-VFT2-∆kpsT was compared to that observed with the single mutants, 
BvgS-VFT2 and ∆kpsT, as well as wild type BPSM strains grown in both 
virulent (Bvg+) and avirulent (Bvg-) culture conditions. As previously reported 
(Herrou et al., 2010; Herrou et al., 2009), the BvgS-VFT2 Bvg+ phase-locked 
mutant displayed a constitutive production of the three virulence factors in 
both virulent and avirulent phases (Figure 3.14 A). Expectedly, production of 
the virulence factors BrkA and PT was clearly down-modulated in avirulent 
phase for BPSM and ∆kpsT compared to the virulent phase (Figure 3.14 A). 
Interestingly, higher amounts of BrkA, PT and to a lesser extent FHA were 
detected with the BvgS-VFT2-∆kpsT double mutant compared to ∆kpsT single 
mutant in virulent phase, with band signal intensities comparable to those 
observed for wild type BPSM (Figure 3.14 A). This observation thus suggests 
that deletion of kpsT alone in a BvgS-constitutive mutant does not affect the 
production of virulence factors.  
 
Furthermore, real-time PCR analysis was conducted and showed that 
down-regulation of the brkA, ptx and sphB1 genes observed with the ∆kpsT 
single mutant was not observed in the BvgS-VFT2-∆kpsT double mutant 
(Figure 3.14 B). The western blot and real-time PCR analyses thus indicated 
that deletion of kpsT in a Bvg+-phase locked mutant does not affect vag 
expression and that VFT2 mutation in the BvgS sensor is dominant over the 
kpsT deletion.  






      A 
 
Figure 3.14: Production and expression of virulence factors in BvgS-
VFT2-ΔkpsT mutant. 
 
(A) Production of bvg-regulated virulence proteins in BvgS-VFT2-ΔkpsT 
mutant.  
BPSM, BvgS-VFT2, ΔkpsT and BvgS-VFT2-ΔkpsT strains were 
exponentially grown in virulent (Bvg+) and avirulent (Bvg-) phase. Western 
blot analysis was performed on whole cell extract (panel a) and 10x 
concentrated (panel b) or non-concentrated (panel c) culture supernatants 
using (a) anti-BrkA, (b) anti-PT or (c) anti-FHA primary antibodies. The 
results are representative of three independent experiments. Molecular weights 



























          
 
Figure 3.14: (B) Relative transcriptional activity of vags in BvgS-VFT2, 
ΔkpsT and BvgS-VFT2-ΔkpsT versus BPSM in virulent phase.  
 
Total RNA was extracted from BPSM, BvgS-VFT2 (solid bars), ΔkpsT 
(striped bars) and BvgS-VFT2-ΔkpsT (dotted bars) strains grown in virulent 
phase. Real-time PCR analysis was performed using primers mapping in the 
brkA, ptx, and sphB1 genes. recA gene was used as the endogenous control. 
Results are expressed for each target gene as average fold change ± SD of 
triplicate Ct values obtained with BvgS-VFT2, ΔkpsT and BvgS-VFT2-ΔkpsT 
versus the Ct value obtained with BPSM strain. The results are representative 
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3.3.1.3 Lung colonization profile !
To assess whether the restoration of the production of virulence factors 
in the BvgS-VFT2-∆kpsT double mutant (Figure 3.15) is able to re-establish 
bacterial virulence, the lung colonization profile was determined in mice and 
compared to that of BvgS-VFT2 and ΔkpsT single mutants. BvgS-VFT2 strain 
was able to persist and multiply in the mouse respiratory tract up to 7 days p.i. 
at least, in contrast to the ∆kpsT mutant, which displayed an attenuated lung 
colonization profile as early as day 3 p.i. (Figure 3.15). The BvgS-VFT2-
∆kpsT double mutant displayed a colonization profile similar to that observed 
with BvgS-VFT2 (Figure 3.15), demonstrating that the kpsT deletion-
associated attenuation phenotype is lost in a BvgS-VFT2 constitutive mutant. 
Altogether, the results indicate that a bvgS constitutive mutation is able to 
restore the production and expression of bvg-regulated virulence factors in 
∆kpsT, and hence restoring the virulence of the bacteria in vivo. The results 
here suggest for a potential crosstalk between the membrane-associated KpsT 
protein and the BvgA/S signaling pathway. 
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Figure 3.15: Lung colonization profile by B. pertussis BvgS-VFT2, ΔkpsT 
and BvgS-VFT2-ΔkpsT strains.  
Balb/C mice were infected intranasally with 5x105 CFU of B. pertussis BvgS-
VFT2 (solid bars), ΔkpsT (striped bars) and BvgS-VFT2-ΔkpsT (dotted bars). 
At the indicated time points, four infected mice per group were euthanized and 
their lungs were harvested, homogenized and plated on blood agar to 
determine the total number of CFU per lung. The results are expressed as the 
mean ± SEM of four mice per group. ** p value < 0.01 relative to BPSM. 
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3.3.2 Study of The Interaction Between the Capsule Locus Members 
and BvgS  
 
3.3.2.1 Construction of the B. pertussis BPSH strain expressing histidine-
tagged BvgS  !!
 Our findings so far indicate that KpsT is required for proper expression 
of bvg-regulated virulence factors and the entire polysaccharide capsule 
translocon spanning the cell envelope is crucial for B. pertussis virulence. 
Based on these findings, we proposed that the polysaccharide capsule 
transport-export complex, including KpsT, directly or indirectly influences the 
activity of BvgS sensor. To date, interaction between a large translocon 
complex with a two-component sensor within the inner membrane of a 
bacteria has never been described. To decipher whether the BvgS sensor 
protein physically interacts with the polysaccharide transport-export 
machinery and/or KpsT at the inner membrane, we constructed a B. pertussis 
recombinant strain expressing the histidine-tagged BvgS as “bait” protein for 
in vivo affinity purification studies. While the conventional strategy of 
detecting interacting partners involves “bait” protein over-expression, 
isolation and purification from E. coli system followed by in vitro binding 
assay with B. pertussis total cell lysate, it was not particularly relevant in our 
study as we aim to pull down potential interacting partners within the 
membrane envelope of B. pertussis. Moreover, due to its high molecular 
weight (137 kDa) and hydrophobic nature, over-expression of full-length 
BvgS membrane protein in E. coli may not be feasible and has been reported 
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to be toxic to the bacteria cell (Wagner et al., 2006). To construct the B. 
pertussis strain expressing a histidine tag at the N-terminal end of BvgS, six 
histidines encoding sequences were inserted downstream of bvgS signal 
peptide (Figure 3.16). The final plasmid constructed using primers listed in 
Table 2.2, termed as pJQ-BvgSHis6PCR1+2 was electroporated into 
electrocompetent wild-type BPSM. The His6PCR1+2 sequence was integrated 
into the bvgS chromosomal locus via allelic exchange, leading to in-frame 
insertion of histidines coding sequence downstream of the signal peptide 
sequences at the N-terminal end. This is to ensure that the membrane insertion 
of BvgS directed by the signal peptide will not be interfered. The rationale of 
cloning the histidines coding sequences nearer to the N-terminal is to avoid 
interfering with the phopho-transfer reaction that occurs at the C-terminal end 
of BvgS where the phosphate receiver and output domain are located (Figure 
3.16). The resulting strain was named BPSH, where His-tag is fused and 





Figure 3.16: Schematic diagram of His-BvgS chimera. 
 
The amino acid residue numbers are specific for B. pertussis Tohama I BvgS, 
figure adapted and modified from UniProt database P16573 (BVGS_BORPE). 
Yellow region represents the position of His-tag insertion in BvgS. 
 
 




To ensure that insertion of six His at the N-terminal end of BvgS 
sensor does not impair its function and activity, expression of several bvg-
regulated virulence genes such as brkA, ptx, fhaB, bvgR and as well as the 
capsule operon, was accessed in BPSH strain by real-time PCR of the 
expression level of these genes was found comparable to that of parental 
BPSM, suggesting that the presence of six His at the BvgS N-terminal end 

























       
 
Figure 3.17: Relative transcriptional activity of vags and kpsT in BPSM 
and BPSH in virulent phase.  
 
Total RNA was extracted from BPSM (solid bars) and BPSH (stripped bars) 
strains grown in virulent Bvg+ phase. Real-time PCR analysis was performed 
using primers mapping in the brkA, ptx, fhaB, bvgR and kpsT genes. recA gene 
was used as the endogenous control. Results are expressed as the average 
relative quantification (RQ) ± SD of triplicate vs Bvg+ phase BPSM. Results 
are representative of 2 independent experiments.  !!!!!!!!!!!!!!!!!!!!!
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3.3.2.2 Optimization of His-BvgS solubilization  !
 
Bioinformatics tools predict that BvgS protein consists of two trans-
membrane helical domain nearer to the N-terminal end, suggesting that the 
sensor is membrane-associated (Figure 3.16). Prior to elucidate whether the 
BvgS sensor physically interacts with the polysaccharide transport-export 
machinery and/or KpsT at the inner membrane, we first optimized the cell 
extracts preparation enriched in BvgS protein in B. pertussis. According to the 
protocol described by Zaretzky and co-workers, B. pertussis outer and inner 
membrane fraction can be separated by ultracentrifugation and differential 
solubilization in presence of 2% Triton-X-100 (Zaretzky et al., 2002). The 
purpose of separating the membrane fraction from total cellular lysates is to 
enrich the fraction in His-BvgS proteins and to reduce contamination with 
other proteins from the cytoplasmic extract prior to Ni-NTA pull down assay.  
 
Total cell extract was harvested from mid-exponential virulent phase 
bacteria grown in 50 ml of SSAB medium as described in section 2.5.2. BPSH 
cells were sonicated in lysis buffer containing 10mg/ml of lysozyme, followed 
by centrifugation at low speed; 4000 x g for 10 min to remove unbroken cell 
debris. The supernate was subjected to ultra-centrifugation at 100, 000 x g for 
1 h to pellet the total membrane fraction containing both inner and outer 
membrane. The total membrane fraction was dissolved in 2% Triton-X-100 on 
a rotating shaker overnight at 4°C. A small aliquot of each fraction obtained 
from low speed centrifugation (cell pellet and crude supernatant in lysis 
buffer) and ultra-centrifugation (insoluble membrane pellet and solubilized 
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membrane proteins in the supernatant) was mixed with Laemelli blue SDS 
loading buffer containing β-mercaptoethanol. Each of these fractions was 
heated at 95°C and analyzed by Western blot using anti-His and anti-BvgS 
antibody for the detection of His-tagged BvgS protein (Figure 3.18).  
 
Despite a thorough enzymatic and mechanical lysis of B. pertussis, 
BvgS was not released into neither the supernatant nor the membrane-enriched 
fraction obtained by ultra-centrifugation and solubilization with 2% Triton-X-
100 (Figure 3.18). Instead, the 137 kDA BvgS was mainly detected in the cell 
pellet fraction consisting of cellular debris and insoluble proteins after 
sonication and low-speed centrifugation, indicating that BvgS is highly 
insoluble and hydrophobic in nature (Figure 3.18). Nevertheless, the detection 
here confirms that the His-BvgS fusion is successfully expressed in BPSH 
strain, and that the level of expression is comparable to the parental BPSM 
(Figure 3.18). The findings here also suggest that insertion of His-tag at the N-
terminal end of BvgS does not affect its expression at the protein level in B. 















Figure 3.18: Western blot analysis for the detection of His-tagged BvgS. 
 
50 ml of BPSH grown in SS medium was harvested in mid-exponential phase. 
Cells were lysed by sonication using a bioruptor, followed by a brief low-
speed centrifugation (4000 x g) for 10 min and ultracentrifugation (100, 000 x 
g) for 1 h. Each of the fractions was heated to 95 °C for 15 min and analyzed 
under reducing 10% SDS-PAGE. Lanes: 1; BPSM, 2; BPSH. MW markers are 
indicated on the left.  !!!!!!!!!!!!!!!!!!!!!!!!!!!
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Due to the insolubility of BvgS under mild lysis treatment, His-BvgS 
from BPSH was solubilized under denaturing conditions. The washed 
bacterial pellet was lysed by mechanical disruption and incubation with 
lysozyme, Triton-X-100 detergent and finally in 6 M urea as described in 
section 2.5.2.2. Total protein content in the solubilized lysate was measured by 
BCA assay. A total of 5 mg of protein from the solubilized lysate was mixed 
with charged Ni-NTA agarose beads and a final concentration of 20 µM of 
imidazole prior loading to a column chromatography. Purification scheme was 
first optimized with lysate from BPSH bacteria as described in section 2.5.4. 
After 5 rounds of stringent washes through the chromatography column with 
wash buffer containing 20 µM imidazole at pH 6.3 to remove unbound 
proteins, His-BvgS was released in batch from the Ni-NTA beads with the 
urea elution buffer containing 250 µM imidazole at pH 4.5.  
 
A small aliquot of the solublized “input” lysate, column flow-through 
and eluted fractions were mixed with equal volume of Laemelli blue SDS 
loading buffer containing β-mercaptoethanol and heated at 95°C for 15 min. 
Each of these fractions was analyzed by Coomassie blue staining (Figure 3.19 
A) and Western blot (Figure 3.19 B). Untag parental control, BPSM was 
harvested and purified concurrently with BPSH. His-BvgS was successfully 
purified from the solubilized cellular extract of BPSH under denaturing 
conditions on a Ni-NTA chromatography column, with a majority of the His-
BvgS protein detected in the second (E2) and third elution (E3) fractions as 
evidenced by the detection of a band of an apparent molecular weight (MW) 
of 140 kDa which corresponds to monomeric His-BvgS (predicted size of 137 
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kDa) on a Coomassie blue stained SDS-PAGE denaturing gel (Figure 3.19 A). 
Western blot analysis using anti-His and anti-BvgS antibodies further 
confirmed the identity of the 140 kDa eluted protein as His-BvgS monomers 
in E2 and E3 from BPSH but not from BPSM extracts (Figure 3.19 B). A band 
at 50 kDa MW was also observed in E3 and E4 from both BPSM and BPSH, 
suggesting that this unknown protein bound to the Ni-NTA agarose beads may 

















Figure 3.19: Expression and purification of His-BvgS by Ni-NTA 
chromatography.  
 
5 mg of solubilize cell lysate harvested from BPSM (untag control) and BPSH 
was mixed with Ni-NTA agarose beads prior to loading onto a 
chromatography column. Solubilized lysate input, flow-through and batch 
eluted fractions were heated to 95 °C for 15 min and analyzed under reducing 
10% SDS-PAGE.  
(A) Coomassie blue staining, Lane IP; Input, FT; Flow through, E1; Eluted 
fraction 1, E2; Eluted fraction 2, E3; Eluted fraction 3, E4; Eluted fraction 4. 
Molecular weights are indicated on the right side.  
(B) Western blot analysis with anti-His and anti-BvgS antibodies. Lane IP; 
Input, FT; Flow through, E2; Eluted fraction 2, E3; Eluted fraction 3. 
Molecular weights are indicated on the right side. 
 
 !!!!!!!!!!!
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3.3.2.3 Detection of purified His-BvgS under reducing and non-reducing 
conditions 
 
A comparative analysis for the formation of protein complexes from 
purified His-BvgS was analyzed by denaturing SDS-PAGE and Western blot 
in the presence and absence of reducing agent β-mercaptoethanol. Western 
blot analysis revealed the presence of a high MW protein complex (greater 
than 260 kDa) which reacts with both anti-His and anti-BvgS antibodies and 
disappears under reducing conditions and/or upon heat treatment (Figure 3.20 
A). Concomitantly, a stronger signal intensity of the 140 kDa band was 
observed under reducing conditions (Figure 3.20 A). The observation here 
thus strongly suggests that BvgS is able to form high MW complexes that 
dissociate upon heat treatment and/or addition of β-mercaptoethanol. The 
denaturing mechanism of urea and guanidine hydrochloride mainly targets the 
intramolecular hydrogen bonds, thus weakening the overall hydrophobic 
structure of a protein (England and Haran, 2011). Given the denaturing 
conditions used for purification of BvgS, it unexpected that such high 
molecular complexes were still detected upon Ni-NTA column elution in the 
absence of heat and reducing agent. This observation may be explained by the 
presence of several functionally important amino acid residues within the 
hydrophobic core of BvgS involved in inter- and intramolecular interactions 
for example covalent, peptide and disulphide bonds that may be involved in 
maintaining the conformational tension of the sensor kinase. 
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To further investigate the nature of the high MW complexes that are 
resistant to guanidine hydrchloride treatment, the corresponding band gel was 
excised from a Coomassie-blue stained non-reducing SDS-PAGE gel and 
subjected to Triple-TOF mass spectrometry analysis (Figure 3.20 B). MS 
analysis further confirmed with high confidence that majority of the protein 
complex consists of BvgS protein with no detection of any of the membrane 
proteins from the capsule transport machinery (Table 3.1). Nevertheless, the 
possibility that KpsT or any other membrane proteins involved in the capsule 
transport machinery interacting physically and directly with BvgS should not 
be disregarded based on this pull-down assay, as potential interacting partner 
for BvgS may be lost under denaturing conditions. The high MW complexes 
captured from His-BvgS purification likely consist of BvgS multimers, 
confirming previous reports on the possible homodimerization of truncated 
domains of BvgS in E. coli (Beier et al., 1995; Perraud et al., 2000).  
 
Due to the solubility of BvgS under denaturing condition which may 
result in the loss of association between proteins, we have attempted another 
alternative pull-down scheme, whereby both BPSM control and BPSH strain 
were treated with cross-linking agent to link potential interacting partners with 
His-BvgS. The solubilized bacteria lysate was subjected to Ni-NTA column 
chromatography as described in Figure 3.19. However, pull-down of His-
BvgS from cross-linked BPSH samples could not be distinguished from 
BPSM untag control due to high non-specific binding to the Ni-NTA column 
(Data not shown). Chemical cross-linkers are known to link protein(s) that are 
in close proximity with the  “bait” protein, leading to high background 
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consisting of non-specific binding partners (Kaake et al., 2010; Klockenbusch 
and Kast, 2010). Thus, a number of membrane proteins spanning the cell 
envelope of B. pertussis were likely cross-linked to His-BvgS and hence co-
purfied with BvgS despite having no true interaction with BvgS. More 
stringent washes conditions before elution from the column could potentially 
























Figure 3.20: Detection of purified BvgS by Western blotting and SDS-
PAGE. 
 
(A) Detection of BvgS associated oligomers and BvgS monomer by 
Western blotting.  
Purified His-BvgS from BPSH cells were mixed with equal volume of 
Laemmli Blue sample buffer containing either no reducing agent (0% β-
mercaptoethanol) or increasing concentrations (2.5% and 5% β-
mercaptoethanol). The proteins samples were then subjected to either no heat 
or heat denaturation at 95°C for 15 min prior to SDS-PAGE analysis and 
Western blotted with anti-His or anti-BvgS antibody. Molecular weights are 
indicated on the right side.  
(B) Non-reducing SDS-PAGE analysis of purified His-BvgS.  
Purified His-BvgS batch eluted from fraction 2 and 3 are subjected non-
reducing SDS-PAGE and Coomassie blue staining. BPSM was used as untag 
control. The asterisk labelled regions of above 260 kDA corresponding to the 
Western blot signals was gel excised for Triple-TOF MS analysis. Lane 1; 























Table 3.1: Protein summary report generated by ProteinPilot software.  
 
Based on Figure 3.20 B, high molecular weight complex observed on the 
Coomassie blue stained SDS-PAGE gel from elution fraction 2 and 3 of His-
BvgS purified from BPSH were gel excised and sent for Triple-TOF mass 
spectrometry analysis, a service provided by the Protein and Proteomics 
Centre, Department of Biological Science, NUS. Identities and scoring were 
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3.3.2.4 Construction of the BPSH strain deleted for kpsT or the entire 
capsule operon 
 
In the context of the bacterial cell wall, the structural stability of 
membrane proteins forming oligomers is fundamental for their function, and 
in this case the stability of BvgS oligomers in signal integration and 
transduction from the extracellular environment. To extend our understanding 
whether the products of the capsule locus affect BvgS oligomerization, 
deletion of the entire capsule operon and kpsT was introduced into the BPSH 
strain.  
 
To construct B. pertussis BPSH strain deleted for the entire capsule 
operon and kpsT, suicide vector pJQSY4 (Neo et al., 2010) and pJQT1-2 
(Section 3.1.1) were used for allelic exchange in BPSH. pJQSY4 and pJQT1-2 
were separately integrated into the B. pertussis genome via double 
homologous recombination, leading to in-frame deletion of the capsule operon 
and kpsT gene, respectively. Positive clones were expanded and subjected to 
Southern blot analysis using the DIG-labeled probing strategy as depicted in 
Figure 3.21 A for the confirmation of BPSH-KOcaps strain, and Figure 3.2 A 
under section 3.1.2 for the confirmation of BPSH-ΔkpsT mutant.  
 
Southern blot analysis revealed the expected sizes for both BPSH-
KOcaps (~1 kb) and BPSH-ΔkpsT (~2.7 kb) relative their wild-type 
counterpart (Figure 3.21 B), thus confirming the deletion of the 10 kb capsule 
operon and kpsT at the correct region. To complement the BPSH-ΔkpsT 
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mutant, pBBR::PcapskpsT plasmid (section 3.1.3) was electroporated into the 
electerocompetent BPSH-ΔkpsT, yielding the chloramphenicol resistant strain 




















Figure 3.21: Southern blot analysis of BPSH-KOcaps and BPSH-ΔkpsT 
chromosomal DNA.  
(A) Strategy for Southern blot analysis for BPSH-KOcaps mutant.  
The DIG-labeled probe binding region (black rounded arrow), restriction sites 
and size of restriction-digested chromosomal DNA for Southern blot analysis 
are as shown. 
(B) Southern blot analysis of B. pertussis chromosomal DNA.  
Restriction-digested chromosomal DNA from BPSH, KOcaps and BPSH-
KOcaps or BPSH-∆kpsT were electrophoresed, transferred onto a 
nitrocellulose membrane and hybridized with the DIG-labeled probe (Refer to 
Figure 3.32 A showed probe binding site for BPSH-∆kpsT). Panel a, SalI-
restricted BPSH, KOcaps and BPSH-KOcaps DNA yielded 4.1-kb and 935 bp 
respectively. Panel b, EcoRI restricted BPSH and BPSH-∆kpsT DNA yielded 
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3.3.2.5 Purification of His-BvgS from BPSH, BPSH-KOcaps and BPSH-
ΔkpsT strains 
 
Affinity purification of His-BvgS from BPSH, BPSH-KOcaps and 
BPSH-ΔkpsT strains was performed as described in section 3.3.2.3. Purified 
His-BvgS fractions from all of the constructs were subjected to Western blot 
analysis under reducing and non-reducing conditions. Strikingly, Western blot 
analysis revealed that under non-reducing conditions, the signal intensity of 
the high MW band >260 kDa was much lower for the BPSH-KOcaps and 
BPSH-ΔkpsT compared to BPSH (Figure 3.22 A, B). Instead, a higher signal 
intensity of the 140 kDa band was observed for both mutants compared to 
BPSH under non-reducing condition. The complemented BPSH-ΔkpsTcom 
displayed a partial parental BPSH phenotype in non-reducing condition 
whereby a greater signal intensity of the high MW band was observed with 
BPSH-ΔkpsTcom compared to BPSH-ΔkpsT (Figure 3.22 B). Under reducing 
conditions, expectedly, the high MW band disappeared and comparable signal 
intensities of the 140 kDa band were observed for all the strains (Figure 3.22 
A, B), suggesting that the capsule locus, including KpsT, is fundamental for 
BvgS oligomerization. Taken together, these pull-down approaches further 
support a link between the capsule locus (KpsT in particular) and BvgS 
oligomerization in B. pertussis.  




Figure 3.22: Detection of BvgS associated oligomers and BvgS monomer.  
(A) Detection of BvgS associated oligomers and BvgS monomer in BPSH 
and BPSH-KOcaps.  
Equal amount of purified His-BvgS from BPSH and BPSH-KOcaps cells were 
mixed with Laemmli blue sample buffer containing either no reducing agent 
or with 5% β-mercaptoethanol. The proteins samples were then subjected to 
either no heat or heat denaturation at 95°C for 15 min. Equal amount of 
protein were loaded for each well for SDS-PAGE analysis and Western 
blotted with anti-BvgS antibody. Molecular weights are indicated on the right 
side.  
(B) Detection of BvgS associated oligomers and BvgS monomer in BPSH, 
BPSH-ΔkpsT and BPSH-ΔkpsTcom by Western blotting.  
Equal amount of purified His-BvgS from BPSH, BPSH-ΔkpsT and BPSH-
ΔkpsTcom cells were mixed with Laemmli Blue sample buffer containing 
either no reducing agent or with 5% β-mercaptoethanol. The proteins samples 
were then subjected to either no heat or heat denaturation at 95°C for 15 min. 
Equal amount of protein were loaded for each well for SDS-PAGE analysis 
and Western blotted with anti-BvgS antibody. Molecular weights are indicated 
on the right side.  !!!!!!!
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3.3.3 Assessment of Membrane Integrity In kpsT-Deleted Mutant  
 
We postulated that absence of KpsT and the polysaccharide capsule 
transport-export machinery may alter the overall cell envelope structure and/or 
the cellular membrane integrity, thus affecting the ability of BvgS to sense and 
integrate extracellular signals, thereby altering the dimerization of BvgS 
and/or signal transduction to downstream regulator protein BvgA. The 
putative KpsM and KpsT protein sequences of B. pertussis are highly similar 
to an ABC transporter protein family, with KpsM harboring the predictive 
trans-membrane domain and KpsT the nucleotide ATP-binding domain. 
Several studies have suggested that alteration of the ABC transporter structure 
or function and absence of the ATP-binding protein cognate partner induces 
membrane stress and damage (Attia et al., 2010; Zhong et al., 1996). 
Therefore, it is conceivable here that the absence of KpsT in B. pertussis may 
alter the inner membrane environment and/or integrity thereby affecting the 
function of other membrane proteins such as BvgS sensor. 
 
To test this hypothesis, we compared the sensitivity of BPSM, ΔkpsT 
and ΔkpsTcom to erythromycin, a large hydrophobic macrolide, and one of the 
most commonly used antibiotics to treat pertussis (Bergquist et al., 1987; 
Trollfors, 1978; Zackrisson et al., 1983). To reach its cytoplasmic target the 
50s ribosomal subunit, erythromycin must cross the bacterial envelope and 
inner membrane. We reasoned that the absence of KpsT protein may modify 
the diffusion rate of erythromycin across the plasma membrane thereby 
leading to a different sensitivity of ΔkpsT mutant to this antibiotic. While the 
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in vitro growth profiles of BPSM, ΔkpsT and ΔkpsTcom in the absence of 
erythromycin were comparable (Figure 3.23, left panel), growth of ΔkpsT was 
completely inhibited in the presence of sub-lethal concentration of 
erythromycin 0.05 µg/ml (Zackrisson et al., 1983), as opposed to parental 
BPSM and ΔkpsTcom which kept multiplying over time (Figure 3.23, right 
panel). The increased susceptibility of ΔkpsT mutant to erythromycin may 
therefore reflect some structural changes and perturbed integrity of the 
bacterial plasma membrane.  
 
 
To further investigate this possibility, ΔkpsT was subjected to other 
chemical treatments known to perturb the bacterial membrane integrity (Attia 
et al., 2010; Baud et al., 2009; Plesa et al., 2006). BPSM, ΔkpsT and 
ΔkpsTcom were incubated with 0.02% SDS for 2 h to induce membrane 
permeabilization and analyzed by flow cytometry for the uptake of propidium 
iodide (PI), a membrane impermeant and DNA specific dye. The results 
indicated a significantly higher percentage of PI+ ΔkpsT bacteria compared to 
the parental and complemented strains (Figure 3.24 A). The increased 
sensitivity to SDS seen with ΔkpsT thus provides further support to the idea 
that in this mutant the membrane integrity and permeability are perturbed.  
 
Cationic chelating agent EDTA induces membrane permeabilization, 
irreversible destabilization and release of LPS from Gram-negative bacteria 
(Leive, 1965; Vaara, 1992). BPSM, ΔkpsT and ΔkpsTcom bacteria were 
incubated with sub-lethal concentrations of EDTA for 2 h and bacteria 
viability was assayed by CFU counting. At both EDTA concentrations of 
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2mg/ml and 1mg/ml, it was found that parental BPSM survived significantly 
better than ΔkpsT mutant (Figure 3.24 B). Parental susceptibility to EDTA-
mediated killing was observed with ΔkpsTcom strain (Figure 3.24 B). It must 
be noted however, that although ΔkpsT mutant is more susceptible to killing 
and permeabilization by these agents, our data do not rule out the possibility 
that absence of the surface capsule polysaccharide may also be a factor that 
may be involved in the increased sensitivity to erythromycin, SDS and EDTA. 
Taken together, these findings support that the membrane associated KpsT 
























Figure 3.23: Growth kinetics of BPSM, ΔkpsT and ΔkpsTcom in the 
presence of erythromycin.  
SS liquid medium was inoculated with BPSM (closed circles), ΔkpsT (open 
circles) and ΔkpsTcom (open squares) at initial OD600nm of 0.1 at time-point 0 
h without (left panel) and with 0.05µg/ml erythromycin (right panel). 
OD600nm was monitored throughout incubation at 37ºC. A representative of 3 



































Figure 3.24: Effect of SDS and EDTA on BPSM, ΔkpsT and ΔkpsTcom 
strain.  
(A) Effect of SDS on BPSM, ΔkpsT and ΔkpsTcom strain.  
BPSM, ΔkpsT and ΔkpsTcom strain were incubated with 0.02% SDS (white 
histogram) and without SDS (grey histogram). Both SDS-treated and 
untreated bacteria were stained with propidium iodide (PI). The fluorescent 
cells were detected by flow cytometry, with 20,000 events counted for each 
sample. A representative experiment is shown from 3 independent 
experiments, with percentage of fluorescent cells indicated in each panel with 
respect to the untreated control for each sample.  
(B) Effect of EDTA treatment on BPSM, ΔkpsT and ΔkpsTcom viability. 
BPSM, ΔkpsT and ΔkpsTcom strains were incubated with 2mg/ml and 1mg/ml 
of EDTA for 2 h. Viable bacteria were enumerated on BG agar after 3 days of 
incubation. Data is expressed as the mean ± SEM from 3 independent 








3.4.1 Construction of B. pertussis Capsule Deficient Mutants  !!
The biological role of the polysaccharide capsule, a complex structure 
often associated with microbial virulence and an important vaccine target for 
many pathogens, remains uncharacterized in B. pertussis. In a previous work, 
our lab showed that B. pertussis bacteria produces an intact and distinct 
polysaccharide capsule at the bacteria surface, and demonstrated that this 
structure does not participate in the classical capsule-defense mechanisms 
including phagocytosis, complement-mediated killing and antimicrobial 
peptides attack (Neo et al., 2010). Although classified as a bvg-repressed gene 
(vrg) with maximal expression in Bvg- growth phase (Antoine et al., 2000; 
Hot et al., 2003), substantial transcriptional activity of the capsule operon was 
detected when bacteria are grown in virulent Bvg+ phase (Nakamura et al., 
2006; Neo et al., 2010), implying that the capsule operon is expressed during 
the virulent phase and may play a role in pertussis pathogenesis.  
 
The role of B. pertussis polysaccharide capsule was investigated by 
constructing an unmarked in-frame deletion of kpsT, kpsE and vipC ORFs 
within the capsule operon of B. pertussis Tohama I derivative strain, BPSM. 
The predicted amino acid sequence of B. pertussis KpsT protein exhibits 
significant degree of homology with several other proteins responsible for 
active transport of capsular polysialic acid polymers, including KpsT from E. 
coli (40% identity) and HexA from Pasteurella multocida (44% identity), 
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supporting that B. pertussis KpsT performs a similar function (Parkhill et al., 
2003). B. pertussis KpsE has been proposed to function as the capsular 
polysaccharide exporter across the periplasmic space, a function similar to that 
of KpsE from E. coli (27% identity) and CtrB of N. meningitides (30% 
identity). Using HMMTOP 2.0 trans-membrane topology prediction software 
(Tusnady and Simon, 2001), KpsT was found to adopt six transmembrane 
spanning domains whereas KpsE has two trans-membrane domains. The B. 
pertussis VipC protein instead does not harbor any trans-membrane domain 
and is homologous to the Vi polysaccharide biosynthesis protein TviD of S. 
typhi (23% identity), thus suggesting a role of VipC in the polysaccharide 
biosynthesis.  
 
Immuno-detection method using anti-Vi antigen antibodies as 
previously described (Neo et al., 2010), suggested that deletion of either ORF 
namely kpsT, kpsE and vipC is sufficient to prevent the detection of a capsular 
structure at the bacterial surface, a similar phenotype observed in ΔkpsT or 
ΔkpsE of E. coli mutant strains (Bronner et al., 1993b; Pavelka et al., 1994). It 
is conceivable that the polysaccharide capsule transport-export process might 
be defective in B. pertussis kpsT and kpsE deleted mutants, thus resulting in 
the accumulation of polysaccharide polymers within the cytoplasm. It has 
been reported that deletion of kpsT in E. coli lead to accumulation of 
polysaccharide polymers at the inner cell periphery due to defect in the 
transport process (Bliss et al., 1996; Pavelka et al., 1994). Similarly, 
intracellular polysaccharide accumulation may also occur in the B. pertussis 
∆kpsT and ∆kpsE strains, which may affect the cell viability and overall 
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fitness. However, no in vitro growth defect was noticed for these mutants. In 
addition, the B. pertussis KOcaps mutant deleted for the entire capsule locus 
and for which polysaccharide accumulation does not occur, displayed an 
attenuation profile in vivo comparable to that seen with the ∆kpsT mutant. 
These observations therefore do not support the hypothesis that intracellular 
accumulation of capsule polysaccharide polymers occurs in the ∆kpsT and 
∆kpsE strains and is responsible for the in vivo attenuated phenotype observed 
with these mutants, which is further discussed in the next section 3.4.2.  
 
3.4.2 Attenuation of B. pertussis Capsule Deficient Mutants  !
Mice lung colonization profile revealed that the membrane-associated 
KpsT and to a lesser extent KpsE are required for optimal and efficient B. 
pertussis colonization whereas VipC is dispensable. This is a key observation 
that indicates that rather than the surface-exposed capsule itself, the 
membrane-associated protein KpsT and to a lesser extent KpsE, is important 
for pertussis pathogenesis. In addition, Western blot and Real-time PCR 
approaches have shown that the production and/or secretion of key virulence 
factors such as BrkA, PT and FHA essential for bacterial colonization were 
slightly impaired in ΔkpsT, and to a lesser degree for BrkA and PT in ΔkpsE, 
whereas the ΔvipC mutant displayed parental levels of PT and FHA 
production. While the transcriptional activity of ptx and brkA was significantly 
reduced in the ∆kpsT mutant, transcription of bvgA/S, bvgR and fhaB was not 
affected. Importantly, complementation of ΔkpsT was not fully restored to a 
parental level expression at the transcript and protein level.  The reason for the 
Chapter 3: Role of The Capsule Locus 
 
! 167!
partial restoration of these genes expression in ΔkpsTcom is unclear whereas 
complete restoration of the in vivo phenotype was observed. It is possible that 
expression of kpsT ORF from a multicopy replicative plasmid (pBBR1MCS) 
(Elzer et al., 1995) may alter the KpsM/ KpsT protein ratio to form an ABC 
transporter complex, which may in turn result in sub-optimal transcriptional 
and/or translational feedback onto these genes.  
 
 The differential down-regulation of these bvg-regulated genes in 
∆kpsT likely reflects the different affinities of each promoter for 
phosphorylated BvgA (P-BvgA), the transcriptional regulator of the BvgA/S 
two component system (Zu et al., 1996). As such, a decrease in P-BvgA levels 
will first affect the bvg-regulated promoters with low affinities for P-BvgA. 
Consistently, the ptx promoter was shown to require higher concentrations of 
P-BvgA than the fhaB and bvgA promoters to activate their transcription 
(Steffen et al., 1996). The affinity of the brkA promoter for BvgA-P has not 
been studied in details, but it appears from our study that it might be rather 
low as evidenced by the 10-fold reduction of brkA transcriptional activity in 
the ΔkpsT mutant.  
 
Nevertheless, the mild attenuation in the production of FHA, BrkA and 
PT is unlikely to account for the in vivo attenuation observed. It is instead 
more plausible that a general effect may occur in the ∆kpsT mutant leading to 
the significant attenuated in vivo phenotype. Indeed, genome wide microarray 
analysis conducted on ∆kpsT mutant further revealed significantly reduced 
transcriptional activity of a number of bvg-regulated genes, in particular those 
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that encode virulence factors associated with bacterial colonization. In 
addition to fhaB, brkA and ptx, the tcfA gene coding for the tracheal 
colonization precursor factor A shown to play a role in bacterial adherence to 
the mouse trachea (Finn and Stevens, 1995), was found down-regulated. Vag8 
encoding the autotransporter Vag8 involved in in vivo colonization (Elder and 
Harvill, 2004; Finn and Amsbaugh, 1998) was also down-regulated in the 
∆kpsT mutant. Interestingly, also down-regulated was sphB1 encoding the 
autotransporter subtilisin-like serine protease SphB responsible for the 
proteolytic cleavage of FHA at the bacterial surface (Coutte et al., 2003; 
Coutte et al., 2001). SphB down-regulation likely explains the lower amounts 
of FHA detected in the culture supernatant but not in the bacterial lysates of 
∆kpsT, supporting that FHA secretion, but not production is impaired in this 
mutant. Altogether, the microarray data thus support that the down-regulation 
in ∆kpsT of a number of virulence genes involved in the colonization efficacy 
is likely responsible for the attenuated phenotype observed in mice. Moreover, 
previous work has shown that, whereas the absence of a single virulence factor 
in B. pertussis resulted only in mild or no attenuation, multiple deletions in 
genes encoding adhesins and toxins significantly impaired the ability to 
colonize the mice lungs, supporting some degree of functional redundancy 
among the different virulence factors (Alonso et al., 2001; Carbonetti et al., 
2005).  
 
In addition to the known vags that have been well studied, other bvg-
regulated genes that might be involved in pathogenesis of B. pertussis were 
also found negatively regulated in the ∆kpsT mutant. Previous studies have 
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suggested that bfrD encoding the TonB-dependent receptor for iron transport 
and hemC encoding the putative iron scavenger, both regulated by the BvgA/S 
system, were up-regulated in wild-type B. pertussis under iron starvation 
condition (Brickman et al., 2011). Down-modulation of these iron-scavenging 
genes in ∆kpsT may suggest that this mutant is impaired in its iron acquisition 
ability, which may likely affect its survival within the host. The T3SS locus 
consisting of bsp22, bopA, bscD and bcrD genes was also found down-
regulated in ∆kpsT. This locus has been reported in several B. pertussis 
clinical isolates and B. bronchiseptica to be necessary for optimal bacterial 
colonization and persistence, and to be involved in host immunomodulation 
(Fennelly et al., 2008; Skinner et al., 2005). However, although 
transcriptionally active under the control of bvg regulation, the T3SS locus in 
the laboratory-adapted B. pertussis Tohama I strain was not translated, as 
opposed to that of B. pertussis clinical isolates, with reports suggesting that 
long-term laboratory passage, minimal contact with host cells and large-scale 
genomic re-arrangements have led to post-transcriptional silencing of the 
T3SS locus (Fennelly et al., 2008; Mattoo et al., 2004). Therefore, the 
attenuated colonization profile displayed by the BPSM Tohama I derivative 
∆kpsT mutant cannot be attributed to the down-modulation of the T3SS locus. 
 
3.4.3 Molecular Cross-talk Between the B. pertussis Capsule Locus and 
bvg-Mediated Signal Transduction  !!
The predominant molecular events that were observed in ∆kpsT mutant 
suggest that bvg-mediated mechanism(s) may be compromised in this mutant. 
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Therefore, this prompted us to elucidate whether the bvg-mediated mechanism 
is dependent or independent of KpsT. Deletion of kpsT in a Bvg+ phase-locked 
background did not lead to reduced vag expression and impairment of in vivo 
virulence as observed with the parental ∆kpsT mutant, thus suggesting a 
regulatory link between KpsT and the BvgA/S-mediated signal transduction 
pathway. Moreover, failure to restore parental colonization of the KOcaps 
mutant by expressing KpsT alone or the KpsMT complex suggested that other 
protein members from the capsule operon are necessary.  
 
The model of a two-component system comprises of a sensor kinase 
and response regulator, which are often thought to organize in a linear mode 
of action, from the perception of stimulus to downstream phosphorelay 
activation and transcriptional responses. Many other studies, however, have 
shown that the complexity of a bacterial two-component system was generally 
overlooked. Direct and/or indirect cross-talk between two-component systems 
and its non-cognate partners have been widely reported as a new paradigm in 
bacterial signal transduction (Casino et al., 2010; Eguchi and Utsumi, 2005; 
Fink et al., 2012; Jung et al., 2012; Krell et al., 2010; Mitrophanov and 
Groisman, 2008). They affect the downstream phosphorylation activity of the 
senor and response regulators, thus modulating the overall output of the two-
component system (Mitrophanov and Groisman, 2008). Furthermore, and 
more relevant to our own observations, reports of inner membrane proteins 
interacting physically and influencing a two-component sensor kinase activity 
have been recently described in different pathogens (Eguchi et al., 2007; Jung 
et al., 2012; Lippa and Goulian, 2009). 




We initially predicted that within the context of cell envelope, the 
polysaccharide capsule transporter-exporter complexes in B. pertussis might 
have a functional or interactional effect on the trans-membrane BvgS sensor. 
In this study, we purified BvgS directly from B. pertussis strains grown in 
Bvg+ phase. Prior to purification, a series of conditions were optimized to 
ensure that BvgS is fully solubilized and released from B. pertussis cellular 
membranes. We noted that full length BvgS was insoluble under native lysis 
buffer even with strong mechanical disruption, unlike the truncated BvgS 
domain previously expressed in E. coli (Beier et al., 1995; Dupre et al., 2013). 
Denaturation of BvgS by guanidine hydrochloride ultimately solubilized His-
BvgS proteins and could be purified via Ni-NTA column. Under such harsh 
denaturing conditions, BvgS is expected to be in unfolded state due to the 
breakage of hydrogen bonds and hydrophobic interactions upon guanidine 
hydrochloride treatment. Nevertheless, we still observed by SDS-PAGE the 
presence of BvgS-associated oligomers, which dissociated into BvgS 
monomers upon heat treatment or upon addition of a reducing agent. While it 
is surprising that such high molecular weight structure is resistant to strong 
denaturant such as guanidine hydrochloride, it has been reported that large 
hydrophobic proteins, in particular membrane proteins or proteins that contain 
proline rich homeodomain are resistant to denaturation by urea or guanidine 
hydrochloride (Gokhale et al., 1996; Makino et al., 1981; Shukla et al., 2012). 
BvgS sensor contains two separate alanine-proline rich regions within the 
cytoplasmic histidine kinase and receiver domains (Miller et al., 1992; Uhl 
and Miller, 1996), and it has been reported in eukaryotic system that proline 
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rich regions mediate protein dimerization and oligomerization (Shukla et al., 
2012; Soufi et al., 2006). Whether these features are responsible for 
maintaining the conformational tension between BvgS oligomers in B. 
pertussis remain to be investigated. In the context of chemical bonds within 
BvgS oligomers interface, it is also plausible that strong covalent bonds and 
disulphide bonds exist within the macromolecular structure associated with 
BvgS oligomers.  
 
Our data demonstrate that the entire polysaccharide capsule translocon 
machinery and KpsT is essential for the oligomerization, presumably 
homodimerization, of the BvgS sensor. Biochemical and structural evidences 
have indeed confirmed that BvgS homodimerizes at two domains within the 
C-terminal cytoplasmic region, namely the transmitter and receiver-output 
domains (Beier et al., 1995). Moreover, active phosphotransfer could be 
reconstituted in trans between BvgS domains, thus further supporting the 
dimerization capacity of BvgS in vivo (Beier et al., 1995; Perraud et al., 2000). 
Dimerization and higher order oligomerization of signalling complexes in 
general and BvgA/S in particular are believed to be important for intrinsic 
phospho-transfer activity and activation of downstream regulator proteins 
(Maeda et al., 2006; Scheu et al., 2010). Our work is the first experimental 
demonstration of the existence of BvgS oligomers in the B. pertussis bacteria 
since all the previous studies were performed in E. coli with truncated BvgS 
proteins (Beier et al., 1995; Perraud et al., 2000).  
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It is conceivable here that the absence of KpsT and the polysaccharide 
capsule transport-export machinery may alter the inner membrane 
environment and integrity such that it affects its ability to sense and integrate 
extracellular signals, thereby altering the dimerization of BvgS and/or signal 
transduction to downstream regulator protein BvgA, which in turn fine tune 
transcriptional regulation of genes involved in pathogenesis. Fine tuning of 
virulence gene expression during B. pertussis in vivo infection is crucial for 
bacterial virulence during different stages of infection within the host 
environment (Beier and Gross, 2006; Strauss, 1995; Veal-Carr and Stibitz, 
2005). From a different perspective, some unknown post-translational 
modification(s) that are involved in the synthesis and dissociation of chemical 
bonds such as covalent bonds, peptide bonds and disulphide bridges, may 
eventually lead to the variation in BvgS oligomerization observed between the 
wild-type bacteria and ΔkpsT mutant.  
 
The precise mechanisms underlying the role of KpsT in BvgS 
oligomerization are intriguing and we reasoned that it might have an indirect 
effect via its role on the overall membrane integrity. Our further observations 
on the sensitivity of ∆kpsT towards erythromycin, SDS and EDTA, compared 
to the parental BPSM strain, seem to land support to the above hypothesis. 
However, the absence of the surface polysaccharide capsule in ΔkpsT mutant 
may also be responsible for these latest phenotypes observed. To distinguish 
between these two possibilities, the ΔvipC mutant should be included in in this 
assay. Indeed, ΔvipC mutant was shown to be capsule-free but did not display 
a drastic in vivo phenotype in the mouse model of pertussis. Should ΔvipC 
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display sensitivity to erythromycin, SDS and EDTA that is similar to that 
observed with ΔkpsT, it will indicate that the PS capsule at the bacterial 
surface is primarily responsible for these phenotypes. Instead, should ΔvipC 
display a parental phenotype, it will support the idea that KpsT is specifically 
involved in the bacterial resistance to these treatments and may therefore 
contribute to the plasma membrane integrity. Absence of KpsT, the ATPase 
cognate partner of the integral membrane KpsM, may indeed eventually lead 
to a complete disorganization of the entire capsule transport machinery within 
the cell envelope which may affect the overall membrane integrity and 
permeability. This is further supported by the observation that in vivo 
attenuation was seen with a ΔkpsE mutant, and that re-introduction of KpsT or 
KpsMT into the KOcaps mutant was not sufficient to restore a parental 
phenotype. Collectively, these findings support that absence of KpsT in the 
ΔkpsT mutant may actually affect the trans-envelope complex formed by the 
PS capsule transport proteins. Further structural analysis would be necessary 
to strengthen this hypothesis.   
 
3.4.4 Role of The Capsule Locus, a bvg-Repressed Factor in Pertussis 
Pathogenesis  !
The pathogenesis of B. pertussis has been extensively studied and 
reviewed for the past 25 years, including the characterization of numerous 
bacterial factors responsible for virulence. As an obligate human pathogen, B. 
pertussis has evolved favorably by expressing a wide variety of virulence 
factors that promote its life cycle, transmission, colonization and defense 
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against host immune responses in the upper respiratory tract. It has been well 
established that the Bvg+ phase-locked B. pertussis and B. bronchiseptica, a 
close relative of B. pertusiss, were able to colonize the respiratory tract as 
efficiently as the wild type strains, indicating that the bvg-activated genes, 
namely the vags are sufficient for B. pertussis virulence (Cotter and Miller, 
1994; Martinez de Tejada et al., 1998). In contrast, the avirulent Bordetella 
variants such as the Bvg- phase-locked mutant, characterized by high 
expression levels of vrgs and low expression levels of vags, displayed an 
attenuated phenotype in vivo (Cotter and Miller, 1994; Martinez de Tejada et 
al., 1998). However, it is necessary to note that transcription and expression 
levels of the capsule locus, albeit reduced, are not totally inhibited in virulent 
bacteria.  
 
Although vrg6 was first reported to play a role in B. pertussis virulence 
(Beattie et al., 1992), later reports disputed that the attenuated phenotype 
observed in mice was actually due to a secondary mutation (Martinez de 
Tejada et al., 1998). Thus, there had been no firm evidence of a possible role 
of a vrg during pertussis pathogenesis. Our work here demonstrates for the 
first time and unambiguously that a vrg locus (the capsule locus) plays a 
critical role in pertussis pathogenesis. Rather than playing a direct and 
conventional role in pertussis pathogenesis such as the adhesins and toxins, 
the determinants involved in polysaccharide capsule transport and export 
affects Bordetella virulence in an indirect manner, via the BvgA/S two-
component regulatory system. 
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3.5 CONCLUSIONS AND FUTURE DIRECTIONS !!
Our work here provides the evidence that the B. pertussis capsule locus 
is instrumental for optimal expression of the pathogen’s virulence factors and 
represents the first report of a vrg locus that is clearly involved in pertussis 
pathogenesis. Rather than the surface polysaccharide capsule, our findings led 
to a novel concept that KpsT and the capsular transporter-exporter system in 
B. pertussis are necessary for bacterial virulence. Specifically, the products of 
the capsule locus, in particularly KpsT, play a role in the regulation of Bvg-
mediated genes in B. pertussis. Mechanistically, KpsT and the capsular 
transporter-exporter system influence the dimeric and oligomeric state of 
BvgS necessary for optimal signal sensing and/or transduction. Our findings 
led us to contemplate that KpsT and the capsular transporter-exporter 
complexes may be responsible for maintaining the plasma membrane integrity 
and permeability, which are crucial for the conformational integrity and 
optimal functionality of membrane proteins such as BvgS sensor.  
 
Therefore, future studies could progress towards elucidating the 
BvgA/S signaling output in ΔkpsT and KOcaps mutant. Perhaps the most 
pertinent strategy is to analyze the phosphorylation state of the response 
regulator BvgA in these mutants compared to wild-type B. pertussis. We 
hypothesized that the pool of phosphorylated BvgA may be compromised in 
ΔkpsT and KOcaps mutant, which correlates with the changes in the bvg-
regulated gene expression. Our preliminary analysis on the pool of P-BvgA 
dimer in B. pertussis cell lysate by SDS-PAGE and Western blot was 
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unsuccessful due to poor specificity of the polyclonal anti-BvgA antibodies. 
However, a group recently reported that by employing the latest Phos-tagTM 
technology, they were able to distinguish the pool of BvgA monomer from its 
phosphorylated counterpart (P-BvgA) in B. pertussis total cell lysates by 
Western blot analysis (Boulanger et al., 2013). Hence, such alternative method 
of detection/quantification of P-BvgA proteins in B. pertussis would provide 
further support, that the sensing and/or transduction of extracellular signals are 
impaired in ΔkpsT and KOcaps mutant.  
 
Moreover, additional controls should be included in several of the 
above-mentioned experiments to refine the overall relationship between BvgS 
and the products of the capsule locus. Given the lack of complete 
understanding on the bonds that maintain BvgS homodimers, the 
oligomerization capacity of BvgS observed in situ in B. pertussis could be 
further confirmed by targeted site-directed mutagenesis on BvgS cysteine 
residues or the alanine-proline residues whose substitutions may abolish BvgS 
dimerization in BPSH strain. Such experimental concepts will provide further 
support on the existence of chemical bonds that are responsible for the 
oligomerization of BvgS and its possible interaction with capsular transporter-
exporter proteins. 
 
It is also worthwhile to construct the recombinant His-BvgS tag fusion 
in the BvgS-VFT2 background strain to leverage on the observation of BvgS 
oligomerization in BPSM and its capsule-deleted counterpart. As the BvgS-
VFT2 mutant contains constitutive active BvgS sensor and hence constitutive 
Chapter 3: Role of The Capsule Locus 
 
! 178!
dimerization, it is nevertheless a necessary control to address the structural 
interactions associated with BvgS and to support our hypothesis that BvgS 
oligomerizes in B. pertussis. Finally, inclusion of ΔvipC mutant in the 
erythromycin, SDS and EDTA sensitivity assays is necessary to support the 
claim that the cellular membrane integrity affects the conformational changes 
of BvgS sensor. 
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CHAPTER 4 GENETIC REGULATION OF THE 
CAPSULE OPERON IN B. PERTUSSIS 
 
The genetic organization of the putative type II polysaccharide capsule 
operon in B. pertussis Tohama I (ATCC BAA-589) strain has been fully 
sequenced by the Sanger Institute, UK (Parkhill et al., 2003). In Chapter 3, we 
have shown that the products of the capsule locus, in particularly KpsT, 
influence the oligomeric state of BvgS necessary for optimal signal sensing 
and/or transduction. However, the genetic regulation of the capsule locus has 
remained largely unexplored. Thus far, the capsule locus in B. pertussis is only 
known as a bvg-repressed gene or vrg, i.e its expression is optimal in Bvg- 
phase. We have also previously reported that the capsule locus is expressed at 
a basal detectable level in Bvg+ phase (Neo et al., 2010). In this chapter, we 
provide some additional information on the regulation of the expression of the 
B. pertussis capsule locus in vitro, ex vivo and in vivo.  
 
(A)  ANALYSIS OF THE TRANSCRIPTIONAL REGULATION OF 
THE CAPSULE LOCUS IN IN VITRO B. PERTUSSIS CULTURE !
4.1 RESULTS  !
4.1.1 Transcriptional Analysis of The Capsule Locus in B. pertussis 
Clinical Isolates  !
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To gain better insight into the regulation of the capsule expression in 
B. pertussis, we systematically analyzed the transcriptional pattern of the 
capsule locus (represented by kpsT) and other transcripts including vrg6, risA 
and bvgR in several B. pertussis clinical isolates grown in in vitro culture of 
Bvg+ and Bvg- phase. For comparison, the laboratory-adapted strain BPSM 
was also included in the study. As previously reported, expression of the 
capsule locus in BPSM, represented by kpsT gene, and another bvg-repressed 
gene vrg6 was significantly elevated in the presence of modulators MgSO4 
which switch the bacteria to Bvg- phase, while basal expression was observed 
in the absence of MgSO4 (Bvg+ phase) (Figure 4.1, black and green bars) 
(Croinin et al., 2005; Neo et al., 2010; Stenson et al., 2005). Unlike bvgR 
whose transcripts were strongly down-regulated in Bvg- phase, expression of 
risA was not significantly modulated between the two Bvg phases (Figure 
4.1), confirming that transcription of risA is independent of BvgA/S 
modulation (Stenson and Peppler, 1995).  
 
Two different clinical strains isolated from pre-vaccination era were 
assessed for the levels of expression of their capsule locus; Tohama I, a Japan 
isolate from year 1954 and strain 18323, a USA isolate from year 1946. 
Tohama-I displayed a similar trend of expression for risA, vrg6 and greater 
expression of the capsule locus in both phases when compared to BPSM 
(Figure 4.1, grey and red bars). However, the levels of bvgR in Bvg- phase 
Tohama-I is not completely repressed unlike in BPSM strain, suggesting a 
BvgA/S-independent basal level of expression of bvgR in Bvg- phase in 
Tohama I. Alternatively, a differential sensitivity of the BvgS sensor to 
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MgSO4 modulator between Tohama I and BPSM may exist. However, despite 
the presence of some bvgR expression in Bvg- Tohama I, significant up-
regulation of vrgs (vrg6 and kpsT) can be observed and to the same extent as 
what is observed with BPSM. This observation suggests the existence of a 
potential transcriptional activator of vrg6 and kpsT that outcompetes BvgR.   
 
Strikingly, expression of risA in strain 18323 was strongly down-
regulated in both Bvg+ and Bvg- phase compared to BPSM and Tohama I 
strains (Figure 4.1, stripped grey and stripped red bars). Consistently, the vrg6 
and kpsT transcripts were significantly reduced in strain 18323, particularly in 
the Bvg- phase compared to BPSM (Figure 4.1). In fact, the vrg6 and capsule 
locus seem to be constitutively expressed in strain 18323 regardless of the 
presence of modulators (Figure 4.1). However, bvgR was modestly enhanced 
to 3-fold in Bvg+ phase, and completely repressed in Bvg- phase in strain 
18323 compared to BPSM (Figure 4.1).  
 
The results here suggest that the reduced levels of risA may account 
for the reduced vrgs expression (kpsT and vrg6) in strain 18323 in both Bvg+ 
and Bvg- phase, as compared to BPSM and Tohama I strains. In addition, the 
variability of vrgs expression, in particular the capsule locus, observed 
between laboratory-adapted and clinical isolates highlight the possibility of 
selective genetic regulation between distinct B. pertussis strains. !!!!!





Figure 4.1: Relative transcriptional activity of risA, vrg6, bvgR and the 
capsule locus in BPSM, Tohama I and 18323 strain in virulent and 
avirulent phase.  
 
Total RNA was extracted from BPSM, Tohama-I and 18323 strains grown in 
virulent (Bvg+) and avirulent (Bvg-, in the presence of 50mM MgSO4) phase, 
as indicated on the figure legend on the top left of the graph. Real-time PCR 
analysis was performed using primers mapping in the risA, vrg6, kpsT and 
bvgR genes. recA gene was used as the endogenous control. Results are 
expressed as the average relative quantification RQ ± SD of triplicate versus 
Bvg+ phase BPSM. Results are representative of 2 independent experiments. 
Dotted line represents RQ equal to 1 in relative to Bvg+ phase BPSM.  
!!!!!!!!!!!!!!!!
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4.1.2 Transcriptional Analysis of The Capsule Locus in ΔbvgAS Mutant 
 
It was previously shown that deletion of bvgR in strain 18323 led to a 
constitutive expression of bvg-repressed gene vrg6 and surface proteins 
VraA/B in both Bvg+ and Bvg- phase (Croinin et al., 2005; Merkel et al., 
1998), demonstrating the role of BvgR as a repressor for vrgs expression in B. 
pertussis. We initially took a similar approach to study the expression level of 
the capsule locus. However, after several attempts we were unable to obtain a 
bvgR-deleted mutant in BPSM strain, suggesting that in this strain, bvgR is an 
essential gene. Assuming that in a ΔbvgAS mutant expression of bvgR will be 
constitutively repressed, we thus performed a transcriptional profile analysis 
on the capsule locus and a few selected genes including risA, vrg6 and bvgR in 
a ΔbvgAS BPSM derivative mutant grown in both Bvg+ and Bvg- phase. The 
parental strain BPSM grown in Bvg+ phase was used as the calibrator for gene 
expression analysis.  
 
We first monitored the expression of risA in wild-type BPSM and 
ΔbvgAS mutant. Expression of risA was not significantly modulated in 
ΔbvgAS and in the presence of modulators, supporting that regulation of risA 
is BvgA/S-independent (Figure 4.2 A) (Jungnitz et al., 1998; Stenson et al., 
2005). As expected, BPSM strongly repressed the expression of bvgR in Bvg- 
phase, but the magnitude of repression was lesser than in the ΔbvgAS mutant 
(Figure 4.2 B). This is a surprising observation, as deletion of the bvgAS locus 
is known to lock the bacteria into a Bvg- phase phenotype and that expression 
of bvgR, a bvg-regulated factor, should be completely repressed (Martinez de 
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Tejada et al., 1998). The basal level of bvgR expression in ΔbvgAS mutant was 
consistently observed in a few independent experiments,# suggesting that a 
basal BvgA/S-independent expression of bvgR exists in BPSM.#As expected 
expression of vrg6 and the capsule locus were up-regulated in Bvg- phase 
BPSM (Figure 4.2 C, D). While the expression level of vrg6 was similar in 
both Bvg+ and Bvg- phase in ΔbvgAS (Figure 4.2 C), expression of the capsule 
locus remained distinctly modulated, where the expression of the capsule 
locus is significantly higher in Bvg- phase compare to Bvg+ phase ΔbvgAS 
(Figure 4.2 D).##
#
The results of this analysis indicate that the lower level of bvgR 
expression in ΔbvgAS mutant (Figure 4.2 B) leads to up-regulation of the 
capsule locus in Bvg+ phase (Figure 4.2 D, BPSM vs ΔbvgAS), but not to the 
level observed in Bvg- phase (Figure 4.2 D, ΔbvgAS Bvg+ vs Bvg- phase). This 
implies the existence of a transcriptional activator present in the Bvg- phase 
that up-regulates the expression of the capsule locus. Additionally, another 
factor repressed in the ΔbvgAS mutant would account for the repression of the 
capsule locus in Bvg+ phase BPSM. It has been formally demonstrated that 
RisA binds to the promoter of vrg6 and activates its transcription in BP536 B. 
pertussis strain (Croinin et al., 2005). Similarly, we postulate that RisA might 
act on the capsule locus promoter. Whether RisA directly modulates the 
expression of the capsule locus in BPSM remains to be investigated.   
 
 




Figure 4.2: Relative transcriptional activity of risA, bvgR, vrg6 and the 
capsule locus in BPSM and ΔbvgAS strain in virulent and avirulent 
phase.  
 
Total RNA was extracted from BPSM (black bars) and ΔbvgAS (dotted bars) 
strains grown in virulent Bvg+ phase and avirulent Bvg- phase. Real-time PCR 
analysis was performed using primers mapping in the risA, vrg6, kpsT and 
bvgR genes. recA gene was used as the endogenous control. Results are 
expressed as the average relative quantification RQ ± SD of triplicate versus 
Bvg+ phase BPSM. Results are representative of 2 independent experiments. 
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4.1.3 Transcriptional Analysis of The Capsule Locus by The Ris-
Regulon !
4.1.3.1 Construction of a ris-deleted mutant in BPSM background strain !
Loss of a functional RisA in B. pertussis would be expected to enhance 
the expression of vrgs, in particular the capsule locus expression as previously 
observed for B. pertussis BP563 strain (Croinin et al., 2005; Stenson et al., 
2005). To investigate the modulation of capsule locus expression by the risA 
locus in the laboratory adapted BPSM strain, we proposed to construct a risA-
deleted BPSM mutant strain. However, despite several attempts, deletion of 
risA by double homologous recombination was unsuccessful; whereby all the 
colonies screened reverted to parental genotype suggesting that risA may be an 
essential gene for BPSM strain. Polar effects are unlikely as construction of 
risA deletion was in-frame and the downstream gene BP3555 is transcribed in 
the opposite direction (Figure 4.3 A). 
 
In contrast, previous studies reported the construction of a risA-deleted 
mutant in the B. pertussis BP536 strain (Croinin et al., 2005; Stenson et al., 
2005). The expression of vrg6, vrg18, vrg24 and vrg73 was reduced to basal 
level in Bvg- phase ΔrisA-BP536 mutant, but no complementation study was 
performed to confirm the phenotype described in the ΔrisA-BP536 mutant 
(Croinin et al., 2005). In a separate study, Stenson et al. found that expression 
of Vra surface proteins and transcription of vrgs in ΔrisA-BP536 mutant was 
reduced to basal level and that expression of these vrgs was restored by risA 
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complementation on a low-copy-number plasmid, thus supporting the 
phenotype observed (Stenson et al., 2005). However, the authors offered no 
explanation on the impairment of in vitro growth profiles and fitness of the 
ΔrisA-BP536 mutant. It is possible that the laboratory adapted BPSM strain 
may have undergone a different selective pressure in terms of genetic 
regulation and fitness compared to BP536 strain (Gaillard et al., 2011; Hot et 
al., 2003; Park et al., 2012), which may result in different physiology and 
fitness status when risA is deleted. As a transcriptional factor, RisA may 
regulate a variety of essential factors in BPSM, thus the absence of RisA 
and/or the Ris-regulated factors may contribute to an overall pleiotropic effect, 
as previously described for B. bronchiseptica (Jungnitz et al., 1998). 
 
Essentiality of a bacterial gene can be demonstrated by successful 
deletion of the target gene only in the presence of an extra copy of that gene 
(Parish and Stoker, 2000; Reyrat et al., 1998). Therefore, to confirm the 
essentiality of risA, we attempted to delete the chromosomal risAS locus in 
BPSM in the presence of a wild-type copy of risA, which was expressed under 
the control of fha promoter in the pBBR1MCS replicative plasmid. Because 
RisS is truncated in B. pertussis and has been shown to be dispensable for the 
expression of vrgs (Stenson et al., 2005), the entire risAS chromosomal locus 
was deleted in this study. We attempted to construct risAS-deletion in BPSM-
Pfha-risA strain via double homologous recombination. Positive ΔrisAS clones 
were obtained in the presence of a wild-type copy of risA expressed on a 
plasmid (Figure 4.3 B), thus demonstrating the essentiality of this gene in 
BPSM strain.  








Figure 4.3: Construction of ris-deleted mutants in BPSM background 
strain. 
 
(A) Genomic organization of the risA and risS locus in B. pertussis BPSM-
Pfha-risA and ΔrisAS strain, pBBR::Pfha-risA vector over-expressing risA is 
shown on the right. Red arrows below each locus/gene indicates the primer 
used to screen for PCR screening.  
(B) PCR screening of Sm resistant ΔrisAS chromosomal DNA with primer 
pairs and expected size as indicated on the bottom of each gel picture. The 
ΔrisAS has been propagated in the absence of Cm antibiotics, thus allowing 
the mutant to loose the pbbR::Pfha-risA plasmid and retain the mutant 
genotype. Lanes; M, DNA ladder (5 µl); 19.2 and 19.3, ΔrisAS clones; pb, 
pBBR::Pfha-risA vactor (10 µl); BPSM chromosomal DNA (10 µl).  
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4.1.3.2 Transcriptional analysis of the capsule locus in BPSM and 
ΔbvgAS strains over-expressing risA  !
Since RisA appears to be essential for BPSM survival, an alternative 
approach to study the role of RisA in capsule regulation is to over-express 
RisA in wild-type BPSM strain. We thus constructed a BPSM strain over-
expressing risA under the control of the strong fhaB promoter, giving rise to 
BPSM-Pfha-risA strain. The capsule locus expression as well as expression of 
other genes (risA, vrg6, kpsT and bvgR) in both parental BPSM and BPSM-
Pfha-risA were monitored in Bvg+ phase by Real-time PCR. As shown in 
Figure 4.4, over-expression of risA in Bvg+ phase BPSM-Pfha-risA led to a 5-
fold increase in risA transcripts compared to BPSM. However, the increased 
risA expression did not significantly enhance expression of neither the vrg6 
locus nor the capsule locus (Figure 4.4). Expression of all the genes analyzed 
were not affected in BPSM carrying empty vector control; BPSM-pbbr1mcs 
(Figure 4.4). From this data, we reasoned that BvgR repressor, which is 
expressed in BPSM-Pfha-risA strain, acts as a strong negative regulator and 
competes with RisA in modulating vrg6 and capsule locus expression in Bvg+ 
phase.   
 
Given the low expression level of bvgR in ΔbvgAS mutant (Figure 4.2 
B), we thus decided to over-express risA in ΔbvgAS using the constitutive 
recA promoter, which is independent of the BvgA/S regulatory system, unlike 
fhaB promoter used in the previous construct (Hot et al., 2003). The resulting 
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strain, known as ΔbvgAS-PrecA-risA was analyzed for its gene expression 
profile in Bvg+ phase. Over-expression of risA under recA promoter in 
ΔbvgAS mutant led to a modest 2-fold increase in risA transcripts compared to 
Bvg+ phase BPSM (Figure 4.5), reflecting that recA promoter appears weaker 
than fhaB promoter. Therefore, expectedly, neither the expression of vrg6 nor 
the capsule locus was found up-regulated in ΔbvgAS-PrecA-risA strain (Figure 
4.5). The modest over-expression of risA also did not result in modulation of 
the expression of bvgR, which remained basal in the ΔbvgAS-PrecA-risA strain 
in both Bvg+ and Bvg- phase (Figure 4.5). Despite the low levels of bvgR 
expression in ΔbvgAS-PrecA-risA strain, we postulate that it is sufficient to 
negatively repress the capsule locus and vrg6, thus overcoming the over-
expression of RisA in the overall modulation. 
 
In conclusion, our risA over-expression approaches failed to provide 
any further information on the possible modulation of the expression of the 















Figure 4.4: Relative transcriptional activity of risA, vrg6, bvgR and the 
capsule locus in BPSM and BPSM-Pfha-risA strain in virulent phase.  
 
Total RNA was extracted from BPSM (black bars), BPSM-Pfha-risA (dotted 
bars) and BPSM-pbbr1mcs (grey bars) grown in virulent Bvg+ phase. Real-
time PCR analysis was performed using primers mapping in the risA, vrg6, 
kpsT and bvgR genes. recA gene was used as the endogenous control. Results 
are expressed as the average relative quantification RQ± SD of triplicate 
versus Bvg+ phase BPSM. Results are representative of 2 independent 
experiments. Dotted line represents RQ equal to 1 in relative to Bvg+ phase 
BPSM. 
 !!!!!!!!!!!!!!!!!!





Figure 4.5: Relative transcriptional activity of risA, vrg6, bvgR and the 
capsule locus in BPSM, ΔbvgAS, ΔbvgAS-PrecA-risA and ΔbvgAS-
pbbr1mcs empty vector control strain in virulent and avirulent phase.  
 
Total RNA was extracted from BPSM Bvg+ phase (black bars), BPSM Bvg- 
phase (green barr), ΔbvgAS Bvg+ phase (grey bars), ΔbvgAS-PrecA-risA Bvg+ 
phase (red stripped bar) and ΔbvgAS-pbbr1mcs Bvg+ phase (stripped bars). 
Real-time PCR analysis was performed using primers mapping in the risA, 
vrg6, kpsT and bvgR genes. recA gene was used as the endogenous control. 
Results are expressed as the average relative quantification RQ ± SD of 
triplicate versus Bvg+ phase BPSM. Results are representative of 2 
independent experiments. Dotted line represents RQ equal to 1 in relative to 




Chapter 4: Genetic Regulation of The Capsule Locus 
 
! 193!
(B) ANALYSIS OF THE TRANSCRIPTIONAL REGULATION OF 
THE CAPSULE LOCUS IN B. PERTUSSIS DURING EX VIVO 
AND IN VIVO INFECTION 
 
In this section, we sought to further investigate whether the capsule 
locus is being expressed and modulated during the course of infection in 
human pulmonary epithelial A549 cells and in mouse macrophages J774.A1 
as well as in the mouse respiratory tract.  
 
4.2 RESULTS !
4.2.1 Transcriptional Analysis of The Capsule Locus in B. pertussis 
During Infection of Lung Epithelial Cells 
 
The human lung epithelial cells represent the major cell type B. 
pertussis interacts with upon infection (Ishibashi et al., 1994; Wilson et al., 
1991). Although B. pertussis has been recognized as extracellular pathogen 
that adheres to pulmonary and tracheal epithelial cells in vitro (Alonso et al., 
2001; Coutte et al., 2003; van den Berg et al., 1999), studies have shown that 
it can also invade the A549 pulmonary epithelial cell line and survive 
intracellularly up to 4 h p.i. (Ishibashi et al., 2001). In this study, expression of 
the capsule locus in BPSM was quantified by real time PCR using primers 
mapping in the kpsT ORF upon invasion in A549 cells. For invasion assay, the 
co-incubation was performed for 1.5 h at 37°C. In vitro BPSM culture applied 
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for the cellular infection was used as comparison for the expression of the 
capsule locus. 
 
As shown in Figure 4.6, expression of the capsule locus in BPSM was 
significantly up-regulated upon during invasion in A549 cells compared to the 
level of expression measured during in vitro Bvg+ culture condition. 
Interestingly, expression of bvgA, an indicator for bvg-regulated response, 
showed a 3-fold increase upon uptake within A549 cells (Figure 4.6), 
suggesting that uptake of B. pertussis into mammalian epithelial cells induce a 
rapid and transient change in the bacteria gene expression.  
 
 !!!!!!!!!!!!!!





Figure 4.6: Relative transcriptional activity of kpsT and bvgA in BPSM 
recovered from A549 versus in vitro BPSM grown in virulent phase.  
Invasion of A549 cells were done by incubating the cells and BPSM at MOI 
of 100 at 37ºC for 1.5 h. Unbound bacteria were washed away prior to total 
RNA extraction from BPSM recovered from infected A549 cells. Real-time 
PCR analysis was performed using primers mapping in the kpsT and bvgA. 
recA gene was used as the endogenous control. Results are expressed as the 
average RQ ± SD of triplicate versus BPSM innoculum. Results are 
representative of 2 independent experiments. Dotted line represents RQ equal 
to 1 in relative to BPSM innoculum. The bottom table shows average Ct 
values for each gene obtained from the mock-infected A549 (as negative 
control) and the no template control.  !!!!!!!!!!!
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4.2.2 Transcriptional Analysis of the Capsule Locus in B. pertussis 
During Infection of Macrophages !
As B. pertussis can invade and persist in human macrophages at MOI 
of 100 up to 48 h p.i. without affecting the viability of the macrophages 
(Friedman et al., 1992b), we further evaluated the response of the capsule 
locus expression during murine macrophages J774.A1 invasion, from which 
BPSM RNA was extracted at different time intervals p.i.  
 
Similar to A549 cell infection assay, expression of the capsule locus 
was significantly up-regulated upon during invasion in J774.A1 when 
compared to in vitro BPSM culture (Figure 4.7). Transcriptional activity of the 
capsule locus was significantly increased within 1.5 h p.i. upon uptake into the 
macrophages compared to inoculum (Figure 4.7). At 3.5 h and 4 h p.i, 
expression of the capsule locus remained elevated when compared to in vitro 
culture, but appeared to be down-regulated with reference to the 1.5 h time 
point after uptake (Figure 4.7). Unlike the capsule locus, levels of bvgA 
expression in BPSM were moderately regulated during the course of infection 
in J774.A macrophages (Figure 4.7).  
 
Taken together, the observations here suggest that uptake of B. 
pertussis into mammalian cells induced a rapid, transient and strong increase 
in the capsule locus expression, supporting that the capsule locus may play an 
important role in the early stages of mammalian cell invasion.!!





Figure 4.7: Relative transcriptional activity of kpsT and bvgA in BPSM 
recovered from J774.A1 macrophages versus in vitro BPSM grown in 
virulent phase. 
Invasion of J774.A1 cells were done by incubating the cells and BPSM at 
MOI of 100 at 37ºC for 1.5 h, 3.5 h and 4 h. Unbound bacteria were washed 
away prior to total RNA extraction from BPSM recovered from infected 
J774.A1 cells. Real-time PCR analysis was performed using primers mapping 
in the kpsT and bvgA. recA gene was used as the endogenous control. Results 
are expressed as the average RQ ± SD of triplicate versus BPSM innoculum. 
Dotted line represents RQ equal to 1 in relative to BPSM innoculum. The 
bottom table shows average Ct values for each gene obtained from the mock-
infected J774.A1 (as negative control) and the no template control.  !!!!!!!!
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4.2.3 Transcriptional Analysis of the Capsule Locus in B. pertussis 
During Infection of The Mouse Respiratory Tract !!
We have shown that deletion of the membrane-associated capsule 
locus-encoded products impaired mice colonization efficiency as early as 3-
days p.i., suggesting that the capsule locus plays an important role in the 
establishment of pertussis infection (Chapter 3). Our ex vivo data also suggest 
that the capsule locus is transcriptionally active at early stage of cellular 
infection (Section 4.2.1 and 4.2.2). Based on these findings, we moved on to 
monitor the capsule expression profile of B. pertussis during the course of 
infection in vivo.  
 
Mice were nasally infected with BPSM bacteria and at different time 
points p.i., the animals were sacrificed and their lungs harvested for bacterial 
RNA extraction and purification. To minimize the changes in bacterial 
transcription during the processing of the infected lungs, infected mice lungs 
were soaked in RNAprotect Bacteria Reagent (Qiagen) for 1 h to immediately 
stabilize B. pertussis RNA prior to RNA isolation procedures. We observed 
that expression of the capsule locus was significantly up-regulated throughout 
the course of infection, with a peak of expression at day 3 p.i. compared to 
BPSM inoculum grown on BG agar plate (Figure 4.8), implying that the 
capsule locus is actively transcribed at early phase of pertussis infection. 
Interestingly, a similar expression profile was observed for another bvg-
repressed factor, vrg6 (Figure 4.8), indicating that BPSM harvested from the 
lungs environment induces the expression of vrgs, including the capsule locus, 
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as compared to BPSM harvested from BG agar plates in the absence of 
modulators.  
 
In contrast to the vrgs, expression of vags including bvgA, bvgR, fhaB 
and ptx was elevated in a step-wise manner from day 0 (3 h post-nasal 
administration) to day 3 and day 7 p.i., likely explaining the peak of bacterial 
multiplication in the lungs at day 7 (Figure 4.8). Expression of the fhaB 
transcript was more greatly induced than the ptx transcript at 3 h p.i.; 
consistent with the fact that fhaB is an “early” bvg-activated gene necessary 
for the initial colonization of B. pertussis (Veal-Carr and Stibitz, 2005). At day 
3 and 7 p.i. when B. pertusiss begins to multiply in the lungs, ptx was greatly 
up-regulated compared to fhaB; a stage where pertussis toxin may be highly 
produced by the bacteria. Surprisingly, elevated expression of bvgR 
contradicts the capsule locus and vrg6 expression during the course of 
infection, indicating an altered vrgs modulation in in vivo versus in vitro 
bacteria. Our findings also support a previous study reporting on the 
differential regulation of vags assessed in a small time frame (between 5 h to 
36 h post-inoculation) by the RIVET system during in vivo infection (Veal-
Carr and Stibitz, 2005).  
 
Despite the fact that the capsule locus has been classified as a bvg-
repressed locus based on in vitro modulating and non-modulating conditions, 
the results here revealed for the first time that laboratory adapted BPSM strain 
activates the capsule locus expression, together with other vrgs during in vivo 
infection. Whether the in vivo lung microenvironment mimics the Bvg+ phase 
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in vitro culture conditions remain to be determined. Moreover, the observation 
here indicates that host-mediated transcriptional changes on the capsule locus 
expression likely reflect a response of the bacteria towards the presence of 
unknown in vivo signals throughout the course of pertussis infection. !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!




Figure 4.8: Relative transcriptional activity of vrgs and vags in BPSM 
recovered from mice lungs versus in vitro BPSM grown in virulent phase.  !
Mice were infected intranasally with approx. 5x107 CFU of BPSM and the 
bacteria were recovered from the mice lungs at different time points (day 0/3 
hours, day 3 and day 7 p.i.) through differential centrifugation. Bacterial RNA 
extracted and purified from group of 4 mice were pooled and subjected to 
Real-time PCR analysis using primers mapping in the kpsT, vrg6, bvgR, bvgA, 
fhaB and ptx genes. recA gene was used as the endogenous control. Results are 
expressed as the average RQ ± SD of triplicate versus BPSM innoculum. 
Dotted line represents RQ equal to 1 in relative to BPSM innoculum. Mock-
infected mice were used as negative control.  !!!!!!!!!!




4.3.1 Genetic Regulation of The Capsule Locus by The Ris System !
Expression of the capsule locus in B. pertussis is highly elevated under 
in vitro modulating conditions that inactivates BvgA/S system or in a ΔbvgAS 
mutant. This supports that BvgA/S signaling system is involved in the 
regulation of the capsule locus in B. pertussis, presumably through the activity 
of the known vrg repressor, BvgR (Merkel et al., 1998; Merkel et al., 2003). 
Interestingly, the clinical isolate B. pertussis strain 18323 expresses low levels 
of the capsule transcripts even under modulating Bvg- phase conditions when 
compared with the clinical isolate Tohama I strain and its laboratory adapted 
derivative strain BPSM. Concurrently, expression of risA, a proposed 
transcriptional regulator of vrgs, was greatly reduced in strain 18323. Whether 
the repression of the capsule locus under modulating Bvg- phase in strain 
18323 is a result of reduced risA expression and/or reduced binding affinity of 
RisA to the promoter of the capsule locus remains to be investigated.  
 
However, attempts in determining the regulatory role of RisA on the 
capsule locus have not been successful due to the failure of obtaining a risA-
deleted mutant in BPSM background strain. We demonstrated the essentiality 
of the risA gene in BPSM, thus somehow likely contributing to the overall 
bacteria in vitro growth and survival. Consistently, in B. bronchiseptica, 
deletion of the ris locus resulted in a general pleiotropic effect on the 
expression of a large numbers of unknown proteins (Jungnitz et al., 1998). 
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Deletion of risA in a Bvg+ phase-locked BP536 strain was also reported 
previously and was found to reduce bacteria invasion when compared to a 
Bvg+ phase-locked mutant in an ex vivo model of infection (Stenson et al., 
2005). These observations land further support that Ris proteins are involved 
in some important biosynthesis or metabolic molecular pathways in Bordetella 
sp. 
 
Over-expression of risA transcripts (upon expression under the strong 
fhaB promoter) did not significantly alter the expression of the capsule locus 
as well as vrg6 in the Bvg+ phase. It is likely that over-expression of RisA (5 
fold) may not be sufficient to overcome the repressive effect of BvgR on the 
expression of these vrgs. Alternatively, RisA may not be involved or may not 
be the main activator for the capsule locus expression in BPSM strain. As 
exemplified by the Rcs signaling system in section 1.1.5.1, the transcriptional 
control of E. coli group 2 gene cluster is regulated by more than one regulator 
involving several overlapping regulatory circuits (Majdalani and Gottesman, 
2005). As RisS is a pseudogene in B. pertussis, it is speculated that phospho-
activation of RisA may be driven by another kinase (Stenson et al., 2005), 
drawing the possibility of molecular cross-talk between two regulatory 
systems in B. pertussis. Since risA expression is BvgAS-independent, it is 
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4.3.2 Genetic Regulation of The Capsule Locus During Mammalian 
Cells Invasion !
Analysis on the B. pertussis capsule locus expression pattern during ex 
vivo infection supports that the capsule locus is expressed during invasion into 
mammalian cells. We have previously shown that capsule-deleted mutant and 
wild-type B. pertussis equally adheres and invades the human pulmonary 
epithelial cells and murine macrophages (Neo et al., 2010). B. pertussis Bvg+ 
phase-locked mutant with constitutive activation of vags and repression of 
vrgs (including the capsule locus) are able to adhere and survive in 
mammalian cells as well as the wild-type bacteria (Stenson et al., 2005). 
Therefore, the increased capsule locus expression during A549 and J774 
macrophages infection is not associated with B. pertussis adherence and 
invasion properties into mammalian cell. The ability for B. pertussis to 
mediate the capsule locus expression in a temporal manner following invasion 
suggests that cellular “signals” may initiate a response governing the 
modulation of capsule locus and other genes expression in B. pertussis. 
Instead of being repressed under a presumably Bvg+ virulent phase (as 
evidenced by the sustained high levels of bvgA transcripts) during mammalian 
cells infection, expression of the capsule locus as a vrg is dynamically 
modulated over the course invasion into epithelial cells and macrophages. The 
findings here argue against the fact that bvg-repressed factors are not 
expressed during infection.  
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Moreover, exposure of B. pertussis to different host cell 
microenvironments, such as extracellular and intracellular compartments may 
also influence signals perceived by the bacteria, and hence the overall 
expression of the capsule locus, vrg6 and other vags. For instance within the 
cellular context of macrophages, B. pertussis was shown to confine into early 
phagosomal compartment and subsequently progress into late phagolysosome 
(Schneider et al., 2000). During the transition from phagosome to 
phagolysosome, the bacteria are exposed to an increasingly hostile 
environment including the presence of bactericidal cationic peptides, 
hydrolytic enzymes and acidic pH (Schneider et al., 2000). It is likely that the 
different environmental stress signals from these compartments play a role in 
activating the regulatory mechanism involved in the modulation of the capsule 
locus expression in B. pertussis during macrophage infection.  
 
Consistently, the modulation of vags was observed for AC toxin during 
entry and invasion into human macrophages; a significant increase in AC 
activity was observed 30 min p.i. followed by a progressive down-modulation 
at 2 h and 4 h p.i. (Masure, 1992). This supports the transition-modulation of 
B. pertussis from in vitro to a host microenvironment, presumably as a 
adaptation strategy for the bacteria to express the appropriate levels of vags 
such as adhesin and toxin necessary for bacterial adherence and invasion in 
mammalian cells (Alonso et al., 2001; Friedman et al., 1992a; Ishibashi and 
Nishikawa, 2002; van den Berg et al., 1999; Vojtova et al., 2006).  
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4.3.3 Genetic Regulation of The Capsule Locus During in vivo Infection !
The striking modulation of the capsule locus during mammalian cell 
infection prompted us to further investigate the expression pattern of the 
capsule locus in B.pertussis during colonization in the mouse respiratory tract. 
Immediately after infection, similar to the ex vivo epithelial and macrophage 
infection model, expression of the capsule locus was up-regulated, reflecting 
the response of B. pertussis towards the host environment changes upon 
infection. Expression of the capsule locus peaked at day 3 p.i. and lowered by 
day 7 p.i. A similar pattern of expression was observed for vrg6 as well. These 
observations demonstrate for the first time that vrgs are expressed during 
infection. However, a previous study indicated that only the Bvg+ phase is 
necessary and sufficient for a successful pertussis infection in mice (Martinez 
de Tejada et al., 1998), implying that the products of vrgs may not play a 
critical role during infection as they are expected to be down-modulated 
during in vivo infection. Here, we show that unlike the common belief, vrgs 
are readily expressed and modulated during infection which supports the idea 
that the in vivo microenvironment(s) encountered by the bacteria during 
infection are likely to be different from the artificial in vitro Bvg+ growth 
condition, implying that the global transcriptional patterns in both in vivo and 
in vitro Bvg+ conditions are likely to be very different.  
 
Expression pattern of several vags was also monitored; in contrast to 
the vrgs, expression of vags (bvgR, bvgA, ptx and fhaB) was increased over the 
course of infection, with highest expression levels observed at day 7 p.i. 
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Consistently, a previous study has shown that in contrast to in vitro B. 
pertussis culture grown on BG agar, the environment in a mammalian 
respiratory tract is more highly inducing towards vags (prn, fhaB, cyaA) 
expression (Veal-Carr and Stibitz, 2005). The authors concluded that the 
environment in the mouse lungs is a Bvg+ phase environment; however, they 
did not investigate the expression of vrgs following intranasal infection in 
mice (Veal-Carr and Stibitz, 2005).  
 
It is interesting to note that whilst the vags are dynamically modulated 
during the course of early respiratory infection, the vrgs including the capsule 
locus are differentially modulated as well. Dynamic modulation of vags and 
vrgs at different days p.i is an important strategy for B. pertussis to 
disseminate from the site of infection to the upper and lower respiratory tract. 
Whereas constitutive expression of vags does not affect bacteria virulence, it 
was reported that ectopic expression of vags (ptx and fhaB) is detrimental to B. 
pertussis in vivo virulence (Kinnear et al., 2001). Furthermore, constitutive 
expression of vrgs in a bvgR-deleted B. pertussis mutant interferes with the 
ability of the bacteria to cause disease (Merkel et al., 1998). Therefore, the 
flexibility of B. pertussis regulon to appropriately express the right amount of 
vags and vrgs at distinct sites and times of infection plays an important part 
for the establishment of pertussis infection.  
 
Modulation of bacterial gene expression in response to host 
microenvironment and host immune responses during infection has been well 
documented in other pathogen, implying the ability of a pathogen to sense and 
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respond to its host microenvironment (Heithoff et al., 1997; Howden et al., 
2008; Talaat et al., 2004). Migration of B. pertussis from the mice nasal cavity 
to the lungs likely results in exposure of the bacteria to different mucosal 
surfaces (nasal, trachea and lungs) and immune cells at different time-points 
p.i (3 h, day 3 and day 7). Infiltrated immune cells such as neutrophils and 
macrophages into the lungs encountered by the bacteria at day 3 and 7 p.i. 
may also contribute to the differential modulation of vags and the capsule 
locus expression in B. pertussis. Besides the major Bvg+ phase virulence 
factors, convalescence immune sera from B. pertussis infected individuals 
were able to recognize several B. pertussis bvg-intermediate phase factors, 
suggesting that during natural infection the bacteria are able to concurrently 
express different surface factors that were categorized as Bvg+ vs Bvgi factors 
under in vitro phase culture (Martinez de Tejada et al., 1998). Therefore, 
despite evidence that Bvg+ phase is sufficient for respiratory infection in 
animal models (Cotter and Miller, 1994; Martinez de Tejada et al., 1998), our 
observations here further support the possibility that B. pertussis is able to 
modulate both the vags and vrgs (the capsule locus) during natural infection.  
 
With multiple putative transcription factors deduced from the full B. 
pertussis genome sequence analysis (Parkhill et al., 2003), regulation of the 
capsule locus in Bordetella sp is likely to be more complex than expected. The 
ability of B. pertussis to sense its environment and dynamically modulate its 
genes expression may confer a selective advantage to the bacteria in 
promoting optimal survival within its host.  
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4.4 CONCLUSIONS AND FUTURE WORK !
4.4.1 Transcriptional Regulation of The Capsule Locus in B. pertussis 
 
Genetic regulation of the polysaccharide capsule locus in B. pertussis 
remains unclear, although the Ris system has been described to positively 
regulate other bvg-repressed factors including vrg6 and surface Vra antigen 
expression in B. bronchiseptica and BP536 strain. Our results show that RisA 
is essential for BSPM, therefore we were not able to isolate a risA-deficient 
mutant strain. Hence, several aspects regarding the function of Ris system 
towards the capsule regulation remain to be determined. Perhaps the most 
pertinent is to delete risA in a B. pertussis strain where RisA is non-essential. 
In addition, further study on the role of BvgR repressor by mutational analysis 
will aid in a better understanding on the capsule locus regulation in B. 
pertussis.  
 
Further work should also be directed at elucidating the binding 
capability of RisA onto the capsule locus promoter, as previously described 
for the vrg6 promoter (Croinin et al., 2005). In vitro DNaseI footprinting 
and/or electro-mobility gel shift assay (EMSA) using purified RisA protein 
(over-expressed in E. coli) and the putative capsule promoter sequence could 
be performed to confirm direct binding of RisA to the capsule promoter and to 
delineate the promoter region to which RisA binds. RisA is speculated to be 
phosphorylated prior to its binding to vrg6 promoter (Croinin et. al., 2005), 
therefore it is likely that binding of RisA to its target DNA motifs may require 
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it to be phosphorylated. Hence, in vitro phosphorylation of RisA should be 
performed prior to EMSA analysis. In addition to RisA, other proteins may 
interact with the capsule promoter. To test this hypothesis, an in vitro DNA-
protein pull-down assay can be performed. The putative capsule promoter can 
first be synthesized and labeled with a high affinity tag (i.e biotin) and 
incubated with enriched cytoplasmic extract of wild-type B. pertussis prior to 
purification using streptavidin agarose or magnetic beads. Such in vitro DNA 
pull-down assay would allow the identification of possible regulatory 
protein(s) (hypothetically RisA, BvgR and perhaps other proteins) that bind(s) 
onto the capsule locus promoter. This approach would eventually help 
characterize the molecular mechanisms involved in the genetic regulation of 
the capsule locus in B. pertussis 
 
4.4.2 Genetic Modulation of The Capsule Locus of B. pertussis During in 
vivo Infection !
The results show that the capsule locus of B. pertussis is highly 
expressed and dynamically modulated during cellular invasion, as well as 
during the course of in vivo infection, reflecting the response of the bacteria to 
the host microenvironments during infection. The fact that the capsule locus, 
classified as a vrg is actually readily expressed and differentially modulated 
during in vivo infection, forces to re-evaluate the role of vrgs during in vivo 
infection. Furthermore, our observations suggest that in vitro culture 
conditions with or without modulators which so far have helped define the 
Bvg– and Bvg+ phases in B. pertussis may be far from the environmental 
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conditions actually encountered by the bacteria in vivo and may not be 
predictive of the potential role and importance of genes during pertussis 
pathogenesis. The current findings add to the growing body of literature on the 
modulation of Bordetella genes during infection. Thus far, there is limited 
knowledge on the genetic regulation of vrgs during infection; this is the first 
report that vrgs including the capsule locus is expressed and modulated during 
infection. A microarray/deep sequencing approach to map the expression of 
vrgs during infection is awaited and would greatly enhance our knowledge 
regarding the role of vrgs during infection. 
 
Similar to the temporal modulation of vags expression during 
infection, the modulation of the expression of the capsule locus during 
infection may imply that the temporal expression of this locus is important for 
optimal virulence of B. pertussis. These findings provide the following 
insights for future work; a further study on the capsule locus and other vrgs 
expression in different laboratory-adapted and clinically isolated B. pertussis 
strains during in vivo infection would provide supporting evidence on the 
genetic regulation of the capsule locus during pertussis pathogenesis. In 
addition, it would be very informative to study the virulence phenotype of B. 
pertussis bacteria in which the chromosomal capsule locus is ectopically 
expressed under the control of a strong vag promoter such as the fhaB 
promoter. Such approach would certainly help apprehend the role and 
importance of the capsule locus during infection. 
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APPENDIX 1: Obtaining the ΔkpsT-Complemented Strain !





Figure 3.7: Colony PCR screening for B. pertussis ΔkpsTcom strains. 
(A) PCR screening strategy for ΔkpsT complemented strain using the primer 
pairs as indicated. pBBR1MCS represents the complement replicative plasmid 
in a ΔkpsT mutant. 
(B) B. pertussis ΔkpsTcom clones screened with kpsTKO2F and kpsEKO1R 
primers. Lanes; M, 100 bp ladder (5 µl); 1 to 17, B. pertussis ΔkpsTcom clone 
1 to 17 (10 µl); 18, ΔkpsT chromosomal DNA; 19, BPSM chromosomal DNA 
(10 µl). Colony PCR screening of ΔkpsTcom strains are expected to show both 
220 bp and 688 bp fragment, while ΔkpsT should have only a 220 bp 
fragment. BPSM should have longer fragment of 688 bp. 
(C) B. pertussis ΔkpsTcom clones screened with kpsTF and kpsTR primers. 





µl); 5, ΔkpsT chromosomal DNA; 6, BPSM chromosomal DNA (10 µl). 
Colony PCR screening of ΔkpsTcom strains are expected to show 446 bp 
fragment, while ΔkpsT should not have any band. BPSM should have a 446 bp 
fragment. 





























APPENDIX 2: Estimated percentage of ΔkpsTcom Cm-resistant colonies 
recovered from the lungs of infected mice at the indicated time-points. 
Twenty random CFUs obtained from plated lung homogenate on BG agar at 
indicated time-points were subjected PCR using primers mapping in kpsT-




































APPENDIX 3: DNA microarray analysis of statistically significant differentially modulated transcripts in ΔkpsT mutant compared to 
BPSM. 
DNA microarray analysis was performed to measure relative transcript levels in ΔkpsT compared to the transcript levels present in wild-type 
BPSM. Differences in transcript levels are listed as mean log2 fold change (FC) from two biological replicates filtered with adjusted p value < 
0.01 and log2 FC  > 0.8 or < -0.8. . Down-regulated transcripts are represented by negative values of log2 FC and up-regulated transcripts are 












BP0454 _ putative exported protein ncbi-geneid:2664448 -4.80 1.05E-14 4.40E-11 
BP0454 _ putative exported protein ncbi-geneid:2664448 -4.75 5.57E-15 4.40E-11 
-4.77 
BP0455 _ putative membrane protein ncbi-geneid:2664449 -4.17 1.67E-13 4.66E-10 
BP0455 _ putative membrane protein ncbi-geneid:2664449 -4.12 1.56E-12 3.27E-09 
-4.15 
BP1201 tcfA 
tracheal colonization factor 
precursor ncbi-geneid:2666888 -1.97 7.05E-10 7.56E-08 
BP1201 tcfA 
tracheal colonization factor 
precursor ncbi-geneid:2666888 -1.95 4.39E-10 5.59E-08 
-1.96 
BP2315 vag8 autotransporter ncbi-geneid:2666501 -1.97 1.31E-10 3.53E-08 
BP2315 vag8 autotransporter ncbi-geneid:2666501 -1.91 6.23E-10 6.94E-08 
-1.94 
BP2925 _ conserved hypothetical protein ncbi-geneid:2667044 -1.70 3.19E-10 5.38E-08 
BP2925 _ conserved hypothetical protein ncbi-geneid:2667044 -1.68 9.06E-12 1.05E-08 
-1.69 
BP2926 _ conserved hypothetical protein ncbi-geneid:2667045 -1.61 2.21E-10 5.38E-08 






putative R_ polymerase sigma 
factor ncbi-geneid:2667457 -1.55 4.09E-10 5.43E-08 
BP2234 brpL 
putative R_ polymerase sigma 
factor ncbi-geneid:2667457 -1.49 1.11E-09 1.01E-07 
-1.52 
BP3694 _ 
conserved hypothetical protein 
(pseudogene) ncbi-geneid:2664938 -1.47 1.81E-11 1.05E-08 
BP3694 _ 
conserved hypothetical protein 
(pseudogene) ncbi-geneid:2664938 -1.46 4.26E-11 1.86E-08 
-1.46 
BP2924 _ putative exported protein ncbi-geneid:2667043 -1.44 1.87E-11 1.05E-08 
BP2924 _ putative exported protein ncbi-geneid:2667043 -1.44 1.76E-11 1.05E-08 
-1.44 
 
BP0499 _ hypothetical protein ncbi-geneid:2664691 -1.40 2.20E-07 4.63E-06 
BP0499 _ hypothetical protein ncbi-geneid:2664691 -1.32 2.93E-10 5.38E-08 
-1.36 
BP0456 hemC putative heme receptor ncbi-geneid:2664098 -1.39 3.41E-09 2.30E-07 
BP0456 hemC putative heme receptor ncbi-geneid:2664098 -1.26 3.27E-10 5.38E-08 
-1.32 
BP3696 _ putative exported protein ncbi-geneid:2664940 -1.35 3.77E-10 5.38E-08 
BP3696 _ putative exported protein ncbi-geneid:2664940 -1.33 3.20E-10 5.38E-08 
-1.34 
BP2261 bcrD 
putative type III secretion pore 
protein ncbi-geneid:2665956 -1.34 8.79E-08 2.44E-06 
BP2261 bcrD 
putative type III secretion pore 
protein ncbi-geneid:2665956 -1.30 2.48E-09 1.90E-07 
-1.32 
BP3011 _ hypothetical protein ncbi-geneid:2665904 -1.25 3.43E-09 2.30E-07 
BP3011 _ hypothetical protein ncbi-geneid:2665904 -1.24 9.49E-10 9.13E-08 
-1.24 
BP1363 _ 
putative amino-acid ABC 
transporter, permeaseprotein ncbi-geneid:2665277 -1.23 2.13E-10 5.38E-08 





transporter, permeaseprotein  
BP1364 _ 
putative amino-acid ABC 
transporter, periplasmicamino 
acid-binding protein ncbi-geneid:2665278 -1.23 5.36E-09 3.21E-07 
BP1364 _ 
putative amino-acid ABC 
transporter, periplasmicamino 




CoA lyase ncbi-geneid:2664939 -1.16 4.97E-10 6.03E-08 
BP3695 _ 
putative hydroxymethylglutaryl-
CoA lyase ncbi-geneid:2664939 -1.22 1.07E-10 3.21E-08 
-1.19 
BP0856 bfrD 
probable TonB-dependent receptor 
for iron transport ncbi-geneid:2664308 -1.19 2.27E-10 5.38E-08 
BP0856 bfrD 
probable TonB-dependent receptor 
for iron transport ncbi-geneid:2664308 -1.15 2.80E-10 5.38E-08 
-1.17 
BP3784 ptxB pertussis toxin subunit 2 precursor ncbi-geneid:2665069 -1.18 1.24E-08 5.84E-07 
BP3784 ptxB pertussis toxin subunit 2 precursor ncbi-geneid:2665069 -1.16 1.81E-10 4.73E-08 
-1.17 
BP0500 _ hypothetical protein ncbi-geneid:2664714 -1.18 7.97E-10 7.94E-08 





ATP-dependent protease, ATPase 




ATP-dependent protease, ATPase 
subunit ncbi-geneid:2666478 -1.08 1.62E-06 1.85E-05 
-1.11 
BP2499 d_K molecular chaperone ncbi-geneid:2666522 -1.13 4.17E-08 1.40E-06 





BP1203 _ conserved hypothetical protein ncbi-geneid:2666845 -1.11 1.77E-09 1.45E-07 
BP1203 _ conserved hypothetical protein ncbi-geneid:2666845 -1.09 2.93E-10 5.38E-08 
-1.10 
BP2262 bscD putative type III secretion protein ncbi-geneid:2665957 -1.11 8.93E-10 8.79E-08 
BP2262 bscD putative type III secretion protein ncbi-geneid:2665957 -1.08 2.33E-09 1.82E-07 
-1.09 
BP0074 htpG heat shock protein ncbi-geneid:2666131 -1.09 3.26E-09 2.23E-07 
BP0074 htpG heat shock protein ncbi-geneid:2666131 -1.03 1.04E-09 9.71E-08 
-1.06 
BP1204 _ conserved hypothetical protein ncbi-geneid:2666846 -1.09 3.69E-10 5.38E-08 
BP1204 _ conserved hypothetical protein ncbi-geneid:2666846 -1.06 1.18E-10 3.39E-08 
-1.07 
BP3575 _ putative exported protein ncbi-geneid:2665198 -1.08 3.08E-09 2.17E-07 




protease ncbi-geneid:2664729 -1.06 5.35E-10 6.13E-08 
BP0216 sphB1 
autotransporter subtilisin-like 
protease ncbi-geneid:2664729 -1.03 2.85E-10 5.38E-08 
-1.04 
BP0822 hyuA hydantoin utilization protein A ncbi-geneid:2664341 -1.05 5.09E-10 6.08E-08 
BP0822 hyuA hydantoin utilization protein A ncbi-geneid:2664341 -1.05 2.33E-09 1.82E-07 
-1.05 
BP3785 ptxD pertussis toxin subunit 4 precursor ncbi-geneid:2665406 -1.04 2.42E-10 5.38E-08 
BP3785 ptxD pertussis toxin subunit 4 precursor ncbi-geneid:2665406 -1.02 3.77E-10 5.38E-08 
-1.03 
BP2263 bscE hypothetical protein ncbi-geneid:2665958 -1.03 2.97E-07 5.73E-06 
BP2263 bscE hypothetical protein ncbi-geneid:2665958 -0.96 1.25E-09 1.10E-07 
-1.00 
BP3432 cysI putative sulfite reductase ncbi-geneid:2666024 -1.02 1.27E-09 1.11E-07 
BP3432 cysI putative sulfite reductase ncbi-geneid:2666024 -0.98 2.19E-08 8.76E-07 
-1.00 
BP3455 _ putative taurine dioxyge_se ncbi-geneid:2666952 -1.00 8.45E-09 4.47E-07 





BP2183 _ conserved hypothetical protein ncbi-geneid:2666908 -0.99 2.08E-07 4.48E-06 
BP2183 _ conserved hypothetical protein ncbi-geneid:2666908 -0.93 1.04E-07 2.73E-06 
-0.96 
BP3405 ompQ 
outer membrane porin protein 
OmpQ ncbi-geneid:2667075 -0.99 9.25E-10 8.99E-08 
BP3405 ompQ 
outer membrane porin protein 
OmpQ ncbi-geneid:2667075 -0.96 7.51E-10 7.75E-08 
-0.97 
BP2141 _ putative exported protein ncbi-geneid:2666978 -0.99 1.36E-08 6.21E-07 
BP2141 _ putative exported protein ncbi-geneid:2666978 -0.97 8.51E-09 4.48E-07 
-0.98 
BP3871 _ putative cold shock-like protein ncbi-geneid:2665120 -0.99 1.09E-08 5.33E-07 
BP3871 _ putative cold shock-like protein ncbi-geneid:2665120 -0.98 2.08E-07 4.48E-06 
-0.99 
BP2662 _ putative aldolase ncbi-geneid:2665526 -0.98 3.46E-10 5.38E-08 
BP2662 _ putative aldolase ncbi-geneid:2665526 -0.95 2.06E-09 1.66E-07 
-0.96 
BP3783 ptxA pertussis toxin subunit 1 precursor ncbi-geneid:2665068 -0.97 1.01E-08 5.12E-07 
BP3783 ptxA pertussis toxin subunit 1 precursor ncbi-geneid:2665068 -0.95 5.02E-09 3.07E-07 
-0.96 
BP1200 bapB autotransporter (pseudogene) ncbi-geneid:2666887 -0.96 3.25E-08 1.17E-06 
BP1200 bapB autotransporter (pseudogene) ncbi-geneid:2666887 -0.88 4.27E-08 1.42E-06 
-0.92 
BP2233 _ hypothetical protein ncbi-geneid:2667456 -0.96 8.19E-09 4.37E-07 
BP2233 _ hypothetical protein ncbi-geneid:2667456 -0.94 1.38E-08 6.29E-07 
-0.95 
BP2253 bopD putative outer protein D ncbi-geneid:2667094 -0.94 5.91E-09 3.41E-07 
BP2253 bopD putative outer protein D ncbi-geneid:2667094 -0.88 6.09E-09 3.49E-07 
-0.91 
BP0162 _ putative membrane protein ncbi-geneid:2664287 -0.91 4.73E-09 2.93E-07 
BP0162 _ putative membrane protein ncbi-geneid:2664287 -0.90 1.11E-09 1.01E-07 
-0.91 
BP2256 bsp22 putative secreted protein ncbi-geneid:2665951 -0.90 2.07E-08 8.49E-07 






putative branched-chain amino 
acid transportpermease ncbi-geneid:2665197 -0.90 9.40E-09 4.89E-07 
BP3574 _ 
putative branched-chain amino 
acid transportpermease ncbi-geneid:2665197 -0.90 5.72E-09 3.34E-07 
-0.90 
BP1362 _ 
putative amino-acid ABC 
transporter, ATP-bindingprotein ncbi-geneid:2665276 -0.89 6.18E-09 3.51E-07 
BP1362 _ 
putative amino-acid ABC 
transporter, ATP-bindingprotein ncbi-geneid:2665276 -0.81 2.30E-08 9.02E-07 
-0.85 
BP2683 paaB 
phenylacetic acid degradation 
protein ncbi-geneid:2665547 -0.88 7.04E-10 7.56E-08 
BP2683 paaB 
phenylacetic acid degradation 
protein ncbi-geneid:2665547 -0.85 3.22E-08 1.17E-06 
-0.86 
BP0723 _ 
probable ABC transporter, ATP-
binding protein ncbi-geneid:2666778 -0.86 2.77E-09 2.02E-07 
BP0723 _ 
probable ABC transporter, ATP-
binding protein ncbi-geneid:2666778 -0.82 9.89E-09 5.06E-07 
-0.84 
BP3786 ptxE pertussis toxin subunit 5 precursor ncbi-geneid:2665407 -0.86 5.90E-10 6.66E-08 
BP3786 ptxE pertussis toxin subunit 5 precursor ncbi-geneid:2665407 -0.86 3.70E-07 6.77E-06 
-0.86 
BP2255 _ hypothetical protein ncbi-geneid:2665950 -0.86 6.18E-08 1.88E-06 
BP2255 _ hypothetical protein ncbi-geneid:2665950 -0.80 1.10E-08 5.33E-07 
-0.83 
BP0120 _ 
inner membrane component of 
binding-protein-dependent 
transport system ncbi-geneid:2664359 -0.84 1.60E-07 3.74E-06 
BP0120 _ 
inner membrane component of 
binding-protein-dependent 








ATP-dependent protease heat 




ATP-dependent protease heat 
shock protein ncbi-geneid:2667055 -0.83 5.24E-08 1.65E-06 
-0.83 
BP3494 brkA serum resistance protein ncbi-geneid:2664892 -0.83 1.01E-06 1.33E-05 
BP3494 brkA serum resistance protein ncbi-geneid:2664892 -0.81 4.78E-08 1.54E-06 
-0.82 
BP3812 _ 
putative outer membrane efflux 
proteinbpe ncbi-geneid:2665087 0.804 5.09E-09 3.08E-07 
BP3812 _ 
putative outer membrane efflux 
proteinbpe ncbi-geneid:2665087 0.805 2.05E-08 8.45E-07 
0.80 
BP3838 ubiE bpe:BP3838 ncbi-geneid:2664850 1.99 1.79E-11 1.05E-08 


















APPENDIX 4: Reagents for gel electrophoresis  
 
4.1 DNA Electrophoresis 
 
4.1.1 50x Tris-Acetate-EDTA (TAE) Buffer  
 Per 1000 ml  
Tris base  242 g 
Glacial acetic acid  57.1 ml 
0.5 M EDTA (pH 8)  100 ml 
Final pH adjusted to 7.8 
 
4.1.2 Agarose Gel 
1%  1.5% 
Agarose   0.5 g   0.75g 
1x TAE  50 ml  50 ml 
1x TAE was prepared by diluting 20 ml of 50x TAE with 980 ml of ddH2O 
 
4.1.3 6x DNA Loading Dye 
Bromophenol blue   0.25% 
Xyelene cyanol    0.24% 
Ficoll (type 400) in ddH2O  25% 
 




4.2.1.1 5x SDS/Glycine Electrophoresis Buffer 
 Per 1000 ml  
Tris base  15.1 g 
Glycine 72 g 






4.2.1.2 SDS-PAGE Seperating/Resolving Gel  
         Per 10 ml 
  8%        10%         12% 
30% Acrylamide-bisacrylamide (29:1)    2.65ml      3.33ml    4ml 
1.5 Tris-HCl (pH 8.8)     2.5ml        2.5ml 2.5ml 
10% SDS       0.1ml        0.1ml 0.1ml 
10% Ammonium persulfate    0.1ml        0.1ml 0.1ml 
TEMED       0.004ml    0.004ml 0.004ml 
ddH2O                                                         4.65ml      3.97ml      3.30ml 
 
4.2.1.2 SDS-PAGE Stacking Gel      
 Per 10 ml 
     5% 
30% Acrylamide-bisacrylamide (29:1)  1.65ml 
1 M Tris-HCl (pH 6.8)    2.5ml 
10% SDS      0.1ml  
10% Ammonium persulfate   0.1ml 
TEMED       0.004ml     



















APPENDIX 5: Reagents for growth media 
 
5.1 E. coli Culture Media  
 
5.1.1 Luria-Bertani (LB) Agar 
 Per 1000 ml  
Tryptone  10 g 
Yeast extract  5 g 
NaCl 10 g 
Agar 15 g 
To ensure sterility, medium was autoclaved at 121°C for 15 min. 
 
5.1.2 Luria-Bertani (LB) Broth 
 Per 1000 ml  
Tryptone  10 g 
Yeast extract  5 g 
NaCl 10 g 
Final pH adjusted to 7.0 
To ensure sterility, medium was autoclaved at 121°C for 15min. 
 
5.2 B. pertusssis culture media  
 
5.2.1 Stainer-Scholte (SS) Medium 
 
Fraction A:    Per 950ml  
Na-L-Glutamate     11.84 g 
L-Proline      0.24 g 
NaCl       2.5 g 
KH2PO4      0.5 g 
KCl       0.2 g 
MgCl2.6H2O      0.1 g 
CaCl2.2H2O      0.02 g 
Tris       1.5 g 




Dimethyl-β-Cyclodextrine    1 g 
 
Fraction B:    Per 50 ml 
L-Cysteine      0.04 g 
FeSO4.7H2O     0.01 g 
Nicotinic acid      0.04 g 
Ascorbic acid      0.4 g 
Glutathione      0.15 g 
 
Dissolve Fraction A and B completely prior to mixing Fraction A and B to a 
final volume of 1000 ml. 
Medium was filter sterilized using 0.2 µm filter unit. 
 
5.2.2 Bordet-Gengou (BG) Agar 
   Per 1000 ml  
Potato infusion from 125 g    4.5g 
NaCL       5.5g 
Agar       20 g 
Glycerol      10 g 
To ensure sterility, medium was autoclaved at 121°C for 15 min. 
10% sterile, defibrinated sheep blood was added at 45°C-50°C. 
 
 
5.3 Tissue culture media  
 
5.3.1 Dulbecco’s modified essential medium (DMEM)  
   Per 1000 ml  
DMEM       900ml 
FCS       100ml 
200mM Glutamax-I     0.02ml 
100mM Sodium pyruvate   0.01ml 







5.3.2 RPM1-1640 medium modified 
 
   Per 1000 ml  
RPMI-1640      900ml 
FCS       100ml 
200mM Glutamax-I     0.02ml 
Penicillin-streptomycin    10ml 






























APPENDIX 6: Reagents for animal work 
 
6.1 Anaesthetic cocktail for nasal administration 
 
Valium       6% 
Atropine     10% 
Ketamine      20% 
1x PBS      64% 
Cocktail must be prepared under sterile conditions. 120 µl cocktail is injected 
intraperitoneally for a mouse of approximately 17 g of body weight. 
